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ABSTRACT

Elastin, a structural protein in the extra-cellular matrix, plays a critical role in the
normal functioning of blood vessels. Apart from performing its primary function of
providing resilience to arteries, it also plays major role in regulating cell-cell and cellmatrix interactions, response to injury, and morphogenesis. Medial arterial calcification
(MAC) and abdominal aortic aneurysm (AAA) are two diseases where the structural and
functional integrity of elastin is severely compromised. Although the clinical presentation
of MAC and AAA differ, they have one common underlying causative mechanism –
pathological degradation of elastin. Hence prevention of elastin degradation in the early
stages of MAC and AAA can mitigate, partially if not wholly, the fatal consequences of
both the diseases.
The work presented here is motivated by the overwhelming statistics of people
afflicted with elastin associated cardiovascular diseases and the unavailability of cure for
the same. Overall goal of our research is to understand role of elastin degradation in
cardiovascular diseases and to develop a targeted vascular drug delivery system that is
minimally invasive, biodegradable, and non-toxic, that prevents elastin from degradation.
Our hope is that such treatment will also help regenerate elastin, thereby providing a
multi-fold treatment option for elasto-degenerative vascular diseases. For this purpose,
we have first confirmed the combined role of degraded elastin and hyperglycemia in the
pathogenesis of MAC. We have shown that in the absence of degraded elastin and TGFβ1 (abundantly present in diabetic arteries) vascular smooth muscle cells maintain their
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homeostatic state, regardless of environmental glucose concentrations. However
simultaneous exposure to glucose, elastin peptides and TGF-β1 causes the pathological
transgenesis of vascular cells to osteoblast- like cells.
We show that plant derived polyphenols bind to vascular elastin with great
affinity resulting in improved resistance to elastolytic digestion. We further show that the
same polyphenols interact with monomeric tropoelastin released by the vascular cells and
dramatically increase their self-assembly in-vitro. In addition, we demonstrate the
elastogenic ability of these polyphenols in aiding the crosslinking of tropoelastin released
by aneurysmal cells converting it into mature elastin.
Finally, we developed a nanoparticle system functionalized with elastin antibody
on the surface that, upon systemic delivery, can recognize and bind to sites of damaged
elastin in the aorta. We are able to show that this nanoparticle system works in
representative animal models for MAC and AAA. These nanoparticles demonstrated
spatial and functional specificity for degraded elastin.
In conclusion, our work is focused on understanding the role of elastin
degradation in vascular calcification and aortic aneurysms. We tested approaches to halt
elastin degradation and to regenerate elastin in arteries so that homeostasis can be
achieved.
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CHAPTER 1

INTRODUCTION

Cardiovascular diseases (CVD) remain the leading cause of death in the United
States. 2004 statistics indicate that 52% of CVD related deaths are due to coronary heart
disease, 17% due to stroke, 4% due to diseases of the arteries and 6% due to high blood
pressure. Congenital CVD and rheumatoid heart disease attribute to 0.5% and 0.4%
respectively.1 In addition, 8.3% of American population are suffering from diabetes, of
which 68% die due to cardiovascular complications.2 It has also been established that
diabetic patients are at a 2-4 times greater risk of vascular disease than healthy people.
These compelling statistics drive the need for research in the area of cardiovascular
disease, both in the fundamental understanding of vascular pathology and in development
of cost effective therapeutic options for vascular diseases.
Elastin is a structural protein present in the elastic fibers, which are of crucial
importance in the well-being of blood vessels. Elastic fibers are organized as concentric
layers in the medial portion of the artery. Its fundamental function is providing elasticity
and resilience to arteries; expand during systole and recoil during diastole thereby
enabling continuous blood flow through arteries. Needless to say, larger arteries are
endowed with more elastin, the degeneration of which affects the physiology of larger
arteries more severely than branching arterioles. Elastin is a highly cross-linked protein
resistant to proteolytic degradation except by a special class of proteases called matrix
metallo-proteinases (MMP), especially MMP2, 7, 9, and MMP12.3 Two fatal arterial
1

diseases, namely medial arterial calcification (MAC) and abdominal aortic aneurysm
(AAA), are primarily elastin degradation related diseases.
Elastin associated calcification observed in MAC is a common and central
pathological trait of type II diabetes mellitus4 and chronic kidney disease (CKD).5 The
hallmark characteristic of type II diabetes is high levels of circulating glucose and insulin.
High glucose concentrations (hyperglycemia) by itself is not a disease, however, it is the
single largest contributor of all the co-morbidities associated with diabetes including
micro-vascular and macro-vascular diseases, retinopathy, nephropathy, neuropathy,
cardiomyopathy, and infection. Amputation of lower extremities and death can occur due
to all the above mentioned co-morbidities. MMP mediated elastin degradation is
commonly observed in peripheral arteries of diabetic patients.5,6 Degradation of elastin
leads to the release of soluble elastin peptides in the blood stream, which further bind to
elastin laminin receptors on fibroblasts and smooth muscle cells present in the artery, thus
activating them and causing possibly unfavorable downstream activity such as
transgenesis of smooth muscle cells to bone-like cells and increased production of elastin
degradative enzymes like MMPs.7,8 In fact, blood serum levels of circulating soluble
elastin peptides are much greater in diabetic patients compared to healthy people.9
Therefore, a useful structural protein, upon degradation can have potentially malevolent
implications on overall vascular health. Additionally, high levels of circulating glucose
undergo a series of oxidant-induced fragmentation leading to the formation of advanced
glycation end products (AGEs) that generate irreversible crosslinks on structural proteins
like collagen and elastin.10,11 The exact pathological mechanisms involving glucose and
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elastin peptides leading to elastin calcification in diabetic patients is not clearly
understood and thus we investigated the mechanistic aspects of hyperglycemia and
elastin peptides in the osteogenesis of vascular cells (pathological conversion of arterial
cells to bone-like cells).
AAA is another arterial disease with potentially severe consequences, mainly due
to its asymptomatic nature. AAA causes structural weakening of a local segment of the
aorta primarily due to accelerated elastin degradation causing faulty load bearing and
insufficient resilience of arteries leading to local ballooning and eventual rupture of the
abdominal aorta. AAAs are characterized by degeneration of arterial ultra-structure,
decrease in medial elastin content, fragmentation of elastic lamellae, infiltration of
inflammatory cells, increased enzymatic activity (especially MMPs), atherosclerosis,
intra-luminal thrombosis and calcification.12 AAA is an idiopathic disease with an
unknown etiology. Although atherosclerosis is a key feature of AAA, atherosclerosis in
small arteries causes opposite remodeling of arteries (expansion in AAA vs. occlusion in
small arteries). Regardless of its initiation mechanisms, AAA is a biomechanical
problem, and rupture of aorta is essentially a mechanical failure of the structural proteins
elastin and collagen. Current surgical methods for AAA treatment include 1) open
aneurysm repair and 2) endovascular abdominal aneurysm repair (EVAR). Though these
procedures have low mortality rates (<5%) and relatively short recuperation times, long
term cardiac and pulmonary complications and other graft related complications can drop
patient survival rates by ~ 50% at 10 years post-operation.13 Currently there are no
pharmacological options for treating AAA. The therapeutics options that have made it to
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clinical trials include statins14-16, β-blockers17,18, ACE inhibitors19, tetracyclines like
doxycycline (mainly works as an MMP inhibitor),20 and anti-inflammatory agents.
However, systemic delivery of these drugs have undesirable side-effects and reduced
effectiveness in treating aneurysms as we will discuss later. Since AAA has a complex
pathology with multi-factorial causal factors, a multi-modal treatment option would serve
as an ideal one. First, as the eventual rupture is due to poor biomechanics of the arterial
tissue (which is because of progressive loss of elastin and collagen), biomechanical
strengthening of the residual ECM and its protection against further proteolytic damage
would lead to halting of further ballooning and rupture. Second, arterial elastin that is lost
during disease development needs to be restored and regenerated to reverse the formed
aneurysm. In this dissertation we explore the use of plant derived polyphenolic
compounds in stabilizing elastin matrix from proteolytic damage and improving
biomechanics of aneurysmal aorta. In addition, we also study whether the same treatment
can aid in cellular deposition of newly formed cross-linked elastin and inhibition of
MMPs. Thus we aim to provide a treatment using polyphenols that can solve multiple
problems in AAA and can halt and reverse aneurysms.
As discussed earlier, diseases like MAC and AAA do not have any
pharmacological treatment till date. The drugs that can be potentially used for vascular
therapy have very low tolerance when delivered systemically. For instance the use to
doxycycline for AAA repair has unpleasant side-effects like skin reactions, tooth
discoloration, gastrointestinal symptoms and yeast infection.21 Furthermore, due to firstpass effect, systemic delivery of drugs causes rapid loss and uneven distribution of drug
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throughout the body and thus very little concentration is present in the diseased site.
Especially in diseases like MAC and AAA, which are primarily matrix disorders, the
drug-matrix interaction is of fundamental importance. Hence development of a drug
delivery system that is capable of targeting the diseased site and delivering the welldefined therapeutic payload of drug to the site becomes an attractive option. The advent
of nanotechnology offers a logical and clever solution making the aforementioned
possible. Polymeric nanoparticles (NPs) can be loaded with drugs/proteins of choice.
Additionally, surface functionalizing of these NPs with ligands capable of recognizing
specific sites enables active targeting in the vasculature. Once these NPs reach the site,
they can deliver drugs to the site in a controlled fashion. Such NPs have been
successfully used for cancer therapy.22 However, targeting therapeutics to diseased blood
vessels still remains a challenge mainly due the heterogeneity of vascular diseases,
tortuosity of arteries, hemodynamic environment within the vasculature with its high
blood flow and limited and transient targets available in the blood vessels. Although
several researchers have attempted targeting inflammation of blood vessels (very
common feature in all vascular disease),23-25 the unstable and relatively low antigen
expression provides sub-optimal targeting efficiency. In the following chapters we will
discuss the development of a novel technology that enhances targeting efficiency to the
site of vascular damage thereby enabling the delivery of drugs to diseased site. As
discussed earlier, elastin fragmentation and degradation is a common and prevalent
feature in several diseases especially diabetic MAC and AAA. We turned this undesirable
pathology to our advantage by using it as a potential target for sites of nanoparticle
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attachment. We formulated polymeric nanoparticles decorated with elastin antibodies that
can recognize and attach to damaged elastin of aorta. This technology can be extended
for delivery of drugs, imaging agents and biomolecules to sites of elastic damage.
Organization of dissertation
1)

In chapter 2, we present a comprehensive overview of:
•

Elastin: its structure, function, biomechanics, physiological relevance in
blood vessels, ultrastructure, mechanisms of elastin synthesis and fiber
assembly in-vivo and in-vitro.

•

Cardiovascular diseases: Pathological significance of elastin in MAC and
AAA, underlying

mechanisms causing MAC and AAA,

current

therapeutic options for MAC and AAA
•

Polyphenols: Their structure, properties and historical uses, interaction
with extracellular matrices, cellular interactions, and role as therapeutics

•

Drug delivery: Local drug delivery options to the vasculature

2)

Chapter 3 describes the project goals, scope, and rationale

3)

In chapter 4, we discuss the effect of high glucose, elastin derived peptides and
transforming growth factor β-1 (TGFβ-1) on the pathogenic transformation of
vascular cells to osteoblast-like cells. We investigate the receptors and molecular
pathways responsible for osteogenesis of smooth muscle cells in hyperglycemic
conditions.

4)

Chapter 5 details the utility of polyphenols for stabilizing elastin against
proteolytic damage and potential use for AAA repair. We study the polyphenol
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interactions with insoluble elastin and tropoelastin. We also compare the effect of
polyphenols on healthy as well as aneurysmal cells in elastic matrix regeneration
and its assembly.
5)

In chapter 6 we develop a novel technology which uses nanoparticles that can
categorically target sites of damage in the aorta which can be used to deliver sitespecific drugs for AAA and MAC repair. Herein, we use established animal
models to test our technology and investigate the tolerance of these nanoparticles
in-vitro and clearance rates in-vivo.

6)

Finally chapter 7 discusses preliminary trials of polyphenol loaded nanoparticles
for in-vivo delivery; final conclusions derived from this multi-faceted project,
recommendations and future directions of the current work.
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CHAPTER 2

LITERATURE REVIEW

2.1 Vascular anatomy
The circulatory system of the body comprises of the heart, arteries, blood vessels
and blood. The main function of the heart is to pump the primary circulatory fluid-blood
through closed conduits called arteries. Arteries branch out into smaller blood vessels and
capillaries that allow exchange of nutrients and waste metabolites from all body tissues.
The metabolites are carried back to the heart via the venous system.
A healthy artery comprises of three fundamental layers (Figure 2.1) - (1)
endothelium (tunica interna) comprising of a monolayer of endothelial cells (2) media
(tunica media) composed of smooth muscle cells (SMC) (3) adventitia (tunica externa)
containing mainly fibroblasts. The medial layer mainly comprising of insoluble mature
elastin is responsible for maintaining structure of the artery during the contractile
pulsations of smooth muscle cells. The elastic property of arteries is provided by elastin
whereas the load bearing properties of the artery are mainly due to the collagen present in
the adventitial layer. The intima is the innermost layer of the arteries which comprises of
endothelial cells resting on a basement membrane made up of extracellular matrix (ECM)
proteins like collagen type IV, laminin and heparin sulfate proteoglycans.26 The internal
elastic lamina (IEL) separates the intima from the media and the external elastic lamina
(EEL) separates the media from the adventitia. The medial layer is usually the thickest
layer in the artery consisting of concentric layers of circumferentially arranged smooth
8

muscle cells interspersed in alternating elastic lamellae. Vascular smooth muscle cells are
responsible for the production of elastin, collagen and other ECM components.

of an artery27
:
Figure 2.1Structure
2.1.1

Structure of aortic elastin

Elastin is the predominant structural protein of the arteries comprising of ~ 50%
of the arterial ECM.28 Elastin is primarily synthesized during embryogenesis, rarely
undergoes remodeling and has a very low turn-over rate. It is a hydrophobic protein
containing a highly conserved peptide sequence ‘VGVAPG’ (Table 2.1). Due to the

9

recurring hydrophobic amino acid residues (XPGX' where X and X' are hydrophobic
residues), elastin is a highly hydrophobic and cross-linked protein and can undergo nearly
2 billion stretch-relaxation cycles in the aortic arch in a lifetime.3

Table 2.1: Amino acid composition of elastin derived from rat aorta. Values expressed as
residues/1000 total amino acid residues29
Amino acid (AA)

Residues per 1000 AAs

Aspartic Acid(Asp)

3.6

Glutamic acid (Glu)

13.9

Serine (Ser)

15.9

Glycine (Gly)

382.1

Histidine (His)

0

Arginine (Arg)

6.6

Threonine (Thr)

10.3

Alanine (Ala)

214.6

Proline (Pro)

104.8

Tyrosine (Tyr)

35.9

Valine (Val)

81.4

Methionine (Met)

0

Cysteine (Cys)

0

Isoleucine (Ile)

24.1

Leucine (Leu)

64.8

Phenylalanine (Phe)

13.9

Lysine (Lys)

1.7

Iodesmosine (Ides)

2.2

Desmosine (Des)

3.4

10

Elastin is a biopolymer with tropoelastin as its single repeating monomeric unit.
The typical amino acid composition consists of non-polar amino acids with few polar
side chain residues. Elastin contains alternating hydrophobic segments and alanine and
lysine rich segments (Figure 2.2).

Figure 2.2: Structural features of elastin showing the repetitive alternating
sequence (square brackets) of β-hydrophobic domains and αcrosslinking areas30
The hydrophobic short segment assumes β-sheet confirmation and is responsible
for the elastic properties of elastin, whereas the α-helical segment of alanine and lysine
rich residues mainly form crosslinks between adjacent molecules. In between these rigid
cross-linking domains, the hydrophobic segments display motility and contribute greatly
to the entropy of the system.31 Despite being greatly hydrophobic, elastin is highly
hydrated by water and swells in vivo.31 The tropoelastin molecules are bound to each
other with crosslinks that can either be bi- (lysinonorleucine) , tri- (merodesmosine) or
tetra-functional (desmosine and iso-desmosine) in nature, and the increase in complexity

11

is thought to progress as the fiber matures and ages.32 These internal links of desmosine
and isodesmosine are extremely stable making elastin a very stable protein, resistant to
conventional enzymatic or solvent based degradation. Extraction of elastin usually
involves a stepwise procedure for the removal of tissue components under relatively mild
conditions thereby preserving peptide bonds. Digestion of elastin using oxalic acid or
boiling sodium hydroxide is commonly used to quantify insoluble mature elastin.33 Being
extremely stable and having a low turnover rate, it can be considered that elastin lasts the
entire lifespan of the individual.
2.1.2

Mechanical properties of elastin

The two most prominent structural arterial proteins are collagen and elastin and
these proteins primarily determine the mechanical properties of the aorta. Elastin plays
rubber-like roles in physiological pressures leading to arterial expansion, whereas
collagen bears high-pressure loads. The most important determinant of the arterial wall
mechanics is the elastin to collagen ratio which varies significantly throughout the
vasculature. Studies show that the uniaxial elastic modulus of collagen is between 0.3 to
2.5 X 1010 dynes/cm2 which is at least a thousand times more than elastin.34 The great
mechanical stiffness of collagen is attributed to numerous inter-chain links that stabilize
the helical structure of collagen. Elastin on the contrary is a stretchy protein that exhibits
high degrees of reversible deformation with high resilience. The physiological properties
of elastin include low stiffness, high extensibility and high resilience. It has been shown
that at physiological pressures, arteries are mostly distensible, implicating the role of
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elastin, whereas at higher pressures arteries tend to be much stiffer indicating the loadbearing tendencies of collagen.

Figure 2.3: A typical stress-strain curve for a blood vessel. Shown are the
respective regimes affected by physiologic state and
organization of collagen and elastin.35

Roach and Burton have shown in their work that elastin mainly bears
circumferential load, which explains their arrangement in the artery, whereas collagen
mainly bears longitudinal loads at much higher pressure.36 They separated the role of
each protein by using trypsin to degrade elastin and formic acid to degrade collagen in
human iliac arteries. Stromberg et al. in their experiments showed that pure collagen
undergoes very small strain before they fracture, which is highly uncharacteristic of total
arterial tissues. This indicates that collagen remains un-stretched in the arteries until the
vessel is distended. They also showed the progressive alignment of collagen fibers in the
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longitudinal direction with increasing stress.37 Elastin is endowed with high resilience
capable to undergoing cyclic stretching (Figure 2.4).
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Figure 2.4:Depiction of elastin recoil
2.1.3

Elastin ultrastructure

Insoluble elastin fibers are made up of 2 major structural components, a central
core of amorphous elastin clumps which lacks a regular structure, and a periphery of
microfibrils. The amorphous content consists about 90% of the mature elastin and is
composed of exclusively elastin while the microfibrillar component consists 10-12 nm
fibrils located around the periphery of the amorphous content with some interspersed
within it.39 Microfibrils contain a number of glycoproteins like microfibril-associated
glycoproteins (MAGP-1,-2,-3,-4); however the majority of the protein is 350 kDa fibrillin
playing an important role both in maintaining the elastic fibers and the matrix-cell
interaction.40 These microfibrillar components especially play an important role during
14

elastogenesis. The monomer tropoelastin interacts specifically with fibrillin and MAGP
which is a vital step for the accurate crosslinking of elastin.
Under transmission electron microscope, elastin appears either in cross-section as
amorphous clumps exhibiting low electron density measuring 100-800 nm at the core
(Figure 2.5) or as longitudinally-aligned, laterally-associating bundles of elastin (Figure
2.6). TEM suggests that microfibrils are mainly tubular in nature appearing as a beaded
chain. Multiple fibrillin molecules may align in a parallel head-to-tail fashion to form
major microfibrils. The microfibrils are found in small bundles under the plasma
membrane and with the development of fibers, elastin begins to appear as an amorphous
bundle within each microfibrillar bundle. These amorphous areas gradually join together
and generate the core of elastin with majority of the microfibrils orienting outwardly.39
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of
cross
section
of
elastin
Figure 2.5:TEM
fibers deposited by rat vascular cells in culture41

and

fibrillin

Besides directing the elastin growth, microfibrils have also shown to mediate
cellular interaction with elastin fibers, regulating the cell phenotype and ensuring
homeostasis.42

Figure 2.6:TEM of longitudinal section of elastin. Elastin is stained in black
and is surrounded by microfibrils39
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2.1.4

Mechanisms of elastin synthesis and fiber assembly

As mentioned earlier, elastin is a hydrophobic structural protein with an
amorphous core and peripheral microfibrils. However, the cellular production,
orientation, assembly, crosslinking and deposition of elastin is a tightly regulated
hierarchical process which is poorly understood. The monomeric form of the bio-polymer
elastin is a 72 kDa soluble tropoelastin which is released by cells. Human tropoelastin is
encoded by a single gene with multiple isoforms. The elastin gene is present with a single
copy on the chromosome-7.43 The human tropoelastin mRNA encodes the 72 kDa soluble
protein which on post translational modification, results in the mature 60 kDa protein.
The tropoelastin protein is secreted by cells after being hydroxylated on a number of
proline residues, mainly located on the protein segment corresponding to exon-18. The Cterminus is highly conserved regions in tropoelastin. It contains two cysteine residues
which form disulfide bond. Human tropoelastin is unglycosylated44 and is produced by
smooth muscle cells, endothelial cells, and fibroblasts in response to mechanical stress.32
The process of elastogenesis is broadly categorized into the following stages: (1)
tropoelastin synthesis (2) coacervation (3) microfibrillar deposition (4) crosslinking
(Figure 2.7).
Once the tropoelastin is released by cells, the process of self-aggregation
(coacervation) begins wherein the ~ 15 nm monomers form larger spherical globules,
primarily due to the inherent tendency of tropoelastin to coacervate due to its excessive
hydrophobicity.45 The tropoelastin coacervates remain attached to cell surface via
glycosaminoglycans and integrins until deposition on microfibrils. Microfibrils play three

17

crucial roles, (1) provide a scaffold directing and propagating elastin growth46 (2) further
promoting coacervation47 (3) recruit lysyl oxidase for the cross linking of elastin.48

Figure 2.7: Elastogenesis schematic. Cells secrete tropoelastin coacervating on the
surface. Coacervates remain attached to cells until deposition on
microfibrils. Microfibrills recruit the crosslinking enzyme lysyl
oxidase (LOX) which oxidizes the lysine residues, triggering the
formation of intramolecular and intermolecular cross-links needed
for formation of stable fibers.49
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Once LOX is recruited to the site of tropoelastin-fibrillar complex, it deaminates
specific lysine residues to form allysines50 thereby initiating spontaneous formation of
intra and intermolecular cross-links.51 Once the intermolecular crosslinks are formed,
elastin gets organized in the three dimensional network. Crosslinking inhibits mobility of
elastin and makes elastin insoluble and a stable molecule.
2.1.5

Stages of in vitro tropoelastin self-assembly

Figure 2.8:Stages of in vitro tropoelastin self-assembly.52
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Tropoelastin displays a spontaneous self-aggregation in an acellular environment
forming aggregates and fibers very similar to that in the presence of cells. This indicates
the inherent ability of tropoelastin of assembly. This in-vitro coacervation can be divided
into two main stages (1) initial phase separation (2) maturation phase (Figure 2.8).
Coacervation is an entropic process and over a very narrow range of temperature
increase (<5°C) there is a rapid monomer-to-polymer assembly without any apparent
intermediate stages.53 Experimentally, this is observed as a sharp rise in turbidity in
solution. With time, the droplets progressively grow until a stable size of 2-6 µm is
reached. When allowed to settle, a liquid-liquid phase separation occurs. The bottom
phase consists of a visco-elastic phase containing concentrated tropoelastin and the top
phase consists of an aqueous solution of tropoelastin at its critical concentration.54 The
initial coacervation phase is a reversible process which dissipates back into solution upon
cooling.55 However, once polymerization is allowed for extended time period, the
maturation stage occurs irreversibly and aggregates do not return back into solution upon
cooling.56 Maturation is observed as the formation of large globules which is
experimentally detected as a decrease in turbidity/absorbance. During the coacervation
phase, the increasing particulate matter scatter light increasing the absorbance. At the
maturation phase, the light scattering ability of the spherules is reduced thereby
decreasing turbidity.57 Bressan et al. observed tropoelastin at 40°C for a few minutes
isolated into filaments of 5 nm diameter and variable length. However, after 10 hours of
incubation, formed a white precipitate consisting of 0.5-2 µm thick amorphous branching
fibers, identical to those seen in normal tissues.58
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As discussed earlier, cellular model of elastin assembly deploys microfibrillar
proteins such as fibrillins, fibulins and MAGP promoting coacervation and
intermolecular alignment. This phenomenon has also been observed in vitro using
tropoelastin.57 Interestingly, fibrillin shows an inhibition in tropoelastin coacervation in a
dose-dependent manner (a property displayed by fibulin-4,-5 and MAGP-1). In the
presence of these proteins, there is a significant delay in the time of maturation indicating
the inhibitory effects of these species. Delaying the maturation enhances the clustering of
tropoelastin into organized network. Also, fibulin-4,-5 deficiencies in humans are
associated with the presence of large globules of tropoelastin in the extracellular space.59
These findings indicate the importance of microfibrillar proteins in modulating the end
size of tropoelastin prior to fiber assembly. Coacervation is a critical step to successful
elastin crosslinking. Coacervation has shown to increase the intra-molecular structure of
tropoelastin for downstream elastogenic events. Lysine oxidation of tropoelastin
coacervates have shown to form spontaneous crosslinks.60 This emphasizes the
importance of coacervation in correct alignment of monomers and orienting lysine groups
such that zero-length crosslinking can occur.61
2.2 Vascular diseases
Cardiovascular disease (CVD) has been the leading cause of death in the United
States. The major risk factors include hypertension, high cholesterol levels, smoking,
sedentary life style, poor eating habits and diabetes. CVD includes coronary arterial
disease, heart valve disorders, high blood pressure, heart failure, aneurysms and stroke
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(Figure 2.9). There is almost a 37% prevalence of CVD causing a mortality of around
830,000.1

:
Figure 2.9Mortality
from CVD in US in 20041
2.2.1. Atherosclerotic arterial disease
Atherosclerosis is an inflammatory disease characterized by luminal deposition of
fatty plaque. Beginning with an initial endothelial injury, this disease progresses causing
changes in endothelial cellular properties like permeability, response to stimulatory
agents, and interaction with other cells types. Over time, the endothelium becomes
increasing permeable to lipoproteins enhancing its uptake and retention in the subendothelial intima.62 This gradual accumulation of low density lipoprotein (LDL)
indirectly damages the arterial wall by inducing biochemical changes such as increasing
the free radical content, initiating platelet adherence and activation, and secreting various
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cytokines that cause proliferation of smooth muscle cells and recruitment of
macrophages. Over a period of years, lipid-laden macrophages (called foam cells)
accumulate in the intima attracting particles of lipid and calcium phosphate, eventually
building upto a fibrous plaque narrowing the lumen and restricting blood flow63 (Figure
2.10). Although atherosclerotic lesions may occur anywhere over the vascular tree,
abdominal aorta, iliac, carotid and coronary arteries as well as vascular bifurcations are
more prone to accumulation.64 Lesions in small diameter arteries are especially fatal as
they occlude the arteries obstructing blood flow possibly leading to myocardial infacrtion
or stroke.

Figure 2.10:
Cut section of an artery showing features of an
atherosclerotic plaque65
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2.2.2

Pulmonary arterial hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a rare but fatal arterial disease causing
an increased blood pressure in the pulmonary artery, pulmonary vein or capillaries
causing a variety of symptoms such as shortness of breath, dizziness, fainting, and
fatigue. The main manifestation of PAH is increased elevated mean pulmonary arterial
pressure (MPAP). PAH is defined as an elevated MPAP of more than 25 mm Hg at rest,
or 30 mm Hg after exercise.66 Increase in MPAP can further correlate to other
complications including increased pulmonary vascular resistance, intimal hyperplasia,
smooth muscle hypertrophy, vascular matrix remodeling, thrombus formation, right
ventricular hypertrophy, calcification, and all of them eventually leading to narrowing of
arteries. PAH is an idiopathic disease with relatively slow progression, symptoms taking
about 2-3 years to develop. Thus delay in diagnosis causes complications and high
mortality of PAH patients mainly due to right ventricular failure. The exact etiology of
PAH is unknown, however, the pathogenesis can be attributed to several proinflammatory conditions including exposure to toxins, proteolytic enzymes, imbalance
between vasodilators and vasoconstrictors, elevated serotonin levels, and potassium ion
channel dysfunction.66 Arterial pericytes undergo differentiation into SMC causing
abnormal proliferation and muscularization of distal alveolar ducts.67 In addition, the
reduction of nitric oxide68 and thromboxane69 (potent vasodilators) further causes
narrowing of the arteries. Serine proteases that are potent elastases are also implicated in
the pathogenesis of PAH. Further, up-regulation of elastases initiates a cyclic process of
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increasing MMPs which further degrades the arterial matrix causing pathological matrix
remodeling. Figure 2.11 gives a summary of the pathogenesis of PAH.

Figure 2.11:Pathogenesis of PAH. This schematic depicts the abnormalities
throughout the pulmonary circulation, including (1) abnormal
muscularization of distal precapillary arteries, (2) medial hypertrophy
(thickening) of large pulmonary muscular arteries, (3) loss of
precapillary arteries, (4) neointimal formation that is particularly
occlusive in vessels 100–500 µM, and (5) formation of plexiform
lesions in these vessels.66
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2.2.3

Medial arterial calcification (MAC)

MAC is the mineral deposition in arteries which may exist with or without
atherosclerosis and has different pathological initiation when compared to atherosclerotic
arterial disease. Chronic deposition of bone-like hydroxyapatite into the elastic layers of
arteries, alters the mechanical properties leading to higher blood pressure, poor
circulation and eventual amputation.70 The deposition of calcium in soft tissues can be
four major variants: atherosclerotic calciphylaxis (discussed earlier), cardiac valve
calcification, vascular calciphylaxis, and medial arterial calcification. This dissertation
will deal majorly with medial arterial calcification (MAC).
MAC, also known as Monckeberg’s sclerosis is a pathological ossification of the
medial part of arteries (Figure 2.12).

Figure 2.12:H&E of a patient with MAC. The arrow depicts calcium
deposits within the media of a peripheral artery.71
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MAC is highly characteristic of diabetes and chronic kidney disease (CKD) and is
associated with significant morbidity and mortality.72,73 The molecular finger printing and
phenotypic traits of MAC in diabetic and CKD patients are strikingly similar.70 Both
CKD and diabetes have now been identified as pro-inflammatory conditions. Initially
thought to be benign, MAC has now been recognized as a severe pathology causing
morbidity and mortality in patients. Initially thought to be a passive deposition of calcium
phosphate on the arteries, MAC has now shown to be active biological process.
Calcification of arteries in diabetes and CKD is a series of well-orchestrated processes
which are tightly regulated involving molecular reprogramming, structural and functional
changes in arterial cells and matrix.74,75 Additionally, the mineral deposition in arteries is
not just amorphous calcium phosphate, but is complex hydroxyapatite. Although the
exact pathological mechanistic links between diabetes and MAC are not clearly
understood, the mineralization highly resembles calvarial (skull) bone formation and
odontogenesis (teeth formation).76 Both MAC and bone formation share similar features
such as 1) no cartilaginous precursor required, 2) bone morphogenetic protein-2 –
homeobox protein Msx-2 (BMP-2-Msx2) drives the process of osteogenesis and
mineralization.77 Up-regulation of Msx2 and Msx1 in diabetic aorta have been shown
earlier.74 Although diabetic patients are prone to both MAC and degenerative
atherosclerotic calcification,70 MAC is a significant predictor of lower limb amputation
and cardiovascular mortality in patients with Type II diabetes78 (Figure 2.13).
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Figure 2.13: Normal arteries seen do not block x-rays whereas calcified arteries
display the railroad pattern of calcific deposits, visualized as white thick
calcified rings upon gross examination.79,80
2.2.3.1

Pathobiology of vascular calcification

Hydroxyapatite present in the vessels is very similar to that seen in bone, which
instigated researchers to compare the molecular mechanisms leading to calcification in
bone and arteries. There is now considerable evidence that arterial calcification is an
active, cell controlled event wherein proteins control the initiation, progression and
inhibition of calcification. Calcification in the arteries occurs mainly due to an
inflammatory stimulus which is more pronounced in the presence of lipoproteins.
However in diabetes and CKD, the native cells of the arteries like smooth muscle cells,
and fibroblasts also participate in the process of calcification. Additionally tissue
macrophages release a potent growth factor called tissue necrosis factor –α (TNF-α)81
which turn smooth muscle cells into osteoblastic cells releasing the bone proteins like
alkaline phosphatase (ALP), osteopontin (OPN), osteoprotegrin (OPG), and bone
sialoprotein (BSP), very similar to what is seen in bone.82 In medial calcification, the
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cellular source of calcification is almost exclusively smooth muscle cells. In fact, the
lesions of patients with MAC have stained positive for α-SMA and SM-22 (both of which
are proteins expressed by smooth muscle cells).83 In addition, these cells also express
bone proteins like collagen type I, II, osteonectin, alkaline phosphatase, bone
sialoprotein, bone morphogenetic protein (BMP)-2, indicating that SMC can also produce
bone proteins.83 In particular, a specific subpopulation of SMC responsible for exhibiting
bone-cell-like characteristics in in-vitro cell culture studies have been nicknamed
“calcifying vascular cells”.84 The most commonly identified proteins in the arteries of
diabetic and CKD patients will be discussed below.
Bone morphogenetic protein-2 (BMP-2)/TGF-β
BMPs are a group of growth factors belonging to the same family sharing
homology with transforming growth factor (TGF-β). All these proteins belong to the
TGF-β super family of proteins.85 There are seven different types of BMPs, however only
BMP-2,-4 have shown to play an important role in osteogenesis and the downstream
process for ossification. In fact recently, it has been suggested that only BMP-2 may be
sufficient for the process of calcification. TGF-β also has shown to play an important role
in calcification of smooth muscle cells. Watson et al. have shown that under the influence
of TGF-β1 and 25-hydroxycholestserol, vascular smooth muscle cells turn into
osteoblasts producing bone proteins and eventually depositing intense calcifying nodules
in culture.86 In particular, TGF-β1 has been observed in association with vascular
calcification and smooth muscle cell trans-differentiation.86,87 TGF-β1 is also upregulated in elastin specific calcification.88 It is known that TGF-β is sequestered by a
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matrix-associated protein called Latent TGF-β Binding Protein (LTBP) on elastin
fibers.89 A pro-inflammatory environment, abundant with proteolytic enzymes, releases
MMPs which cleave LTBPs thereby releasing active TGF-β1, which is not free to react
with cells causing several downstream effects. Chapter 3 provides some experimental
evidence of such downstream effects caused by TGF-β1 in vascular smooth muscle cells.

Figure 2.14: Schematic of regulation of TGF-β in normal and diseased arteries.
(1)Extracellular matrix microfibrils bind latent TGF-β, latency
associated peptide (LAP), LTBP. (2) MMP mediated degradation
releases TGF-β in the environment thereby activating it. (3) Free TGF-β
binds to its celluar receptor causing several downstream effects leading
to phenotypic changes such as osteogenesis, aneurysm, and mitral valve
prolapse. (adapted from Ramirez and Dietz90)
Runt related transcription factor-2 (RUNX-2)
RUNX-2 also known as core binding factor alpha -1 (CBFA-1) is a key
transcription factor associated with osteoblastic differentiation. RUNX-2 -/- mice exhibit
complete lack of osteoblasts and die soon after birth.91 RUNX-2 also plays an important
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role in expression of different bone markers genes needed for terminal differentiation and
maintenance of osteoblasts.92 Jono et al. showed that human aortic smooth muscle cells
respond to externally added phosphate concentrations in a dose dependent manner
increasing RUNX-2 and mineral deposition.93 We have previously shown in a series of
cell culture and animal experiments that RUNX-2 is strongly up-regulated in the process
of elastin calcification. When pure elastin is implanted sub-dermally in the back of rats,
they undergo severe calcification and exhibit typical bone proteins including RUNX-2.88
Alkaline phosphatase (ALP)
ALP is an important component of matrix vesicles in increasing the
orthophosphates required for the growth of the hydroxyapatite crystal. Hypophosphatasia
is a disease characterized by the lack of ALP causes severe malformation in bone.94 ALP
has been implicated in the process of vascular mineralization. Lomashvili and group
demonstrated that strips of normal aorta when cultured in vitro in the presence of ALP,
calcified to form rings of hydroxyapatite similar to those seen in diabetic patients. In
addition, they also showed that normal healthy aorta produced inhibitors of calcification
which were destroyed by ALP.95
Osteocalcin (OCN)
OCN is also known as bone gla protein contains 3 gla residues and is the most
commonly found non-collagenous bond extracellular matrix protein. OCN is almost
exclusively produced by osteoblasts and thus may serve as a useful marker for identifying
calcifying vascular cells. OCN-/- mice have increased bone density with normal
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resorption in female mice. However, ovariectomized 6-month-old animals, the mineral
content (mineral:matrix ratio) in the wild-type cortices increased from periosteum to
endosteum, whereas, in the knockout animals' bones, the mineral:matrix ratio was
constant. Ovariectomized knockout cortices had lower carbonate:phosphate ratios than
wild-type, and crystallite size and perfection resembled that in wild-type trabeculae, and
did not increase from periosteum to endosteum. These data provide evidence that
osteocalcin is required to stimulate bone mineral maturation.96
Osteopontin (OPN)
As per Vattikuti and Towler, diabetic MAC is initiated by the migratory adventitial
myofibroblasts population that respond to the osteopontin (OPN) production by smooth
muscle cells in diabetic conditions (Figure 2.15). Increased OPN production in diabetic
patients is a consistent observation83,97,98 and surgical resection of adventitia has shown
prevention of MAC in rat model.99
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Figure 2.15:Working model for diabetic vasculopathy.77
2.2.3.2 Role of hyperglycemia in MAC
Hyperglycemia (high glucose concentrations) is the hallmark of diabetes, which
in itself is benign, however, over long periods of circulation causes irreversible and
devastating damage to almost every tissue in the body. There are four different
mechanisms proposed to be working either independently or in tandem towards the
pathology of diabetes: 100
1) Increased flux through polyol pathway
2) Intracellular production of advanced glycation end products (AGE)
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3) PKC activation
4) Increased hexosamine pathway activity
Although all the four pathways will be discussed, the main focus of this
dissertation is the PKC activation and its implications in the pathobiology of diabetes.
Aldose reductase is an enzyme that normally reduces toxic aldehydes in the cells
to inactive alcohols, however under hyperglycemic conditions, aldose reductase converts
glucose to sorbitol, which later is oxidized to fructose. In the process, an essential
cofactor NADPH is consumed, which is also critical for maintenance of intracellular
oxidative stress. It has been shown that diabetic dogs treated with aldose reductase
inhibitor for 5 years prevented diabetes-induced defect in nerve conduction101 indicating
the significance of aldose reductase and sorbitol in the complication of diabetes.
AGEs are proteins or lipids that get glycated after being exposed to sugars. Over
time, as glucose circulates in the blood, it glycates the blood proteins (mainly albumin)
causing the formation of AGEs. AGE interacts with its receptor (RAGE) causing a
variety of microvascular complications. Generally, AGE crosslinks molecules in the
vascular matrix permanently altering cellular structure, and interacting with RAGEs on
cell surface altering the cellular functions.102
As glucose is metabolized by cells, diacyl glycerol (DAG) concentrations
increase, which is an important cofactor for several protein kinases (PKC) like – β, δ and
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α.103,104 When intercellular hyperglycemia is increased, the cellular PKC concentrations
increase which then activates several pathways leading to pathological consequences.
2.2.3.3

Treatment options

Currently there is no cure for MAC. However, treatment options for reversal of
calcification are being extensively investigated by researchers. The mineral deposited in
the arteries are crystals of hydroxyapatite which is a highly insoluble material.105
Treatment for MAC entails removal of hydroxyapatite from arteries which is a great
challenge. The first mode of action towards treatment is overall change in lifestyle like
change in diet, elimination of smoking, exercise and such. Since reversal of calcification
is faced with great challenges, most therapeutic options target prevention of progression
of calcification instead. Discussed below are some strategies towards calcification
therapy:
Chelation and demineralization therapy
Chelation therapy refers to the permanent removal of calcium phosphate crystals
using chemicals with a very strong affinity for calcium. Most commonly,
ethylenediamine tetraacetic acid (EDTA) combined with vitamins, trace elements and an
iron supplement is injected intravenously repeatedly throughout the course of
treatment.106 Chelation therapy has shown to be effective in the reversal of atherosclerotic
occlusive disease, and peripheral arterial disease (MAC).107,108 It has been argued as a
potentially valuable alternative in severe cases of MAC requiring amputation. Chelation
therapy was initially used as a treatment for lead poisoning and a chance observation was
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made where patients undergoing chelation therapy reported relief against angina
pectoris.109 Ever since its chance discovery, EDTA chelation therapy has been under
scrutiny as a use for anti-calcification therapy for MAC. However, the debate remains if
the benefits of chelation therapy outweigh its potentially severe side effects. A systematic
review was conducted in 2000 that summarized all clinical evidence for or against the
effectiveness of chelation therapy, which concluded that chelation therapy should be
considered obsolete due to complete lack of evidence for efficacy and its adverse side
effects.110
Vitamin K
Matrix gla protein (MGP) is a calcium binding protein that has glutamate residues
which are carboxylated post translation. This process is vitamin K dependent process.
Many of MGP’s protective roles are unknown; however, it appears that many of its vital
functions are dependent on the γ-carboxylation which is a vitamin K dependent process.
Thus vitamin K, which can increase γ-carboxylation might be effective in preventing
progression of calcification. Reversal of warfarin induced MAC has been observed when
rats were fed Vitamin K making this an important therapeutic strategy.111
Statins
Statins (hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors)
are a class of compounds, known to lower lipids by inhibiting the activity of HMG-CoA,
which is a key enzyme in cholesterol anabolism in the liver.112 Statins also exhibit
pleiotropic effects on vascular vessel walls that increase release of protective factors like
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eNOS and decrease pathological factors like MMP expression, interleukins production
platelet activity and oxidative stresses.112 Crisby et al. studied the effects of Pravastatin
24 patients with carotid artery stenosis. They found that Pravastatin significantly reduces
lipid content in the plaque area (16% decrease), decreases oxidized LDL
immunoreactivity

(7%

decrease),

reduces

MMP-2

and

increases

TIMP-1

immunoreactivity.113 Thus, the benefits of statins on vascular health are established.
Although the protective effects of statins on progressive coronary calcification in
atherosclerosis has been demonstrated, statins have shown to be ineffective in diabetic
and CKD patients with MAC.114 Since statins are believed to lower inflammatory
cytokines mediated by lipoprotein infiltration, it is possible that the pathology of medial
calcification which is primarily due to infiltration of macrophages independent of lipid
deposition is the reason for the ineffectiveness of statins in reducing calcification.
Apparently, calcification progresses most rapidly when the volumetric calcification
scores are low,115 therefore the best option for calcification treatment in terms of
regression or retarding progression with statins is during the early stages of the disease.
Estrogen
A strong association between gender and vascular calcification has been
observed. Especially post-menopausal women exhibit greater tendencies for vascular
calcification and osteoporotic disease. It has been shown that both men and women with
post-menopausal arterial calcification have lower serum estradiol levels with gender
controls.116 Additionally, women on hormone replacement therapy have reported lower
coronary artery calcium levels.117 However, the cardio-protective effects of hormone
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therapy is now under question. Participants in the HERS (heart and estrogen/progestin
replacement study) who were post-menopausal with coronary artery disease were treated
with estrogen and medroxyprogesterone. 4.1 years later, there was no difference in the
cardiovascular outcomes of patients treated with our without estrogen.118 On the contrary,
estrogen treated groups had more events in the first year, but fewer in years 4 and 5.
Calcium channel blockers
Calcium channel antagonists can be proved effective in reducing arterial calcium
deposition. Calcium channel blockers (CCB) have been studied extensively ever since the
pioneering work of Fleckenstein in demonstrating its anti-atherosclerotic effects.119 CCBs
like Amlodipine, Aranidipine, Clevidipine, Felodipine, Nifedipine, etc, have been tested
for the same. CCBs could prevent calcium overload in cells during atherogenesis in a
rabbit experimental model.120 However, the effect CCBs have on human arteries is
unknown. One long term morbidity and mortality clinical trial done with amlodipine
showed no benefit in the progression of arterial atherosclerotic lesions, however arterial
calcification was not examined.121
2.2.3.4

Animal models

Animal models mimic human pathology and serve as a good platform to (1) study
successive stages of the pathology providing insight about the mechanism and molecular
pathways underlying the pathology (2) to test new therapeutics on target pathologies.
Small animals like rodents serve as valid species for studying vascular diseases as they
are easy to manipulate, relatively cost-effective, have a short lifespan of about 2 years,
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resemble human physiology and metabolism, contain the same number of genes as the
human genome which are also highly conserved throughout mammalian species.122 There
are several rodent models for vascular calcification that mimics calcification with or
without the co-existence of atherosclerosis; however this literature review will deal only
with non-atherosclerotic arterial calcification, a characteristic of medial arterial
calcification.
A. Warfarin + vitamin D model
Administering warfarin to rats leads to increased levels of calcification throughout
the vasculature.123,124 Cerebral arteries, veins, and capillaries are not affected by this
model.123 It is believed that warfarin interferes with the γ-carboxylation of the matrix gla
protein (MGP) causing the excessive calcification in major arteries. MGP has an
important role in preventing arterial calcification. Because of the presence of gammacarboxyglutamic acid (gla) residues, it is thought to bind to hydroxyapatite, creating a
protein layer that inhibits further mineralization.123 It has been shown that the N-terminus
of MGP (with its 5 gla residues) is essential for MGP to bind to BMP-2.125 Thus, MGP
that is produced in the presence of warfarin is ineffective because of the lack of these
vitamin K-dependent modifications. Recently it has also been shown in juvenile rats that
vitamin D added to warfarin is highly synergistic to arterial calcification.126
B. Vitamin D3 and nicotine (VDN)
Upon delivering vitamin D3 and nicotine to young rats, a 20-35 –fold increase
was recorded in the calcium content of the aorta. This increase in calcification was also
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accompanied by subsequent stiffness in the aortic wall and systolic hypertension.127
Vitamin D has shown to increase alkaline phosphatase production while suppressing
expression of parathyroid hormone related peptide (PTHrp).128,129 In cell culture studies,
an inverse relationship between PTHrP and calcification has been demonstrated.128
Calcium deposition by the VDN model occurs preferentially on the internal elastic lamina
and other fibers leading destruction of elastin fibers of the artery. This clinical relevance
of this model lies in that there is a decrease in elastin-specific amino acids desmosine and
isodesmosine causing high concentration of these peptides in circulation.130 There is also
a strong negative correlation between the quantity of elastin-specific peptides and
calcium content, clearly suggesting that VDN treatment cause calcification and loss of
arterial compliance due to elastin degradation.
C. Genetically altered mice models
Several knock-out mice models of genes regulating bone formation have been
used for understanding the pathogenesis of arterial calcification. MGP-/- mice have
shown extensive calcification of the aorta, its branches, muscular arteries, elastic arteries,
and coronary arteries.131 MGP-/- mice do not survive past 2 months and die of vascular
rupture essentially due to calcified and severely brittle aorta. There are several other
genetic models for aortic calcification including osteoprotegrin-/-,132 smad6-/-,133
carbonic acid anhydrase isosyme-/-,134 fibrillin-1-/-,135 klotho-/-,136 ApoE-/-,137 and
LDLr-/-,138 the discussion of which is beyond the scope of this dissertation.
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D. Animal models of local calcification
All the above models for calcification induce systemic calcification throughout
the vascular tree. In addition, these models also cause calcification in the general organs.
For studying effects of drugs locally, local and site specific models of calcification can be
extremely valuable. To this end, there are two main models for studying calcification: (1)
subdermal rat model (2) calcium chloride injury model. The subdermal model involves
subdermal implantation of soft tissue (on which calcification needs to be evaluated) into
the back of juvenile rats. The implanted elastin undergoes calcification without any other
added factors. When pure elastin, for instance, is implanted sub-dermally, the
calcification observed histologically is identical to that visualized in calcified arteries.88
Similarly, Paule et al. have shown that when glutaraldehyde cross-linked prosthetic heart
valves when implanted subdermally into juvenile rats develop severe calcification on
both collagen and elastin fibers.139 Calcium chloride injury model on the other hand is a
circulatory model of vascular calcification. In this model, adult rat aorta is exposed and a
localized portion of the aorta is perivascularly treated with calcium chloride. This acute
insult to the artery induces an accelerated and extensive calcification accompanied by
intense inflammation and severe elastin degradation.140
2.2.4

Abdominal aortic aneurysms

Abdominal aortic aneurysm (AAA) is a local dilatation of the aorta with respect
to the original arterial size or the adjacent area of the artery (Figure 2.16). As a
convention, arterial diameter greater than 1.5 times the normal size or greater than 3 cm
in diameter, is considered aneurysmal, although the definition may vary somewhat by age
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and body surface area.1 AAA is a pathological condition characterized by structural
weakening, wall thinning, arterial remodeling, luminal expansion, intra-luminal thrombus
and trans-mural inflammation. Aneurysms can be classified based on the location they
are found like cranial aneurysms, thoracic aortic aneurysms, thoraco-abdominal
aneurysms, abdominal aortic aneurysms, peripheral artery aneurysms (popliteal artery
aneurysm), visceral aneurysm (hepatic, spleen). Although they have different etiology,
risk factors and clinical presentations, local dilatation in the vessel wall remains a
common feature. Abdominal aortic aneurysm (AAA) will be the primary focus of this
literature review.

Figure 2.16:Ballooning of the abdominal aorta 141
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Based on the shape (Figure 2.17), AAA can be fusiform (the weakened portion is
a near symmetric bulge), saccular (the weakened portion is an asymmetrical blister-like
bulge) or pseudo-aneurysm (false aneurysm which develops only around the arterial
wall).

Figure 2.17: Types of AAA142
A. Epidemiology
AAA is 10 fold more commonly present in men than in women in an age range of
65-75 years.143 Arterial occlusive diseases, however, almost has a similar male: female
ratio. The incidence of AAA reported has increased in the last couple of decades due to
increased smoking, poor life-style, ageing of population and improvements in diagnostic
and screening techniques.
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A. Risk factors
Age: the prevalence of acquired AAA under the age of 60 is almost insignificant.
Screening studies by ultra-sonography have shown 8.8% prevalence of AAA in people
over 60 years of age; 88% of these were 3.5 cm or less.144
Smoking: Cigarette smoking is shown to be the biggest environmental risk factor for
AAA.145 The smoking and AAA association is four times higher in smokers than in nonsmokers. Also there is direct positive correlation between AAA development and the
number of smoking years, which decreases significantly after quitting smoking.146
Race and gender: AAA development has an evident race and gender bias with Caucasian
men having twice as much as propensity of developing AAA, although the trend is
reversed in atherosclerosis.147 Occurrence of AAA is four times greater in men than in
women.148
Hypertension: According to the AHA, there is not significant relationship between
hypertension and AAA prevalence149, however, the prevalence of aneurysms were higher
in patients treated for hypertension. The exact association between the two is yet to be
determined. Most probable reason for increased aneurysms may be due to the increased
stress on arteries in hypertension.

44

A. Clinical manifestations
Un-ruptured AAAs
AAAs are usually asymptomatic until rupture and early aneurysms are mostly
detected accidently during an extensive vascular examination. AAAs develop at an
exceedingly slow but steady rate of 1 cm/year, displaying very few symptoms, thereby
making detection impossible.150 Once detected, the patients are monitored once every six
months for the increase in the arterial diameter. Medical intervention becomes necessary
when the arterial diameter is more than 5.5 cm or if the rate of progression is more than 1
cm/year (Figure 2.18). Sometimes, AAAs are discovered in patients as a result of distal
thrombotic/athero embolism. This is called disseminated intravascular coagulation (DIC),
i.e., that is embolism due to dissociations of plaque or thrombus.
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Figure 2.18:A large AAA before surgical repair151
Aboulafia and Aboulafia conducted a study of 67 patients of which only 2
patients had DIC.152 In both instances, the coagulation was resolved post-surgery. The
only symptom of an un-ruptured AAA is chronic lower back and abdomen pain, which
can often be ignored by the patient. The pain occurs mainly due to direct pressure on
adjacent tissues and its distention. Physical examination may also reveal a pulsatile and
expansive mass right above the iliac bifurcation.
Ruptured AAAs

Figure 2.19: AAA rupture into the retro-peritonial space.153
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When left undiagnosed, the rupture of an AAA is indicated by the onset of an
excruciating pain in mid/lower abdomen and presence of palpation in abdominal mass.
Rupture can be of 2 types: antero-lateral rupture, which almost always leads to
exsanguinations and death, whereas, retroperitoneal rupture (Figure 2.19), which is more
contained and the wall break is temporary sealed till surgical intervention.154
B. Classical features and pathobiology of AAA
The gross characterization of abdominal aortic aneurysms include locally dilated
aorta, atheromatous plaque deposition and mural thrombosis, whereas typical histological
characterization include trans-mural inflammation, increased pro-inflammatory and
immune markers, extensive local proteolytic activity, apoptosis, local oxidative-stresses
and neovascularization. In addition, genetic predisposition and certain infection can
increase the propensity of AAA development and progression. Figure 2.20 gives a brief
description of the events in AAA pathology. To date, the exact etiology of AAA is
unknown and AAA has been established as a local disease with the interplay of multiple
factors as discussed below.
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Figure 2.20: Schematic describing the events in AAA pathology. Known risk
factors (I), leads to recruitment of leukocytes into the aortic media
(II), macrophage activation, and production of proinflammatory
molecules (III). Macrophages also produce proenzyme forms of
MMPs (pro-MMPs) (IV), which are activated in the extracellular
space (V). TIMPs may neutralize MMP activity (VI), but this appears
insufficient to prevent degradation of structural matrix proteins(VII).
Over a period of years, elastin degradation, cyclic strain, and elevated
wall tension bring about progressive aortic dilatation (VIII). Collagen
degradation further weakens the aortic wall (IX); apoptosis and
cellular senescence cause SMC depletion (X), and interstitial collagen
appears disorganized (XI). Aneurysm tissues exhibit infiltration by T
cells, B lymphocytes, plasma cells and local deposition of
immunoglobulins, reflecting a cellular and humoral immune response
(XII).EDPs, elastin degradation peptides; MPh, macrophages; PGs,
prostaglandins; ROS, reactive oxygen species.155
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C. Matrix changes and luminal expansion: Role of matrix degrading
proteinases
Proteinases or proteases, as the name suggests, are a class of enzymes that
degrade a whole array of proteins. Proteases are classified into six major divisions based
on the peptides they cleave. This includes serine proteases, cysteine proteases, aspartate
proteases, threonine proteases, glutamic acid proteases and matrix metalloproteases.
Abdominal aortic aneurysms are associated with a significant loss of matrix protein
integrity (Figure 2.21) and tissue remodeling which alters the native mechanics of the
artery, exposing it to increasing hemodynamic load and abnormal wall stresses.

Figure 2.21: An aneurysmal wall so thin that a ruler can be read
through the wall 156
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D. Matrix metalloproteinases (MMP)- MMP-1,2,9,12
Of particular interest are the class of Matrix Metalloproteases (MMPs) that are
known to degrade insoluble matrix proteins like collagen and elastin. Although elastin is
an insoluble protein resistant to most proteases, certain MMPs and elastases are potent in
degrading elastin fibers. Until date about 20 different MMPs have been identified each
one of them acting on one or more different types of matrix proteins. MMP-1 was the
first identified MMPs isolated from fibroblasts. Welgus and colleagues were one of the
first groups to identify the specificity of MMP-1 (collagenase) isolated from human skin
fibroblasts on the degradation of collagen type1.157 Their findings indicated that
approximately 25 molecules of collagen are degraded per molecule of MMP-1. Only 10%
of the collagen molecules are accessible for initial degradation, exclusively within their
triple helix domains, the remainder 90% become prone to degradation only after the
initial catalytic degradation. MMP-1 is physiologically found in fibroblasts, dermal cells,
keratinocytes and inflammatory cells, which mark its involvement in cell proliferation,
wound repair, and matrix remodeling. However, excessive localization of MMP-1 in the
arterial tissues can prove damaging. Irazarry et al. demonstrated the localization of MMP1 in the adventitia of eight AAA patients’ aorta, which was almost undetectable in normal
infra-renal aorta.158
MMP-2 (a 72-kDa protein) and MMP-9 (a 95-kDa protein), commonly known as
gelatinases, exhibit specificity for collagen type IV. In the recent years both MMP-2 and
MMP-9 have shown to be associated with the lysis of intact elastin fibers. Senior et al.
showed that both MMP-2 and MMP-9 have a high ability to degrade Kappa-elastin in an
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in-vitro system. MMP-9 especially has a 30% higher elastin degradation activity
compared to human leukocyte elastase.159 Both these gelatinases have been shown to
degrade type IV collagen which is found in the basement membrane, in addition to elastin
degradation. MMP-9 has been identified in abundance in human aneurysmal adventitia.
Thompson et al. indicated almost eight-fold increase in the activity of MMP-9 in
aneurysmal tissue compared to healthy tissues.160 Furthermore, they indicated an eightfold greater activity of the natural inhibitors of MMP-9, tissue inhibitors of matrix
metalloproteinase-1 (TIMP-1), in the diseased tissue. This indicates the physiological
homeostatic response to elevated MMP-9 levels; however, their successful interaction at
the particular site is questionable. Pyo et al. used MMP-9-/- mice to investigate the role of
MMP-9 in AAA formation.161 They observed that MMP-9 gene knock out suppresses
AAA formation despite the presence of macrophage infiltrate. This study led researchers
to believe that a single MMP-9 gene is sufficient to cause the disease, at least in the
mouse model. Longo et al. showed in their experiments that neither MMP-9-/- nor MMP2-/- mice develop aneurysms, whereas wild type mice do.162 This indicated to the fact that
MMP-2 and MMP-9 work in concert and have complementary role in the pathogenesis of
AAA. However, this understanding was recently challenged by Xiong et al.163 They
harvested macrophages from MMP-9-/- and MMP-2-/- mice and demonstrated that those
macrophages degraded similar quantities of elastin in vitro as the wild-type macrophages.
Thus, it appears from their studies that MMP-9 and MMP-2 may be indirectly influencing
disease development. Some researchers believe that the frequency of rupture is directly
related to proteolytic activity in the tissue. Freestone and colleagues indicated that small
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aneurysms (4-5cm) had higher MMP-2 activity whereas larger aneurysms (>5cm) mainly
consisted of MMP-9.164 Although MMP activity is seen in aneurysms, which cells secrete
these enzymes is still investigated. One of the sources may be polymorphonuclear
leukocytes (PMNs). AAA is almost always associated with severe atherosclerosis and
thrombosis in humans. The blood continues to flow through the mural thrombus.
Fontaine et al showed the presence of PMNs at the luminal end of the thrombus along
with a strong activity of MMP-9. This suggests that degranulation of these PMNs can
potentially release MMP-9 around the thrombus.165 MMP-2 activity is shown to be
several fold higher in AAA tissues compared to normal or any other diseased tissue.166
Smooth muscle cells constitutively produce MMP-2, however this production is elevated
during pathological conditions.
Human macrophage elastase, also known as MMP-12, is a 22-kDa proteinase that
was first identified in the peritoneal cavity of mice. This work also confirmed the ability
of MMP-12 to efficiently degrade insoluble elastin.167 MMP-12 is usually not evident in
normal tissues, however, Curci et al. showed an eight time increased MMP-12 activity in
aneurysmal aortas compared to normal arteries. They also showed macrophage colocalization with MMP-12.168 Overall, MMPs are either secreted by inflammatory cells or
native SMCs may take part in ECM degradation in aneurysms.
E. Diagnosis of AAA
Currently there are only a very few imaging techniques that are used to detect and
monitor AAAs.
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Ultra-sonography is currently the safest, easiest and most economic examination
for the diagnosis of AAAs. It can be used as the initial assessment or as the follow-up
surveillance. Ultrasound is reported to have a sensitivity of 99.99% for AAA detection
with anterior-posterior diameter measurements more reproducible than the transverse
diameter.169 Ultrasound also gives a good definition of AAA associated abnormalities
like intra-luminal thrombus, aortic dissections, extent of lesions, etc. Ultrasound
definitely is the safest and easiest way of measuring luminal expansion, but this technique
has certain limitations. Sonography can become difficult and imprecise with obese
patients and with those with abundant bowel gas. It is the preferred mode of detection for
initial assessment and monitoring, however once the diameter increases enough for
medical intervention, a CT is performed to determine what kind of repair is preferable.
Computed tomography accurately demonstrates the size and extent of AAA and
also detects thrombus (crescent sign) effectively. CT can also be used to visualize the
retroperitoneum thus allowing the detection of abnormalities and complications like
aneurysmal leaks, fibrosis and ureteral obstruction. Ct is the preferred detection method
after surgical repair. One drawback of CT includes exposing the patients to ionizing
radiation.
Magnetic resonance imaging (MRI) demonstrates features without the need for a
contrasting agent. MRI is completely non-invasive.
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Angiography is used to evaluate the state of the renal arteries and other smaller,
but vital arteries in AAA patients. This method is especially important after an
endovascular repair to ensure the optimal positioning of the graft.
2.2.4.1

Current treatment options

Once an aneurysm has been detected (>3 cm luminal diameter), it is monitored
once every six months. Arterial diameter more than 5-5.5 cm or a rate of progression
more than 1 cm/year often needs surgical intervention. Currently there are two different
methods to manage AAAs in patients- an open repair or an endovascular approach.
A. Open repair
Aneurysmectomy is the most standard procedure for AAA treatment. This
procedure involves a long midline incision or a wide transverse incision of the abdomen.
Once the peritoneum is exposed, the neck of the aneurysm is identified and clamped
using surgical hemostats. The weakened aorta is then excluded from circulation and a
synthetic mesh is sutured to the normal portion of the aorta (Figure 2.22). The upper
anastomosis is always end-to-end type and the distal anastomosis depends of the extent of
AAA. The distal end of the graft can be sutured the aortic bifurcation, iliac bifurcations
or the femoral arteries. The native diseased aortic wall is then sewn back. A
retroperitoneal approach of repair is recommended for certain patients with pulmonary
diseases. In this case, the patient is made to lie slightly tilted to the right side and the
incision is made from right side of the belly to the supra-umbilicus region. Accessibility
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of intraperitoneum and right iliac arteries can pose as a challenge to surgeons in this
particular approach.170

Figure 2.22: Open surgical repair171
Since the first open repair performed in 1952, significant advances have been
made in pre-operative and post-operative care to reduce mortality rates. The mortality
rates for elective open repair as low as 5%.172 This procedure also has a long term
durability and majority of the patients do not experience any noteworthy graft-related
complications for the rest of their lives.173 However, such an invasive procedure may be
unfit for a substantial number of aged patients with co-morbidities. In addition, some
patients who undergo distal anastomosis in the femoral arteries tend to develop
infections. Open surgery may in some cases also cause myocardial infarction, renal
failure or coronary artery disease.174 This procedure also has post-operative recovery
rates that take upto 3 months of more. In a very interesting and preliminary study, Coggia
and group have described a total laparoscopic procedure for AAA tissue repair.
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Laparoscopy evidently is a minimally invasive procedure with reduced pain and surgical
trauma, however, a procedure as complex as described requires experience and further
assessment.175
B. Endovascular repair
In 1991, Parodi et al introduced an endovascular technique for treating abdominal
aortic aneurysm wherein a woven polyester or Dacron graft, mounted on a self-expanding
stent is deployed within the vessel, at the site of aneurysm.176 The basic design of a
endoluminal stent-graft consist of a tubular synthetic graft that is supported by stents
along the entire length. This technique is commonly referred to as endovascular
aneurysm repair (EVAR). An interventional radiologist and a vascular surgeon perform
the procedure. Two incisions are made in the groin region near both the femoral arteries
to allow passage of the guide wire, sheath and crimped stent-graft. Using X-ray the
catheter delivers the graft to the site of AAA. On identification of the proper position, the
graft is deployed at the site (Figure 2.23). The tip of the catheter has a balloon which is
inflated once the right position is located. This inflation, secures the proximal end of the
graft to the healthy artery. The ends have anchors/hooks/barbs that facilitate the secure
positioning of the stent-graft. Removal of the introducer system restores blood flow
through the tubular stent-graft thereby relieving the wall stresses from the weakened
aorta. Post-deployment, the aneurysmal sac wraps around the graft.
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171

Figure 2.23:Endovascular repair

EVAR may not be practical for all patients. The feasibility mainly depends on
anatomical factors of the patient. A proximal neck shorter than 15 mm is widely accepted
as a contraindication for EVAR. Diameter, length, angulations, tortuosity, calcification
and thrombus in the neck region are the most frequent causes of exclusions from
EVAR.177
Although EVAR is an attractive option for patients with significant co-morbidities
and age, long-term cardiac, pulmonary and graft-related complications can occur in
EVARs. Flow of blood into the diseased sac eliminated from circulation, referred to as
‘endoleaks’, is one of the most common complications of EVAR and occurs in 24% of
the patients undergoing EVAR.178 Post procedural leakage, if left un-attended, can cause
fatal ruptures. Endoleaks are broadly categorized into four different types: 174
Type I: inadequate seal at the proximal or distal ends of the grafts leading to
leakage
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Type II: blood flow from collateral arteries into the aneurysmal sac
Type III: Leakage from the graft modules due to compromised graft integrity
Type IV: porous graft material
Endotension refers to the progression of AAA and enlargement of arterial wall
without any evident endoleaks into the sac.179 It is a rare but a fatal complication seen in
patients with EVAR. The exact reasons for the luminal expansion are unknown, however
some evidence has been shown to believe the transmission of pressure into the sac
through an attachment defect or through a thrombus, that seals an endoleak.180
Device migration is yet another EVAR associated issue that is reported in 4% of
the patients.181 Zarins et al. noted that patients whose length of neck covered by the stent
was less than 10mm, had a greater chance of graft migration.182 They pointed out that the
fixation distance from the renal arteries was a predictor for migration. Thus, poor
imaging at the time of graft deployment is one of the major causes for migration. Graft
migration may be minimized by deployment of the graft right below the renal arteries.
In a study by Jacobs and group, 10% of all the grafts used had incidents of
fracture within the first 4 years of implantation.183 Fracture of stents may lead to type II
endoleaks. In the first few years of EVAR, occlusions in the stent-graft limbs led to distal
emboli formation. Infection, dissection and angulation are some other complications that
may arise in endografts. Patients are generally kept under surveillance if any of these
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complications are detected, which is usually followed by a re-intervention or an open
surgical repair.
2.2.4.2

Pharmacological strategies for AAA repair

Currently there are no well-defined pharmacological therapies for the treatment of
AAA. Once an aneurysm is detected, clinicians wait until surgical intervention is
necessary. Therefore, early detection of small aneurysms followed by therapeutics that
can inhibit further enlargement or regress already enlarged aneurysms will be a
significant advancement in improving patients’ lives. In this context three main
approaches have been identified: (1) inhibition of further tissue damage and expansion
(2) stabilization of the ECM and rendering it resistant to proteolytic damage (3)
regression of aneurysmal tissue by regenerating the fundamental ECM proteins
Statins
Several animal as well as clinical studies have attempted to investigate the effect
on statins on the progression of abdominal aortic aneurysms. Steinmetz et al. proved the
suppression of development of AAA when treated with Simvastatin in wild type as well
as ApoE-/- mice perfused with porcine elastase.184 Subcutaneous delivery of Simvastatin
reduced the incidence of AAA formation in wild type mice by 33% and in hyperlipidimic
mice by 30%. 21% and 26% reduction in aortic diameter was noted in wild type and
hyperlipidimic mice respectively. The statin treated mice also showed preservation of
smooth muscle alpha actin in the medial layers. Relative MMP-9 gene expression went
down 20 fold in the Simvastatin group compared to the vehicle treated controls, and
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TIMP-1 mRNA expression was 9-fold higher in the drug treated group compared to
vehicle control. In another study, Wistar rats perfused with porcine elastase, received
Simvastatin daily in water and systemic effects of the drug was studied on the AAA
development.185 Arterial diameter was significantly less in Simvastatin group compared
to control group (30% reduction) and statin groups reduced the MMP-9 expression by
half. A complete gene microarray analysis indicated the down-regulation of genes
responsible for inflammation, immune function and ECM remodeling. Organ culture of
human infra-renal AAA has also shown around 50% reduction in total MMP-9 activity
when treated with Cerivastatin for 48 hours.186 In a clinical trial consisting of 108 men
and 22 women diagnosed with AAA, only 5% of the patients treated with statins died,
whereas 16% of the patients given placebo died due to rupture.187 Evans et al. studied the
effect of pre-operative administration of Simvastatin in 21 patients scheduled to undergo
open surgical repair and showed a 40% reduction in MMP-9 activity in the excised
tissue.188 Schouten and colleagues also made similar findings where patients undergoing
statin therapy had a 1.16 cm/year slower growth than patients without treatment.189
Despite all these clinical results, in a systematic meta-analysis done by Twine and
Williams, 12 human cohort studies with 11,933 patients did not show any significant
reduction in 30-day post-treatment mortality rates. No significant difference was noted in
the expansion of AAA either.190 However, the 1, 2, 5 years post-operative survival rates
were higher in statin treated patients. Thus, the ACC/AHA guidelines for AAA treatment
do not recommend statin therapy in small AAA due to lack of substantial evidence in
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randomized trials.191 The reduction in mortality rates after statin therapy is probably
attributed to the better vascular health due the lipid lowering ability of statins.
β-blockers
Beta androgenic blockers are a class of drugs that are known to benefit cardiac
health by blocking the action of endogenous catecholamines like epinephrine and norepinephrine, which are stress hormones that mediate the ‘flight or fight’ response. One
specific b-blocker, propranolol, has been extensively studied for AAA treatment. Studies
show that propranolol when delivered to aneurysm prone turkeys/ blotchy mice, result in
150% increase in insoluble elastin and 54% increase in insoluble collagen, suggesting the
direct effect of the drug on cross linking matrix proteins.192,193 Slaiby et al. also
demonstrated the AAA inhibitory effects of propranolol in a hypertensive rat model.
They created AAA by perfusing elastase in genetically hypertensive wistar-kyoto rats and
delivered propranolol subcutaneously for 14 days to find a 50% in arterial diameter in
normotensive rats and a 25% in hypertensive rats.18,194 Two retrospective cohort studies
by Gadowski et al195 and Leach et al196 showed a 60% reduction in the aortic diameter
expansion rates when treated with androgenic beta- blockers. These promising results led
to the randomized trial for propranolol in 548 small aneurysm patients. This clinical trial
indicated the complete failure of propranolol to prevent or inhibit AAA progression in
patients.197 There was no significant difference is rate of arterial expansion and mortality
in the groups treated with and without propranolol. On the contrary, propranolol caused
poor tolerance in patients leading to poor standards of life and subsequent discontinuation
of medication. In another clinical study by Lindholt et al. 60% of AAA patients receiving
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propranolol dropped out of the study because of dyspnea.198 During follow-up, 16.7%
patients in the beta-blocker group died compared to 4.2% in the placebo group. These
findings led the investigators to terminate the study after 2 years. Thus current clinical
status of the use of beta-blockers, at least propranolol, is of debatable efficacy based on
the high rate of adverse effects.
ACE inhibitors and ATII receptor inhibitors (sartans)
Angiotensin II is one of the key hormones in the body that regulates blood
pressure by vasoconstriction and release of aldosterone from the adrenal cortex.
Angiotensin is implicated in several cardiovascular diseases including hypertension,
atherosclerosis, and restenosis after angioplasty and heart failure. However, the
mechanisms by which angiotensin functions to contribute to the pathology of the diseases
are not well defined. Daugherty et al. described the probable role of angiotensin II in
AAA development in a hyperlipidimic mouse model.199,200 Angiotensin-I converting
enzyme (ACE) plays a significant role in increasing blood pressure by two main
mechanisms: catalyzing the conversion of angiotensin I to angiotensin II and by
degrading bradykinin, a potent vasodilator. 201 Also Angiotensin II binds to two types of
receptors, AT1 and AT2, both of which have equal affinity for angiotensin II. Therefore,
inhibition of ACE and ATR (angiotensin receptor) are attractive pharmacological
approaches to inhibit vascular diseases. In the Angiotensin II/ ApoE-/- AAA model,
Inoue et al. subcutaneously delivered a ACE inhibitor (Lisinopril) and ATR inhibitor
(Candesartan) and demonstrated a 18% and 23% reduction in the aortic diameter after 40
weeks.202 Liao et al. confirmed similar results in a rat elastase model, with ACE inhibitor
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Enalapril preventing increase in arterial diameter by 88%.203 Without restraining
inflammation, the inhibitors seemed to preserve the medial structure. Hackam and
colleagues conducted a human cohort study to investigate the effects of ACE inhibitors
on 3426 patients.204 They showed that those patients who received the treatment for 1.25
years were more protected to rupture risk than patients not receiving ACE inhibitors. To
corroborate this finding, they showed that patients who initially received ACE inhibitors
for one year and discontinued its use for three months had increased rate of rupture. This
study has certain shortcomings like a potential bias of healthier patients receiving ACE
inhibitor treatment. Besides, Hackam did not address as to how discontinuation increased
the propensity of rupture as compared to the patients not receiving the treatment. In a
very recent retrospective cohort study, Sweeting et al. demonstrated a completely
opposite finding.205 In this study, 169 patients that were on ACE inhibitors had a
significantly higher aneurysm progression rate compared to patients without treatment
(0.33 cm/year Vs 0.27 cm/year). This necessitates an elaborate randomized trial to
elucidate the efficacy of ACE on the AAA patients.
A lot of ongoing research strives to block ATR (receptors for angiotensin II) to
prevent the progression of AAAs. Losartan is an AT I inhibitor which has shown
promising results in animal models. Daugherty et al. indicated that subcutaneous delivery
of Losartan completely inhibited the formation of AAA with 0% incidence, whereas
delivery of a synthetic inhibitor for AT II receptor dramatically increased the blood
pressure, incidence, complexity and atherosclerotic lesion in the AAA.206 This study
indicates the protective role of AT II receptor and the probably efficacy of Losartan as an
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AAA drug. Fujiwara et al further exemplified the potential of Valsartan, another AT I
inhibitor, as a therapeutic for AAA.207 Valsartan inhibited macrophage infiltration
followed by reduced MMP-2,3,9 and 12 expression and reduced elastin destruction.
Further investigation is required to determine the efficacy of ATRs in AAAs in human
populations.
Tetracyclines
Tetracyclines non-specifically inhibit MMP activity and inhibit neutrophil
activation. The role of one particular tetracycline, Doxycycline, has been extensively
studied in aneurysm tissue repair. Sho et al. showed that both systemic and local
periaortic infusion of Doxycycline in rat-elastase model of AAA, significantly reduced
AAA diameter, macrophage infiltration and SMC proliferation.20 Local Doxycycline
delivery and systemic subcutaneous delivery resulted in a 35.2% and 45.9% aortic
diameter reduction respectively. However, elastic lamellae preservation was not apparent
in this study. In the Angiotensin II model of AAA, Manning et al demonstrated a
dramatic reduction in the incidence of AAA formation (35% in Dox group Vs 86% in
control group) in the mice groups receiving oral Doxycycline.208 A notable point is that
the mice received Doxycycline a week before the infusion of Angiotensin II thereby
implying a protective role of the drug. Curci et al. demonstrated a 2.5 fold reduction in
MMP-9 activity and 5.5-fold reduction in mRNA compared to control group in eight
patients treated with Doxycycline one week before elective repair.209 Despite the
promising results in animal studies, a population study by Baxter et al. did not show any
significant contribution of Doxycycline in AAA repair. 36 AAA patients were monitored
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for six months to evaluate the effect of Doxycycline. 92% of the patients completed the
six-month program; however, the remainder patients discontinued the drug due to several
side effects including cutaneous photosensitive reactions, tooth discoloration, gastrointestinal symptoms and yeast infection.210 Forty-seven percentages of the patients
showed almost 50% reduction in plasma MMP-9 levels after 6 months, however no
change in aortic diameter was recorded in the patients before and after the treatment. Due
to the side effects of systemic Doxycycline delivery, Bartoli et al attempted to study the
local effects of Doxycycline on AAA progression. They showed that local periadventitial
delivery of Doxycycline was as effective as systemic delivery, even at doses 100-fold
lower than that used in systemic delivery. Thus localized delivery of Doxycycline holds a
promising future in AAA repair, perhaps as a pharmacological adjunct to EVAR.
Anti-platelet therapy
As discussed in section 2.3, the past few years have drawn the attention of
researchers to investigate the role of ILT in AAA. Anti-platelet therapy can potentially
mitigate the consequences of thrombosis in the development and progression of AAA.
Dai et al. showed the effect of a synthetic inhibitor (AZD6140) of a platelet receptor
(P2Y12), on inhibition of platelet activation and prevention of AAA progression in
transplantation model in rats.211 AZD6140 inhibited the aggregation and activation of
platelets until 10 days, reduction in thrombus development and platelet CD41 expression.
Subsequently, a 28% reduction in arterial diameter was observed at the end of 42 days.
Karlsson and colleagues investigated the effect of an anti-platelet agent, acetylsalicylic
acid (asprin), on 247 AAA patients.212 Additionally patients were given statins as an anti-
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inflammatory. The groups that received aspirin and statins had a significantly reduced
expansion rate compared to the placebo group (0.14 cm/year Vs 0.27 cm/year). It is
unclear if the observed results are due to the effects of statins or aspirin or the synergistic
effect of both. Although anti- platelet therapy is not officially recommended by the AHA
guidelines191, these drugs can potentially improve life expectancy in AAA patients.
Anti-oxidant therapy- Vitamin E
Since local oxidative stress is high in aneurysmal tissue, reduction of oxidative
stress can prove to be a potential therapy for AAA repair. Gavrila et al, showed for the
first time, that dietary intake of Vitamin E, in the hyperlipidimic Angiotensin II mice
model, decreases aortic diameter by 24%, reduces elastin fragmentation and fatal rupture
by 44% and diminishes macrophage infiltration.213 Vitamin E had no effect on blood
pressure, MMP activity and serum lipid profile in the animals. As of date, the effect of
Vitamin E has not been tested on patients with AAAs. However, a randomized trial
conducted to see the effect of Vitamin E on lung cancer patients with a history of
smoking, indicated no significant difference in AAA rupture and repair between the
control and Vitamin E groups.214 Since AAA repair was not the intention of this trial,
there is no record of the true incidence and rate of development. Thus, the benefits from
vitamin E in the context of AAA repair are yet to be determined. However, key points to
be noted are, the dose of Vitamin E given to patients was a lot lesser than in rodent model
(50IU/day in humans Vs 2IU/g of diet in mice). Additionally, the mice were fed Vitamin
E a week before Angiotensin was delivered, suggesting the preventive role of Vitamin E.
Most importantly, humans need supplementary Vitamin C to scavenge the pro-oxidant
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tocopherols that Vitamin E yields (which was not provided in the human trials), whereas
mice can synthesize Vitamin C de novo from L-gulono-ɣ-lactone oxidase, an enzyme
that humans lack.215 Thus further trials are needed to elucidate the beneficial effect of
tocopherols like Vitamin E in prevention/treatment of AAAs.
Anti-inflammatory agents
Since inflammation is a prominent feature of AAA, scientists have tried to
dampen inflammation using anti-inflammatory agents to study its effect on AAA. As
discussed earlier, cyclooxegenase (COX) converted to prostaglandin, mediates
inflammation and MMP production. In a case control study, Walton et al. showed that 15
patients taking Non-steroidal anti-inflammatory drugs (NSAIDs), had a 50% retardation
in AAA growth rate compared to 63 control patients that were not on NSAIDs.216
Inhibition of COX-2 with Celecoxib decreased the incidence and severity of AAA
formation in the Angiotensin-II mice model (drug delivered a week before Angiotensin
infusion) but no difference was noted with inhibition of COX-1.217 In addition, COX-2
knockout mice were completely resistant to Angiotensin induced AAA in mice.218
Using the elastase induced AAA in a rat model, Dobrin et al. demonstrated the
inhibitory effects of prednisolone and cyclosporine in AAA progression. Nine days post
perfusion, drug treated rats had a 33% reduced arterial diameter compared to the control
groups. Cellular infiltration was dramatically reduced in the medial region of the drug
treated rats compared to the control group by day 14.219
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Blocking of pro-inflammatory cytokine TNF-α220 and MCP-1 inhibits the
progression of AAA in rat elastase model, however blocking receptors for IL-1 shows no
change in post-perfusion arterial diameter.220
2.2.4.3

Animal models for AAA

Over the years researchers have developed several animal models that somewhat
simulate the human AAA pathology in terms of matrix degradation, inflammatory
infiltration, atherosclerosis and mural thrombus formation. These animal models are
discussed below. Every model has distinct advantages as well as disadvantages over
others and none of the models completely mimic the true human aneurysms formation.
A. Elastase perfusion model
AAA induction in the rat model by perfusion of porcine elastase was first
described by Anidjar et al. in 1990.221 A midline incision was made on anesthetized rats
and the abdominal aorta was exposed. After clamping the infra-renal and supra-iliac
regions of the aorta, the artery was catheterized and perfused with porcine elastase for 2
hours. This intra-luminal perfusion leads to an aortic dilation of 100-120% in a period of
2-4 weeks. This is one of the most frequently used animal models to investigate the
mechanisms of AAA pathology and to deliver therapeutics. The elastase model is
characterized by chronic infiltration of mononuclear leukocytes leading to extensive
elastin fragmentation and luminal expansion, all of which are key features of human
AAA. Although elastase is delivered exogenously, after a week several endogenous
proteases like MMPs have been detected in this model.222 The major drawbacks of this
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model include the lack of atheromatous plaque and mural thrombus formation. Besides,
this procedure involves a very challenging micro-surgery, lacks calcification of arteries
and causes significant necrosis due to prolonged exposure to aesthesia. Nackman et al.
also showed that this model induces adventitial angiogenesis, as observed in human
AAA.223 To elucidate the involvement of specific factors responsible for AAA formation,
the elastase model was adopted in genetically deficient mice. For instance, Pyo et al.
showed that MMP-9 knock-out mice do not develop AAA in the elastase model
illustrating the role of MMP-9 in AAA formation.161 Additionally, MMP-12 knock-out
mice do not contribute in any protective role against AAA development, at least in the
elastase perfusion model. MMP-9 and MMP-12 double knock-out mice however, enjoy
greater preservation of aorta compared to other groups.
B. Calcium chloride model
The calcium chloride injury model was first established in a rabbit carotid
aneurysm model by Gertz et al.140 By then, the presence of calcific deposits in
atherosclerotic plaque was well established. Gertz and group showed the link between
calcification and aneurysm formation by peri-adventitially applying calcium chloride to
carotid arteries. Later Chiou et al. adopted the same method of peri-adventitial calcium
chloride application to develop AAAs in a mouse model. They described the presence of
inflammatory infiltrates and elastin fragmentation which contributed to the AAA
formation.224 Similarly Isenburg et al. described the increase in MMP-2 and MMP-9
activity in the aortas exposed to calcium chloride in a rat model.225 They also detected
calcific deposits in the aneurysmal arteries, which is a common feature in human AAA.
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C. Genetically altered mice models
One of the latest models of AAA have been developed by Daugherty et al.199
They discovered this model based on the role of Angiotensin II in promoting
atherogenesis and vessel wall inflammation. They showed that subcutaneous delivery of
Angiotensin II via osmotic mini-pumps into ApolipoproteinE (ApoE) knock-out mice for
upto one month led to the development severe atherosclerotic lesions as well as massive
aneurysms throughout the vasculature. The atherosclerotic lesions had abundant
macrophages and lymphocytes. Although Angiotensin is a potent hypertensive agent, no
significant change in blood pressure was detected in their studies. The most interesting
result of this study was that the aneurysmal tissue had all the characteristics of human
AAA tissues, which no other animal model currently has to offer. The site of aneurysm
was characterized by medial fragmentation, luminal expansion, thrombus formation,
neovascularization and extensive inflammation. Very similar observations were also
made by subcutaneously delivering Angiotensin II to Low density lipo-protein receptor
(LDLR) knock-out mice.226 According to Daugherty et al, the earliest (within 48 hours)
event occurring in this model, is the infiltration of macrophages into the media leading to
elastin fragmentation and dissection.227 Between 4 and 10 days a vascular hematoma was
also observed in the animals which was histologically characterized by abundant
macrophages at the edge of the thrombus. After 14 days, aneurysmal tissue matured with
increased matrix deposition in the regions which was previously filled with thrombus.
Elastin fragmentation continued until 28 days. Atherosclerotic lesions were detected only
beyond 28 days, at least in the ApoE-/- mice. One drawback of this model is that the
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aneurysms develop in the aortic arch, thoracic aorta and supra-renal abdominal aorta,
whereas in human, infra-renal abdominal aortic aneurysms are the most common.
However, this particular model has provided significant insight on the pathogenesis and
factors involved in the progression of aneurysms.
2.3 Plant derived polyphenols
Based on the literature reviewed so far, it is clear that MAC and AAA are fatal
diseases of the arteries. Although there are limited clinical management strategies, there
is still no cure for either of the diseases. It has been shown in literature and also by
several animal and cell-culture models in our lab that elastin degradation is a key
characteristic of both MAC and AAA. Degradation of elastin accelerates calcification and
also causes aneurysm formation. Depending on several other factors such as
inflammation, hyperglycemia, hyperuremia, duration of disease, nature of vascular insult,
presence/absence of atherosclerosis, life style choices of individuals, the fate of aorta
might lead to arterial calcification or aneurysm or both. Regardless, the common feature
to both diseases is elastin degradation. This research explores the use of plant derived
polyphenols for stabilizing elastin and therefore preventing elastin degradation mediated
MAC and AAA. Polyphenols are reviewed in the following section.
Polyphenols are chemicals derived from plants that have a hydrophobic core and
multiple external phenolic (-OH) groups. They can be typically divided into condensed,
complex or hydrolysable varieties. They are micronutrients found in plant sources such as
green tea leaves and have been under the scrutiny of research for the past decade for its
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multiple valuable properties. Depending on the number of phenol rings and structural
elements between phenolic rings, polyphenols can be divided as: phenolic acids,
flavonoids, stilbenes, and ligans.228

Figure 2.24:Types of polyphenols228

Phenolic acids are further classified as derivatives of benzoic acids or derivatives
of cinnamic acids. Structure of flavonoids consists of two aromatic rings (A and B)
bound together by three carbon atoms that comprise an oxygenated heterocycle (ring C).
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Flavonoids are categorized into 6 subclasses based on type of heterocycle involved:
flavones, isoflavones, flavanones, anthocyanidins, and flavanols (catechins and
proanthocyanidins).228 For our studies we have chosen three different polyphenols for

comparing and investigating their interactions with elastin. We used pe
pentagalloyl
ntagalloyl glucose
(PGG), (-)-Epigallocatechin-3-O-gallate (EGCG) and (+)-Catechin, the structures for

which are shown in Figure 2.25.

Figure 2.25: Structure of (A) PGG, (B) EGCG, (C) Catechin

2.3.1

Polyphenols interaction with matrices

Phenolic gallotannins have been shown to bind to hydrophobic regions of elastin
and collagen specifically to the proline-rich regions.229,230 Tannic acid (another
polyphenol) has been used commonly in electron microscopy, sometimes in combination
with glutaraldehyde for visualizing the ultra-structure of elastin.231 This observation
suggested that tannic acid like polyphenols bind to elastin with great affinity.
Polyphenols are also effective antibacterial agents and reduce inflammation and
antigenicity.232 Tannic acid and PGG has also shown to bind strongly to vascular elastin
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preventing it from proteolytic degradation.30,233 Previously, we have also shown that a
single time peri-adventitial application of PGG to abdominal aorta of rats prevents
formation and progression of AAA without any detectable changes in serum or toxic
effects in liver.225 This suggests the biological safety and efficacy of PGG as an AAA
treatment when applied as a single dose. Recently PGG has been used for tissue
engineering and regeneration applications as a matrix stabilizer. Moderately crosslinking
collagen scaffolds from porcine pericardium with PGG exhibited excellent mechanical
properties, inhibited in-vivo calcification, prevented enzymatic degradation and
supported cellular infiltration, thereby making a suitable scaffold for tissue engineered
heart valve.234 Similarly, elastin scaffolds treated with PGG served as excellent arterial
scaffolds conducive to cellular infiltration and neo-matrix deposition.235 Finally, PGGtreated scaffolds resisted diabetes-induced crosslinking and stiffening, were protected
from calcification, and exhibited controlled remodeling in vivo, supporting future use of
diabetes-resistant scaffolds for cardiovascular tissue engineering in patients with
diabetes.236
2.3.2

Polyphenols interaction with cells

Pharmacological properties have been investigated for many years mainly for
their anticarcinogenic, antimutagenic, antiviral, and antimicrobial capabilities.237
Observations such as inverse correlation between green tea consumption and frequency
of gastric cancer led to deeper investigation between the molecular interaction of
polyphenols and cells.238 Animal research produced evidence in that the use of tea
polyphenols inhibited skin cancer in mice,239 and colon tumors in rats.240 Polyphenols
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also act as scavengers for free radicals thereby proving very effective anti-oxidants. Antioxidant properties of polyphenols have been demonstrated both in-vitro and in-vivo.
Polyphenols are shown to reduce oxidative stress by inhibiting activation of nuclear
factor κB (NF-κB) and activator protein-1 (AP-1) in culture cells.241 EGCG is particular
has shown several anti-inflammatory properties. Human umbilical vein endothelial cells
(HUVECs) when treated with EGCG, exhibited lower monocyte adhesion due to TNFα.242 EGCG also has protective effects against ultraviolet B induced AP-1 and NF-κB
dependent transcriptional activation.243 PGG has shown to inhibit cellular proliferation by
arresting cell cycle at G1 phase through the down-regulation of cyclin dependent kinases
2 and 4 and cyclin dependent kinase inhibitors p27 and p21 in human breast cells.244,245
More recently polyphenols like tannic acid and ellagic acid have demonstrated the ability
to help in regeneration of elastin in cell culture models. Skin fibroblasts when treated
with polyphenols showed greater and well oriented elastin fiber orientation compared to
untreated controls. Additionally, once the polyphenols were removed from culture and
reverted back to normal growth medium, the groups previously treated with polyphenols
showed resistance to enzymatic attack.246
2.4

Local drug delivery options in the vasculature
AAA is a focal condition and MAC occurs heterogeneously along the vascular

tree, concentrating on some areas. Thus local therapy directed to the diseased site will be
an attractive option for the treatment of MAC and AAA. This is advantageous for two
reasons: (1) For treatment of matrix disorders such as that in MAC and AAA, greater
efficacy of treatment is expected with direct drug-target interaction, (2) systemic delivery

75

of drugs may have adverse effects on other organs (as mentioned in the human trials of
Doxycycline).
Although regression of the aneurysmal/calcified tissue appears to the ideal
treatment, early detection and inhibition of progression is a more realistic approach to
clinically deal with AAA/MAC. Historically, small aneurysms have different rates of
growth, both within and between patients. Current diagnostic techniques are not very
precise in predicting growth rate and rupture risk of AAAs. This emphasizes the need to
develop sensitive and accurate methods for detecting biomarkers of AAAs in circulation
or other easily accessible body fluid. Also, MAC is almost inevitable in patients with
diabetes and CKD, hence early detection and prevention of elastin degradation and
calcification is required.
The next section will discuss the local delivery options for AAA/MAC repair. The
two main aims of local delivery are: (1) maximize drug effects in the tissue and (2)
minimize undesired systemic effects. The ideal delivery device would deliver and
maintain required amounts of drug in the vessel wall for a period adequate to ensure
therapeutic effect, without causing local damage and hindrance to blood flow. In theory,
two possible approaches to deliver drugs to the vasculature include: (1) intra-luminal
delivery or inside-out delivery and (2) peri-adventitial delivery or outside-in delivery
Currently there are no FDA approved drugs for the systemic/local treatment of
AAA/MAC, thus there is a dearth of literature pertinent to devices for local delivery of
therapeutics in vasculature. However, in the past decade, researchers have made great
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efforts to develop local vascular drug eluting devices to inhibit restenosis after successful
percutaneous transluminal angioplasty (PTA). To the best of my knowledge, all the
clinically approved devices employ percutaneous intraluminal route instead of periadventitial routes. However, varieties of peri-adventitial delivery devices have exhibited
their efficacy and potential in animal studies. The following section discusses the list of
intra-luminal devices approved for clinical use and the peri-adventitial devices used in
animal studies. Knowledge of drug delivery devices of small arteries like coronary
arteries is beneficial for development of devices for large arteries like abdominal aorta.
2.4.1 Intra-luminal delivery devices – FDA approved product designs
1) Balloon catheter systems
The three basic mechanisms used to design catheter systems are passive diffusion,
pressurized infusion and electrical and mechanical infusion.
Passive diffusion
The first balloon catheter used to deliver drugs was the double balloon catheter.
This device comprises of two inflatable balloons at the distal and proximal end with
perforations in the catheter between the balloons for delivery of drug solution (Figure
2.26). Deployment of the balloons creates a closed circuit for delivery of drugs, allowing
passive drug diffusivity through the lumen. Adequate drug delivery requires 15-30
minutes perfusion leading to the risk of local ischemia. Besides, this method leads to drug
loss into collateral or bifurcating vessels. Jorgensen et al. used double balloon catheter in
6 patients undergoing PTA to deliver tissue-type plasminogen activator and heparin for
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30 minutes and observed recanalization and remission of symptoms at the end of 30
days.247

Figure 2.26:Double balloon catheter 248
The coil balloon catheter is another modification of the basic balloon catheter.
The Dispatch™ (Boston Scientific Scimed) consists of a perforated helical infusion
balloon wrapped around a non-porous sheath (Figure 2.27). The sheath allows antegrade
blood flow and the helical inflation coil diffuses drugs to the vessel lumen on
deployment. This device has shown some clinical success, however homogenous drug
delivery remains an issue. Intracoronary infusion of heparin using Dispatch™ after
balloon angioplasty has shown improved patency and reduced thrombosis in 22 patients
compared to patients depending solely on systemic anti-thrombotic agents. 249
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Figure 2.27:The Dispatch™ 250
The hydrogel coated balloon catheter swells like a sponge on perfusion of the
drug solution and allows passive diffusion of drugs once the balloon is inflated. A clinical
study suggested that hydrogel coated balloons can be safely used to locally deliver
urokinase to attain coronary thrombolysis.251 Ninety-five patients receiving urokinase
displayed reduced thrombus after angioplasty. However, around 10% of the patients
suffered from other complications like distal emboli, abrupt closure, no reflow and late
closure. Since these devices are designed to diffuse drugs rapidly, speedy release of the
drugs immediately after entry into the blood stream may prove problematic. Therefore
incorporation of a protective sheath over the balloon helped overcome this concern.
Pressure delivery
The porous balloon catheter is one of the best examples for a pressure driven
device. The balloon itself has pores/micropores that directly deliver drugs to the wall
after deployment. The depth of penetration is proportional to the perfusion pressure. The
Vascular ClearWay™ is a micro-porous balloon catheter designed especially for the
removal of soft, fresh emboli and thrombi before angioplasty. Traditional pressure
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devices are known to cause damage to the intima at the time of delivery, but the
ClearWay™‘s soft and tough material exerts similar pressure as conventional porous
balloon, but does not cause as much tissue damage (Figure 2.28). It consists of an inner
balloon with an array of pores and an outer membrane with thousands of micropores.

Figure 2.28:The ClearWay™ micro-porous catheter
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Mechanical or electrical devices
The needle injection catheter has fine needles that penetrate the media to deliver
therapeutics to the perivascular tissue including the adventitia. Despite its invasive
nature, this device is shown to cause limited injury and trauma. Ikeno’s group
successfully delivered Tacrolimus into the adventitia of swine coronary arteries using this
system (Figure 2.29).253
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Figure 2.29: Periadventitial delivery using needle injection catheter
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The Trellis infusion catheter is a novel percutaneous device that is employed for
embolic protection in peripheral vessels especially in Deep vein thrombosis (DVT). This
system has two balloons (distal and proximal end) with infusion holes located between
the balloons. The catheter has a central lumen which facilitates the movement of the
guide wire and a dispersion wire. The dispersion wire is oscillated after the perfusion of
the lysis agent. Once the thrombus has been lysed, the contents are aspirated through the
pores in the catheter. The balloons that had isolated the vessel is deflated to allow
restoration of circulation (Figure 2.30).
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Figure 2.30:The Trellis catheter with the oscillating dispension wire
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Drug eluting stents
Bare metal stents are the clinical standard therapy for arterial occlusive diseases.
Stents coated with biodegradable polymer containing drugs like Paclitaxel are deployed
to the site of occlusion. While most of these drug eluting stents reduce the incidence of
restenosis, they are shown to cause greater incidence of late stage thrombosis.255
Although these drug eluting stents are being questioned about their efficiency in terms of
vascular healing, they still exhibit an efficient way to delivery drug locally.
2.4.2 Peri-adventitial delivery methods- research in animals
Several studies conducted in animals demonstrate the successful peri-adventitial
delivery of therapeutics/growth factors in local AAA tissue. In a canine vein-patch
aneurysm model, Kajimoto et al. implanted basic fibroblast growth factor (bFGF) coated
stent-graft to study the reduction of endoleaks. The stent graft was impregnated with 10%
soluble elastin and 0.5% heparin salt to bind the materials. Later, these grafts were
soaked in a solution containing bFGF, dried and implanted. At the end of four weeks,
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there was a six-time greater intimal proliferation in the groups treated with bFGF than the
ones without growth factors.256
Villa et al used a silicone polymer matrix loaded with dexamethasone to study
neointimal proliferation after balloon angioplasty in a rat–carotid model.257 The drugloaded matrix wrapped around the carotid artery, was harvested three weeks later (Figure
2.31). From their observation, local dexamethasone delivery at two different
concentrations markedly inhibited neo-intimal proliferation after three weeks. The use of
silicone rubbers enclosing hydrophobic drugs has distinct advantages as an arterial
implant because it does not exhibit swelling effects as any water-soluble drugs in
synthetic polymer does. Hydrophobic drugs like dexamethasone come to equilibrium
with the extracellular fluid or plasma and form a solid phase solution when implanted.

Figure 2.31:Drug eluting polymer wrap 257
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Research groups have also used polyvinyl alcohol (PVA) foams loaded with
drugs for peri-adventitial delivery.20,258 Sho et al. used a mini-osmotic pump loaded with
Doxycycline guided by a catheter into a PVA foam (Figure 2.32). Controlled and sitespecific delivery of Doxycycline was achieved by placing the PVA foam on the
abdominal aorta of the rat. Although they did not display the local release profile of
Doxycycline, Doxycycline in the blood did not vary at the end of 14 days, indicating the
local drug metabolism in the tissue. Besides, the inhibition of disease progression was
comparable in both local as well as systemic delivery. Thus, peri-aortic treatment might
improve clinical outcome of AAA treatments.

Figure 2.32:PVA foam sutured to the artery20
Simons et al used a novel in-situ polymerization technique for delivering drugs
peri-adventitially for upto two weeks. They used Pluronic® F-127 gel, which facilitates
solubilization of water-insoluble compounds. This gel has a unique property of being
soluble at 4°C and solidifying on contact with tissues at 37°C. Their intent was to study
the effect of peri-adventitial delivery of anti-sense phosphorothioate in neo-intimal
accumulation of cells after balloon angioplasty.259
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In another experiment, Brauner et al. developed one sided Ehtylene Vinyl-Acetate
(EVA) based peri-adventitial matrices for Verapamil to inhibit experimental neointimal
cell proliferation. The EVA copolymer and Verapamil hydrochloride was dissolved in
methylene chloride and molded into rectangular pieces for peri-adventitial delivery. To
facilitate uni-directional drug release, one side of the matrix was sealed with blank EVA
using methylene chloride as glue. These polymer patches were then sutured to rabbit vein
grafts.260
Pires and colleagues developed perivascular cuffs made out of poly-caprolactone
(PCL) to reduce restenosis. The cuffs (cylinder with 0.5mm and 1mm internal and
external diameter respectively) were loaded with drugs like Paclitaxel and Rapamycin
and secured around the femoral arteries of mice. Sustained release of Paclitaxel and
Rampamycin caused a 76% and 75% reduction in intimal thickening respectively.261
2.4.3 Novel vehicles for drug delivery
Endovascular delivery methods discussed above, focus on the direct delivery of
drugs to the site of pathology. However, sustained release of drug to the particular site
may be an attractive option to minimize side effects and optimize drug-effects. Some
examples of novel drug-delivery vehicles for the vasculature are discussed below.
Very recently, Ogata et al. developed a Doxycycline loaded controlled release
biodegradable fiber (DCRBF) for local administration in AAA tissue (Figure 2.33).262
These Doxycycline incorporated poly-lactic acid fibers showed a controlled in-vitro drug
release of 28 days and in-vivo release of upto 84 days. The research group further tested
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the efficacy in an ex-vivo mouse model and in-vivo Angiotensin-II model. 14 days coculture of DCRBF and arteries showed 33% greater quantity of elastin. DCBRF reduced
protein expression of MMP-2,9, IL-6 and TNF-α and increase in the TIMP-1 activity in
the Angiotensin-II model.

Figure 2.33: (A) gross appearance of DCBRF (B),(C) TEM images of
DCBRF 262

Frank et al. successfully created Hydrocortisone loaded microspheres and
delivered them via perforated balloon catheters into rabbit arteries after balloon
angioplasty.263 Westedt et al. also formulated nanoparticles that were infused coupled
with porous balloon catheter (Figure 2.34).264 This prevented the second deployment as in
the case of Frank’s study. Both these studies showed the successful delivery of particles
to the site of disease.
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Figure 2.34: TEM showing the nanoparticles eluting out of the
porous balloon 264
The literature reviewed above discusses the different methods of delivering drugs
to the vasculature. However, all these methods require surgical manipulation which
makes these techniques less than desirable in certain cases. Also, in several vascular
pathologies like that of MAC, the diseased area is spread heterogeneously along the
vascular tree. Thus, an ideal delivery method should be able to recognize the precise site
of calcification/damage and deliver drugs at the precise site. This dissertation talks about
one such approach in Chapter 6.
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CHAPTER 3

PROJECT RATIONALE

3.1

Project objective and aims
Based on the literature reviewed earlier, the main objectives of this project are:
a) Investigate the potential combined action of glucose and elastin peptides
in the presence of transforming growth factor beta-1 (TGF-β1) in the
osteogenesis of vascular smooth muscle cells
b) Evaluate the impact of polyphenols like PGG, EGCG and catechin on the
quality and quantity of elastin matrix synthesis and stabilization of mature
elastin preventing it from elastolytic degradation
c) Develop a minimally invasive nanoparticle mediated drug delivery system
that can target damaged elastin, attach and degrade to deliver drugs to
diseased vessel

3.2

Specific aims and rationale
Specific Aim 1:
Determine the combined effect of soluble elastin peptides (a result of degradation

of insoluble mature elastin) along with TGF-β1 and high levels of glucose in the
osteogenesis of vascular smooth muscle cells.
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Rationale: From the literature reviewed in Chapter 2, it is clear that diabetes
mellitus causes severe calcification of elastin in the artery causing hardening of arteries
which affects the mechanical properties of the arteries, leads to poor circulation,
infection, and eventual amputation of lower extremities in affected individuals. From
research that has been done in MAC observed in CKD or diabetic patients, it is
understood that calcification of arteries is a multi-factorial process and works in two
fundamental pathways: (1) A passive deposition of hydroxyapatite on the arterial matrix
and (2) a tightly regulated and active cell mediated deposition of hydroxyapatite by
native cells of the artery. Whether these two processes have a chronological occurrence,
work independently or work together has been an unclear debate for decades. MMP
mediated elastin degradation is accelerated in diabetic patients which is observed as
soluble elastin peptides in circulation. Also, diabetic tissues have abundant TGF-β1
which is released due to MMP mediated conversion of its inactive to active. Chapter 2
discusses the sequestration of latent TGF-β1 by matrix associated glycoproteins like
LTBP. With increasing inflammation and MMP activity, there is a progressive
degradation of elastin and LTBP. This cleavage activates latent TGF-β1 into active forms
available for cellular interaction. It is unclear whether elastin peptides and TGF-β1
interact with glucose contributing to the overall process of vascular calcification. Thus,
the first aim of this project is to isolate these factors and test their pathological effect in a
cell culture experimental set up.
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Specific Aim 2:
•

Evaluate the efficacy of plant derived polyphenols like PGG, EGCG and
catechin in binding to vascular elastin and protecting against proteolytic
degradation.

•

Determine the benefits of delivering exogenous polyphenols towards
elastin synthesis and matrix deposition in a cell culture model. Study the
difference between elastin fiber deposition between healthy and
aneurysmal cells.

Rationale: From Chapter 2, we know that elastin degradation is a primary cause
of MAC and AAA. Currently there is no FDA approved clinical therapy for reversal of
arterial calcification or for aneurysm repair. Patients with diabetes and CKD almost
inevitably develop vascular calcification, and AAA shows elastin degradation. Since
elastin degeneration is a common causal factor for both MAC and AAA, there is a
pressing need to develop a therapeutic that can prevent elastin degradation in the early
stages of AAA, diabetes and CKD. With the prevention of elastin degradation, we can
protect the progression of vascular calcification and aneurysm. Based on earlier work, we
tested if polyphenols that are known to have strong affinity to elastin can prevent elastin
degradation and at the same time allow deposition of new elastic fibers.
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Specific Aim 3:
Develop elastin-antibody coated PLA nanoparticles (ENPs) for luminal targeting
in elasto-degenerative diseases for drug delivery and imaging.
Rationale: Delivering drugs specifically to the arteries is a considerable challenge
for several reasons: (1) Vascular diseases in large arteries like MAC and AAA, are
heterogeneous and the precise spatial identification remains a challenge (2) Because of
their anatomy and general inaccessibility, drugs can be delivered to arteries either via
laparoscopic route (peri-adventitial) or through endovascular route (intra-luminal), both
of which require surgical intervention. We have seen in chapter 2 that current attempts of
delivering drugs to the blood vessels are relatively invasive causing probable damage to
the luminal side of the artery. It is not sufficient to discover novel drugs for vascular
therapy. In the case of pre-emptive drugs (as we suggested in aim 2), surgical drug
delivery options are undesirable and will have minimal patient compliance. This
necessitates the invention of a drug delivery technique that does not mandate surgery, is
cost-effective and provides desired therapeutic effect without causing systemic side
effects. The third aim of this project is to use nanotechnology to formulate polymeric
nanoparticles that can recognize sites of vascular damage and home themselves to the site
and deliver drugs in time dependent fashion.
3.3

Clinical significance
Cardiovascular diseases are the leading cause of death worldwide. The global

diabetic epidemic further accentuates the statistics of cardiovascular events. Blood vessel
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replacement is a common treatment option for diseases such as atherosclerosis, restenosis
and abdominal aortic aneurysms. Although synthetic vascular replacements have a high
success rate, they still warrant surgical intervention, increase overall cost of treatment and
lead to complications requiring revision surgeries. Currently there are no FDA approved
drugs for MAC and AAA treatment and the very few that have reached clinical trials
have failed either due to lack of therapeutic value or extreme side effects. By
understanding the fundamental mechanisms that cause vascular calcification, exploring
novel chemicals with therapeutic potential and exploiting current advances in
nanotechnology, we can develop minimally invasive treatment options for MAC and
AAA.
It has been shown that PGG and polyphenols as such bind to elastin with strong
affinity and protect it from degradation in an elastolytic environment.265 In small animal
models PGG has shown to prevent AAA progression225 and also dramatic protection
against MAC in diabetic rat models.236 It has been shown earlier that MMP mediated
elastin degradation is a precursor to elastin calcification.88 Additionally, these degraded
elastin products provoke osteogenesis in smooth muscle cells turning them into osteoblast
like cells.7 Taken together, polyphenols can bind to elastin in the arteries and (1) prevent
AAA progression by directly binding to elastin and preventing inflammatory degradation
(2) prevent diabetic MAC by directly binding to elastin, preventing its degradation and
indirectly maintaining vascular homeostasis.
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The long term goal of this research is to bring about a new site-specific delivery
of agents for more effective treatment in patients suffering from elastin related disorders
such as MAC and AAA.
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CHAPTER 4

ROLE OF ELASTIN PEPTIDES AND GLUCOSE IN OSTEOGENESIS OF
SMOOTH MUSCLE CELLS

4.1

Introduction
Cardiovascular calcification has been shown to be an independent marker for

mortality in patients with advanced cardiovascular diseases.26,266 Two pathological
patterns of vascular calcification include: intimal calcification and medial calcification.
Intimal calcification occurs mostly in association with atherosclerosis subsequent to lipid
deposition, macrophage infiltration, and smooth muscle cell proliferation.267 Medial
arterial calcification (MAC) on the other hand may exist with or without atherosclerosis
and is characterized by the presence of calcific deposits on the elastic lamellae.268 As
MAC progresses, it forms dense circumferential sheets in the medial layer of the artery
which depicts features very similar to that of physiological calcification in bone. MAC is
most commonly observed in the distal arteries of patients with diabetes and end-stage
renal failure, or with advanced age. It can lead to stroke and lower limb amputations.
In recent years it has been established that vascular calcification is an active and
tightly regulated biological process that involves cross-talk between cells and extracellular matrix of the arteries and resembles physiological bone formation.269 In vitro cell
culture studies with high concentration of glucose exposure has been shown to accelerate
vascular smooth muscle cell (VSMC) calcification. For example, Chen et al showed that
bovine VSMCs when incubated with high concentrations of glucose (25 mM), coupled
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with inorganic calcifying agents like β-glycerophosphate and ascorbic acid, underwent a
more pronounced osteogenic differentiation compared to cells with normal glucose (5
mM) concentrations, indicating the role of hyperglycemia in the increased vascular
calcification.270
The role of elastin degradation on medial calcification as observed in MAC is not
understood

well,

specifically

in

diabetic

high

glucose

conditions.

Matrix

metalloproteinases (MMPs) are known to degrade elastic fiber and it has been shown that
MMP activity is increased in diabetic arteries.5,6 This may lead to an accelerated
degradation of elastic fibers.

Elastin derived peptides (EDPs), a product of elastin

degradation, can be detected in the serum of diabetic patients.9,271 In fact, a direct positive
correlation has been established between the concentrations of serum elastin-derived
peptides (EDPs) and the development of micro-vascular complications in diabetic
patients.9,271 Elastic fiber degradation in arteries, along with degradation of TGF-β
binding protein associated with elastic fibers, releases sequestered TGF-β.89,272 Thus
elastic fiber degradation can increase concentration of free TGF-β. In our previous study,
to test the effect of EDPs and TGF-β1 on VSMCs, we incubated rat VSMCs in vitro with
increased concentrations of TGF-β1 and EDPs. We showed that EDP and TGF-β1 have a
synergistic effect in the process of osteogenesis of vascular smooth muscle cells, which
was characterized by the over-expression of runt-related transcription factor 2 (RUNX2),
alkaline phosphatase (ALP) and osteocalcin (OCN).7 We found increased osteogenesis in
absence of any external calcifying agents added to the cell culture such as βglycerophoshate. However, previous studies were performed in high glucose culture
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medium and the effects of normal glucose levels were not clearly examined. To elucidate
the effects of glucose concentrations, we compared the degree of osteogenenis of VSMCs
in the presence of EDPs and TGF-β1 in high and low concentrations of glucose.
4.2

Materials and methods
Cell isolation and cell culture
Primary rat aortic smooth muscle cells (VSMC) were purchased from Cell

Applications, Inc. Passage number 4-8 were used for all the experiments. Cells were
cultured in 6 well plates (1.5x105 /well) in either Dulbecco’s modified Eagle’s Medium
with Low glucose (HyClone Laboratories, Inc., Novato, CA) or Dulbecco’s modified
Eagle’s Medium with High glucose (Cellgro-Mediatech, Herndon, VA), containing 10%
fetal bovine serum (HyClone Laboratories, Inc., Novato, CA), 100 units/ml penicillin and
100 units/ml streptomycin (Cellgro-Mediatech, Herndon,VA) in a humidifier incubator at
37°C, with 5% CO2. Media was replenished every 3 days.
Elastin peptides were purchased from Elastin Products Company (Owensville,
Missouri, USA) which were a mixture of elastin fragments, purified from bovine neck
ligament, ranging between a molecular weight 1000 to 60,000 kDa, and were highly
soluble in water. Recombinant TGF-β1 was purchased from Peprotech (Rocky Hill, NJ).
Cells were also treated with SB-431542 and lactose (Sigma, St. Louis, MO) to block the
activin receptor-like kinase (ALK-5) and Elastin laminin receptor (ELR-1) respectively.
In addition, cells were treated with GF109203X (Enzo Life Sciences, Farmingdale, NY)
to block intracellular protein kinase C βII (PKCβII).
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Experimental design and time points
VSMCs were grown in low glucose DMEM (LGC), low glucose DMEM with
elastin peptides and TGF-β1 (LGET), high glucose DMEM (HGC), high glucose DMEM
with elastin peptides and TGF-β1 (HGET). Test additives were administered to sub
confluent cells (n=6 per group) as follows: 100 µg/ml elastin peptides and 10 ng/ml TGFβ1.
Additionally, to study the response of inhibition of the respective receptors of
elastin peptides (ELR-1) and TGF-β1 (ALK-5), 5 mM lactose or 10 ng/ml SB-431542
was added along with elastin peptides and TGF-β1. For PKCβII inhibition studies, 10µM
GF109203X was added to cell cultures and relative gene expression of representative
osteogenic genes were investigated.
Cells were grown for 1, 3, and 7 days at the end of which total cellular protein and
total cellular RNA were isolated. The spent media was collected for protein analyses at
the end of each time point.
Gene expression
At each time point, cell monolayers were scraped and homogenized using a
PowerGen 125 homogenizer (Fisher Scientific, MA). The total RNA from the cells was
isolated using the RNeasy mini kit (Qiagen, Valencia, CA). The quality and quantity of
the RNA was analyzed by Agilent 2100 Bioanalyzer using 6000 Nano lab-on-a chip kit
(Agilent Technologies, Foster City, CA). 1µg of RNA was reverse transcribed using
Qiagen RT kit. The cDNA samples were then amplified using Qiagen SYBR green kit in
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Rotorgene RT-PCR machine (Corbett Research, Mortlake, NSW, Australia). The primer
sets used (forward and reverse primers) are tabulated in Table 4.1 along with their
accession numbers and PCR product sizes. All primers were procured from Integrated
DNA Technologies (IDT, Coralville, IA). Each sample was normalized to the expression
of β-2 microglobulin (β2-MG) as a housekeeping gene and compared to LGC group cells
(cells cultured in low glucose DMEM alone), using the 2-∆∆CTmethod.273
Table 4.1: PCR primers used in the study
Gene

Name

Primer
(forward)

Primer (reverse)

Product
size (bp)

ß2-MG

Beta 2microglobulin

CGTGATCTTT
CTGGTGCTTG
TC

ACGTAGCAG
TTGAGGAAG
TTGG

123

NM_012512

CBFA 1

Core binding
factor alpha-1

CAACCACAG
AACCACAAG
TGC

CACTGACTCG
GTTGGTCTCG

120

AF053950

Alkaline
phosphatase

TCCCAAAGG
CTTCTTCTTG
C

ATGGCCTCAT
CCATCTCCAC

108

J03572

OCN

Osteocalcin

TATGGCACC
CTGTGCCGTC
ACCGTTTAGG CATACTTTCG
G

123

NM_013414

ELR1

Elastin-laminin
receptor

GTCAGCGTC
ATCTCCTCCA
G
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NM_017138

ALP

GAAGGTCCC
AGGTGTGAA
GC
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Accesion
number

Protein isolation
Cell monolayers were washed twice in PBS and cells were isolated in a
mammalian extraction buffer. To prepare the buffer, 1 tablet of protease inhibitor cocktail
(Sigma, St.Louis, MO) was added to 10 ml of Solulyze-M mammalian extraction buffer
(Genlantis, San Diego, CA). Cell layers were homogenized using PowerGen 125
homogenizer and centrifuged at 10,000 g for 15 minutes. The supernatant was collected
and assayed for different proteins of interest.
Immunofluorescence for ELR-1 and ALK-5
VSMCs were grown on glass chamber slides (Lab-Tek II Chamber Slide system,
nunc, Thermo Fisher Scientific, Rochester, NY) and then incubated with elastin peptides
and TGF-β1 for 3 days. The cells were then washed twice with PBS and fixed in 4%
formaldehyde for 10 minutes in room temperature followed by incubation with a 5%
bovine serum albumin blocking serum. The primary antibody, a rabbit polyclonal anti67kDa laminin receptor (Abcam, Cambridge, MA) or a rabbit polyclonal anti-TGF beta
receptor I antibody (Abcam, Cambridge, MA) at 1:100 dilution was applied overnight at
4°C. Alexafluor 488 chicken anti-rabbit IgG secondary antibody (Molecular Probes,
Eugene, OR) was applied at a dilution of 8µg/ml for 2 hours at room temperature.
Coverslips were mounted in glass slides using aqueous mounting medium with antifading agents (Biomedia corp., Foster city, CA). The slides were examined by fluorescent
microscopy.
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ALP assay
After quantifying the total cellular protein, cell lysates were analyzed for alkaline
phosphatase using p-nitrophenol phosphate (pNPP) (Thermo Fisher Scientific, Rochester,
NY ) as a substrate in diethanolamine buffer (Pierce, Rockford, IL). Alkaline phosphatase
level was calculated using a p-nitrophenol standard curve and was normalized to the total
protein content. Additionally, cells in culture were stained with 0.2 mg/ml 5-bromo-4chloro-3-indoyl-phosphate, 0.4 mg/ml 4-nitroblue tetrazolium, and 5 mM MgCl2 in 50
mM Tris buﬀer, pH 9.5 (Sigma,St. Louis, MO) to localize the activity of ALP in cell
cultures.
Osteocalcin assay
Culture medium samples from each group were analyzed in triplicates for
secreted soluble osteocalcin, using a rat osteocalcin enzyme-linked immunoassay kit
(Biomedical Technologies, Stoughton, MA) and values were normalized to the total
protein.
Inhibition of ELR-1 and ALK-5 receptors
Lactose (5 mM) was used to block the ELR-1 receptor, the concentrations of
which were optimized in previous studies.7 SB-431542 (10µM) was used to block ALK5 receptor.274
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Live dead assay
A live-dead assay (Molecular Probes) was performed as per the manufacturer’s
protocol. Cells were observed under a fluorescent microscope. Red fluorescence
indicated dead cells while green fluorescence indicated live cells.
Statistical data analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.
4.3

Results
To examine the cytotoxicity of the concentrations of elastin peptides and TGF-β1

used in this study, we performed a live-dead assay. None of the groups were significantly
more cytotoxic compared to the low glucose control group at the end of 3 days (Figure
4.1). However, there was a distinct morphological change in the VSMCs from a typical
spindle shaped one to that of an atypical rounded morphology (Figure 4.1). This effect
was evident only in the groups treated with EDP and TGF-β1 and high concentrations of
glucose did not seem to contribute to the effect.

101

Figure 4.1:Live-Dead assay of VSMCs cultured in the presence of low glucose
baseline control (LGC), high glucose (HGC), low glucose + elastin
peptides + TGF-β1 (LGET) and high glucose + elastin peptides + TGFβ1 (HGET). Live and dead cells are indicated by green and red
fluorescence respectively. Original magnification, 100X. Inset
demonstrates cellular morphological differences among the groups.

High glucose is required for expression of osteogenic markers in VSMCs
To investigate the effect of high glucose concentration coupled with growth factor
TGF-β1 (10 ng/ml) and elastin peptides (EDP) (100 µg/ml), VSMCs were incubated with
both these additives either under the presence of high concentrations of glucose (4.5 g/L)
or normal concentrations (1.1g/L) of glucose. Cells were cultured for 1d, 3d, and 7d to
study the relative gene expression of RUNX2, OCN and ALP, all three of which are
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known to be commonly associated with osteogenesis.275,276 At the end of 1d, there was
~1.5 times (p < 0.05) over-expression of the RUNX2 relative gene expression in high

glucose control (HGC), low glucose (LGET) and high glucose (HGET) groups with
additives as compared to cells gr
grown
own in low glucose control DMEM alone (Figure 4.2).

Figure 4.2:Relative gene expression of VSMCs cultured in the presence of
low glucose baseline control (LGC), high glucose (HGC), low
glucose + elastin peptides + TGF-β1 (LGET) and high glucose +
elastin peptides + TGF-β1
1 (HGET). Bars represent gene
expression relative to cells exposed to low glucose baseline
basel
control. Relative RUNX2 gene expression after 1, 3 and 7 days of
exposure to glucose, elastin peptides and TGF-β1.

This early over-expression was independent of glucose concentration and by the

end of 3d; its expression was significantly suppressed. RUNX2 is a transcription factor
and it is the earliest marker for osteogenesis; so its over-expression at 1d was expected. In
contrast to RUNX2, the relative gene expression for ALP, a key enzyme in the
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physiological and pathological calcification, and OCN, bone specific marker, were
significantly greater in the presence of high glucose (HGET) groups compared to the low
glucose (LGET) groups at 3d and 7d, clearly showing that high glucose levels are

essential for the overexpression of these important bone markers (Figure 4.3a and 4.3b).

Figure 4.3:Relative gene expression of VSMCs cultured in the presence of low
glucose baseline control (LGC), high glucose (HGC), low glucose +
elastin peptides + TGF-β1
1 (LGET) and high glucose + elastin peptides +
cells
TGF-β11 (HGET). Bars represent gene expression relative to cel
exposed to low glucose baseline control. (a) Relative ALP gene
expression after 3 and 7 days of exposure to glucose, elastin peptides
1. (b) Relative OCN gene expression after 3 and 7 days of
and TGF-β1.
exposure to glucose, elastin peptides and TGF-β1.

We also measured the protein activity of ALP by a colorimetric quantitative
method using a BCIP/NBT that is a specific for ALP.7 At 7d, there was almost a 4-fold (p
< 0.05) increase in the activity of ALP enzyme seen in the HGET groups, (Figure 4.4a).
Staining for ALP in cell cultures showed notably higher purple coloration in the HGET
samples around the cells indicating a higher activity of ALP (Figure 4.4b). In addition,

104

we observed a clustering of VSMCs under the influence of EDP and TGF-β1 which

indicates the probable initiation of calcification nodules (Figure 4.4b).

Figure 4.4:Regulation of osteogenic protein activity by VSMCs cultured in the
presence of low glucos
glucosee baseline control (LGC), high glucose
(HGC), low glucose + elastin peptides + TGF-β1
1 (LGET) and high
glucose + elastin peptides + TGF-β1
1 (HGET). (a) Alkaline
phosphatase activity in cell lysates. (b) Histochemical staining of
enzyme activity in VSMCs.

Osteocalcin protein activity was also found to be 2-fold (p < 0.05) higher in the
cell culture media of HGET group as compared to any other group at 7 days (Figure 4.5).
The protein expression was higher in HGET group as compared to high glucose control
(HGC) clearly showing that high glucose levels were not sufficient to increase the

osteogenic protein activity in SMCs and exposure to high glucose in combination with
high EDP and TGF-β11 was necessary.
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Figure 4.5:Regulation of osteogenic protein activity by VSMCs cultured in the
presence of low glucose baseline control (LGC), high glucose
(HGC), low glucose + elastin peptides + TGF-β1
1 (LGET) and high
glucose + elastin peptides + TGF-β1
1 (HGET). Levels of OCN
protein secreted by VSMCs in the culture media.

Role of ELR-1and ALK-5 in osteogenesis

It is been shown that TGF-β1 binds to the ALK-5 receptor on cells to cause a
series of cellular cascade that are responsible for a variety of cellular phenomenon.277
Similarly EDPs bind to elastin-laminin receptor on VSMCs. Activation of ELR-1 has
been shown to regulate a variety of biological and pathological phenome
phenomena
na including cell
proliferation278 and chemotaxis.279 Thus we wanted to test if these receptors are involved

in rendering osteogenic response in VSMCs. When cells were exposed to high
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concentration of glucose, along with EDP and TGF-β1, both ELR-1 (Figure 4.6a) and
ALK-5 (Figure 4.6b) receptors on VSMCs were overexpressed showing that these

receptors may be involved in signaling towards osteogenic pathway. Glucose
concentration in the culture medium did not affect the expression of ELR-1 and ALK-5
as negligible signal was detected in the LGC and HGC groups and no detectable
difference was observed between the LGET and HGET treatments.

Figure 4.6:Immunocytochemical detection of (a) ELR
ELR-1
1 and (b) ALK-5
ALK on
VSMCs when exposed low glucose baseline control (LGC), high
glucose (HGC), low glucose + elastin peptides + TGF-β1 (LGET)
and high glucose + elastin peptides + TGF-β1
1 (HGET). Original
magnification, 200X.

We further blocked the respective receptors by incubating cells with agents
known to block their activities: ELR-1 with 5mM lactose and TGF-β1
1 receptor ALK-5 by
10µM SB-431542. Relative gene expression was studied at the end of 1d and 3d. Figure
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4.7 shows inhibition of ELR-1 and ALK-5 caused significant down-regulation in the

RUNX2, ALP and OCN relative gene expression in these cells even though they were
exposed to high concentration of glucose, EDPs and TGF-β1.
1. These data clearly suggest
that ELR-1 and ALK-5 mediated signaling is required for osteogenesis of VSMCs.

Interestingly blocking only one of the two receptors had similar effect in inhibition of
osteogenic markers (Figure 4.7). This data is suggestive of cross-talk between the two
receptors; suppression of one leading to the down-regulation of the other.

1 day RUNX2
Figure 4.7:Relative gene expression of RUNX2, ALP and
OCN by VSMCs when exposed to high glucose +
elastin peptides + TGF-β1
1 (HGET), 5 mM lactose
(ELR-1 inhibited), 10µM SB-431542 (ALK-5
inhibited). Bars represent gene expression relative
to cells exposed to HGET positive control
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Involvement of PKCβ
PKCβII in osteogenesis
Involvement of the PKC signaling pathway in the up-regulation of RUNX2, OCN
and ALP has also been studied in literature.270 We wanted to investigate the involvement

of PKCβII
II in our cell culture model of osteogenesis. At the end of 7 days, cells exposed
to high glucose, elastin peptides and TGF-β1,
1, showed a five times greater PKCβII
PKC
relative

gene

expression

(Figure

4.8a
4.8a),
),

which

was

confirmed

by

higher

PKCβII
II in HGET (data not shown). Furthermore,
immunofluorescence staining for PKC
exposing cells to GF109203X (a potent inhibitor of PKC
PKCβ)) in the presence of high
glucose, elastin peptides and TGF-β1, a strong down-regulation of 2 representative
osteogenic markers (RUNX2 and ALP) were noticed (Figure 4.8b).

II expression showing highest levels in HGET group as compared to
Figure 4.8:(a) PKCβII
others relative to LGC. (b) Blocking of PKC
PKCβII
II reduces gene expression of
RUNX2 and ALP.

109

4.4

Discussion
Our results indicate that the presence of high concentration of glucose amplifies

the osteogenesis of vascular smooth muscle cells in the presence of elastin peptides and
TGF-β1. Our data also indicates that a cross-talk in the ELR-1 and ALK-5 receptor
mediated transduction pathways is involved in osteogenic response.
Medial arterial calcification (MAC) is a commonly observed pathology in
diabetes, end stage renal disease (ESRD) and ageing. MMP mediated elastin degradation
releases soluble elastin peptides, which have been shown to induce a wide range of
chemotactic effects, angiogenesis,280 cell proliferation,281 and proteolytic activity.282 In
previous publications, we have demonstrated that TGF-β1 when coupled with elastin
peptides in a dose-dependent manner, induce osteogenesis in vascular smooth muscle
cells7 and skin fibroblasts8 by activating the elastin laminin receptor-1 and overexpressing three representative osteogenic markers namely, RUNX2, ALP, and OCN. In
addition, these additives also increase the cellular production of MMP-2, which can
further exacerbate elastin degradation and release of soluble elastin peptides. However, in
that study normal DMEM medium was used that contains a very high level of glucose. It
was unclear if the osteogenic transformation effects were due to exposure of cells to high
glucose.
Our results here indicate that under high glucose conditions, relative gene
expression of RUNX2 is up-regulated by 1.5 (p < 0.05) times compared to baseline low
glucose control group at 1d. RUNX2 expression decreases at 3d onwards, however, two
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other osteogenic genes namely ALP and OCN show a 4.7 and 2.5 fold (p < 0.05) overexpression respectively, at 3d and continually overexpressed at 7d. Interestingly,
although RUNX2 is equally up-regulated in both LGET and HGET groups after 24 hours,
the sustenance of ALP and OCN relative gene expression is visible only in the presence
of high glucose. In addition, the ALP enzymatic activity is significantly greater in the
HGET groups at the end of 7 days. Our data suggests that exposure to elastin peptides
and TGF-β1 alone may initiate the process of osteogenic transformation by
overexpression of RUNX2, earliest transcription factor marker for osteogenesis,
however; progression of osteogenic pathway needs high glucose conditions. ALP and
OCN genes and proteins were only overexpressed when cells were exposed to EDPs,
TGF-β1 in presence of high glucose.
It should be noted that high glucose alone did not affect osteogenic gene
expression. Hyperglycemia has been implicated in vascular calcification in several invitro studies. Chen et al. have shown the increase in the relative gene expression of ALP
and OCN and formation of calcifying nodules by vascular smooth muscle cells in a
hyperglycemic culture medium.270 Liu et al. have also corroborated the importance of
RUNX2 in diabetic vascular calcification. They have shown an increase in intracellular
calcium content, greater relative expression of RUNX2, ALP and BMP2 in vascular
smooth muscle cells in the presence of high glucose concentrations.283 Subsequent BMP2
inhibition via noggin partially blocked RUNX2 expression and osteoblastic
differentiation of smooth muscle cells. BMPs, which belong to the TGFβ superfamily,
have also shown to strongly mediate arterial calcification in diabetic rats as well as in a
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cell culture model of hyperglycemia.284 Our results are in agreement with current
understanding of hyperglycemic induction of calcification of smooth muscle cells;
however, it is of notable importance that our experimental setup is devoid of any external
calcifying/phosphate elevating agents such as β-glycerophosphate that are used in
aforementioned in vitro cell culture studies. Addition of these agents itself can cause cells
to show osteogenic activity.93,285 We show that exposure of elastin peptides (due to
degradation of elastic fibers9) and TGF-β1 (due to its release from TGF-β1 binding
protein associated with elastic fiber89), and high local concentration of glucose (diabetic),
conditions known to occur in in diabetic vascular pathology, can cause smooth muscle
cellular transformation to osteoblast-like cellular behavior.
Transforming growth factor-β1 (TGF-β1) is a cytokine with a wide-range of
biological functions regulating cell-matrix interactions, cellular proliferation and
inflammation. In particular, TGF-β1 has been observed in association with vascular
calcification and smooth muscle cell trans-differentiation.86,87 TGF-β1 has also been
shown to mediate apoptosis induced calcification of sheep aortic valve interstitial cells.286
These cells develop characteristic calcifying nodules under the effect of TGF-β1 and
express ALP and apoptosis markers. Our results indicate that TGF-β1 and elastin
peptides cause a visible morphological shift in the vascular smooth muscle cells, which is
independent of glucose levels in the culture medium. This is in agreement with previous
publications where vascular smooth muscle cells have undergone a spindle to cuboidal
morphological shift under the effect of the cytokine tumor necrosis factor-α (TNFa).287 It
is unknown how high glucose levels alter cellular interactions of growth factors and
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EDPs. Some previous studies shed light on these events. For example, TGF-β1 has been
shown to increase the cellular uptake of glucose by activating the GLUT1 receptors in
mesangial cells.288 This TGF-β1-GLUT1 axis can influence the cellular glucose
metabolism resulting in vascular pathology. Induction of protein kinase C (PKC) pathway
in diabetic tissues has been co-related with several vascular complications. Up-regulated
activation of the diacylglycerol (DAG) – PKC pathway in the aorta and heart has been
demonstrated in diabetic animal models289,290 and subsequent blocking of PKC has shown
mitigation of vascular291 and glomerular dysfunction.292 In-vitro cellular PKC activation
by vascular endothelial and smooth muscle cells under hyperglycemic conditions has also
been established.293-295 Blocking of PKCβ has also shown a significant down-regulation
in the TGF-β1 activity in diabetic rat models suggesting positive correlation between
them.292,296
Elastin-laminin receptor (ELR-1) is also suspected to increase cellular DAG
concentrations thereby facilitating PKC translocation in the cells.297 Thus, EDPs in
presence of high glucose may enhance ELR-1 activity and PKC translocation and thus
increase ALK-5 activity. Consistent with current understanding, our data indicates an
increased PKCβII expression by vascular smooth muscle cells under the influence of high
glucose, EDP and TGF-β1. Finally, involvement of the PKC signaling pathway in the upregulation of RUNX2, OCN and ALP has also been identified.270 We show that blocking
PKCβII does decrease osteogenic gene expression in SMCs. Taken together; these
findings suggest the possible role of PKCβII in the osteogenic responses of vascular
smooth muscle cells. Based on current research, (shown in the schematic in Figure 4.9)
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we hypothesize that EDPs and TGF-β1
1 released by elastic fiber degradation under high
glycemic condition in vessels can lead to increased ELR-1, ALK-5, and PKCβII
PKC
expression in SMCs and lead to osteogenic transformation of SMCs. Overexpression of
bone proteins can lead to mineral deposition on degraded elastin. Elastin is known to
have calcium binding sites.298 This in turn can lead to elastin specific medial calcification

as seen in diabetic patients. Further in vivo research with diabetic animal models is
needed to confirm the findings of this in vitro cell culture results.

Figure 4.9:Schematic illustrating the osteogenesis of SMC and the responsible
receptors
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4.5

Conclusion
In conclusion, we have demonstrated that glucose plays a fundamental role in the

osteogenesis of smooth muscle cells when coupled with EDP and TGF-β1. Blocking of
ELR-1, ALK-5, or PKCβII suppresses the osteogenic response in the cells thereby
suggesting a possible cross talk among various pathways. This glucose mediated
accelerated osteogenesis of vascular smooth muscle cells can broaden our understanding
of medial arterial calcification in diabetic patients.
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CHAPTER 5

ELASTO-PROTECTIVE AND ELASTO-REGENERATIVE PROPERTIES OF
POLYPHENOLS

5.1

Introduction
As discussed in detail in Chapter 2, abdominal aortic aneurysms (AAA) is a fatal

disease of the artery characterized by accelerated inflammation mediated loss of matrix
proteins such as elastin and collagen leading to structural weakening and eventual rupture
of the artery.299 There are approximately 18,000 deaths each year due to aneurysms in the
United States making it the 15th largest cause of death.300 Currently, there are no
pharmacological repair options for AAA. Aneurysmectomy is the most standard
procedure for AAA treatment, wherein the weakened aorta is excluded and replaced with
synthetic graft.301 A lesser invasive option includes the endovascular deployment of
stented vascular grafts.176 Surgical intervention may not be a suitable option for elderly
patients, especially since AAA is a disease of the elderly.144 Endovascular surgical repair,
although minimally invasive, has undesirable complications like endotension,179 graft
migration181 and endoleaks.178 Additionally, the heterogeneity of AAA, tortuosity of
artery, presence of thrombus and calcific deposits may deem EVAR unfit for many
patients.177 Most importantly, none of these clinical interventions provide therapeutic
relief in preventing or reversing the pathology.
Since AAA is primarily an inflammatory disease, non-surgical treatment options
mainly include inhibitors of matrix metalloproteinases (MMPs) like doxycycline,302,303
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proteinase inhibitors such as tissue inhibitors of MMPs304 and chemical crosslinking of
artery.305 However these options provide a one handed approach in stabilizing the
damaged artery and prevention from further damage. Although of great importance, the
ideal treatment option should work dually in preserving elastin, protecting from further
damage and regenerate new elastin leading to disease reversal and cure.
In prior studies, we have demonstrated the ability of plant derived polyphenols to
bind to elastin and prevent it from elastolytic degradation.306 We have also shown, in a rat
model, that a single time application of pentagalloyl glucose (PGG) can bind to aortic
elastin with minimal toxicity and stabilize AAA.305 An added impetus in terms of
elastogenic factors can enhance the formation and accumulation of net elastin thereby
regressing AAA. This work explores the potential of polyphenols as a multi-folded
treatment option in AAA by stabilizing elastin, preventing enzymatic degradation,
renewing cross-linked mature elastin and inhibiting MMPs.
5.2

Materials and methods
Pure elastin preparation
Pure porcine elastin was prepared and characterized as described earlier.88,306

Briefly, ascending porcine aorta were procured from local slaughterhouse, cleaned to
remove fat and adherent tissues and finely shredded in a food processor. Aortic elastin
shreds (~2 mm) were subjected to 4-5 washes in 2 L of 0.9% NaCl to remove cloudy
waste, following which they were washed with 1 L cold saline every hour for 3 hours
(4°C) and left in shaking overnight in saline at 4°C. After washing, 1ml of the wash
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solution is removed, centrifuged at 12,000 × g for 15 mins and evaluated for soluble
protein using Peirce BCA protein assay (Thermo Scientific, Rockford, IL). The washing
steps were repeated until no protein was detected in the supernatant. The tissue shreds
were then autoclaved, 2-3 times in water, and were replaced with fresh warm water after
each autoclave cycle. Finally, the aorta were defatted and dehydrated with ethanol and
diethyl-ether and lyophilized. This procedure eliminates cellular, collagenous and noncollagenous material including elastin-associated glycoproteins and leaves elastin
intact.307
Polyphenol binding kinetics
Pure aortic elastin (10 mg, as described above) was suspended in 1 ml of 10, 25,
50, 100 µg/ml concentrations of Pentagalloyl glucose (PGG), Epigallocatechin gallate
(EGCG) and catechin. Pentagalloyl glucose (PGG) was a gift from Ajinomoto,
Epigallocatechin gallate (EGCG) and Catechin were purchased from TCI America
(Portland, OR). The polyphenols were dissolved in 10% ethanol in Phosphate buffered
saline (PBS). 100 µl of the sample buffer was drawn at various times and absorbance was
measured at 280 nm.
Methanol extraction of polyphenols
~10 mg elastin was treated with 10, 100, 1000, 10000µg/ml of PGG, EGCG,
Catechin for 48 hours in 37°C. Unbound polyphenols were washed in de-ionized water
and elastin samples were dialyzed against water overnight, lyophilized, and weighed.
Samples were homogenized and polyphenols were extracted in methanol and were
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quantified using a standard curve for polyphenols. The amount of polyphenols bound to
pure elastin was expressed as micrograms of polyphenols bound per mg dry elastin. All
experiments were conducted in triplicates.
Resistance to enzymatic degradation
Lyophilized elastin (~5 mg) was treated with 10, 100, 1000, 10000µg/ml of PGG,
EGCG, Catechin for 48 hours in 37°C. Unbound polyphenols were washed in de-ionized
water and elastin samples were dialyzed against water overnight, lyophilized and

weighed. Elastin samples were treated with high purity porcine elastase (10U/ml, 24hrs)
(Elastin products company, Owensville, MO). Elastase was dissolved in 10 mM Tris
buffer, 1 mM CaCl2, 0.02% NaN3, (pH 7.8). Dry weights before and after enzyme

digestion were used to calculate percent digestion (n=3). The supernatant from elastase
digestion experiment was collected and assayed for fragmented elastin using polyacrylamide gel electrophoresis (PAGE) followed by Coomasie blue staining.

Histology and polyphenol stain
Elastin samples were incubated with polyphenols for 48 hours, and washed to
remove free unbound polyphenols. Elastin samples were embedded in Tissue Tek OCT
compound (Sakura Finetek, U.S.A. Inc., Torrance, CA), and frozen at -80°C. Sections (6
µm) were cut using a cryostat (Microm HM 505 N, Mikron Instruments, Inc.) and

collected on glass slides. Sections were acclimated at room temperature for 5 minutes,
fixed in cold acetone for 5 minutes and stained with 10% ferric chloride (FeCl3) in

methanol and counterstained with 1% light green. Ferric chloride stains polyphenols
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deep-purple to black. In addition, elastin samples were stained with Verhoeff’s Van
Gieson (VVG) (Poly Scientific, Bay Shore, NY) to study structural integrity of elastin.
Cell culture
Primary rat aortic smooth muscle cells (RASMC) were freshly isolated. Briefly,
freshly harvested abdominal aorta from healthy adult male Sprague Dawley rats were
isolated and cleaned. Endothelium was scraped off and the adventitia was removed with
scalpel blade. The medial layer was minced and digested in 125U/ml Collagenase
(Worthington, Biochemicals Lake-wood, NJ) and 3U/mg elastase (Elastin products
company, Owensville, MO) in Dulbecco’s modified Eagle’s Medium-F12 (Hyclone,
Thermo Scientific, Rockford, IL) with 10% fetal bovine serum. The SMCs leave aorta
and attach and grow in petri dishes.
RASMCs isolated from rat aorta with advanced abdominal aortic aneurysm were
received from Dr. Ramamurthi at Cleveland Clinic, the experimental procedure for which
has been described in detail earlier.308 Briefly, the posterior lumbar aortic branches were
ligated; infra-renal aorta was surgically exposed and injured via catheter mediated intraluminal elastase perfusion. The aortic diameter was measured before aortotomy, after
aortotomy and after harvest. The aneurysms were allowed to develop for 14 days before
they were harvested and cells were isolated with the same procedure as described above
for normal aorta.
Passage numbers 4-8 were used for all the experiments. Cells were cultured in 12
well plates (200,000/well) in Dulbecco’s modified Eagle’s-F12 medium containing 10%
fetal bovine serum (HyClone Laboratories, Inc., Novato, CA), 100 units/ml penicillin and
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100 units/ml streptomycin (Cellgro-Mediatech, Herndon,VA) in a humidifier incubator at
37°C, with 5% CO2. Media was replenished every 3 days.
Experimental design
Healthy RASMCs / aneurysmal RASMCs (EaRASMC) were cultured in medium
containing polyphenolic additives (1 µg/ml, 10 µg/ml; n=3/condition) for 14 days.
Polyphenols were dissolved in Dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis,
MO) to prepare stock concentration of 10 mg/ml and filter sterilized using 0.2 µm
membrane filters (Corning Incorporated, Corning, NY) prior to addition. Control groups
received only vehicle (DMSO) and no polyphenols. Cell culture media was changed
every 3 days and spent medium was collected at each media change, frozen at -20°C and
biochemically assayed for tropoelastin and lysyl oxidase. After 14 days, the cell layers
and soluble proteins were collected and analyzed.
Protein isolation
Cell monolayers were washed twice in PBS and cells were isolated in a
mammalian extraction buffer. To prepare the buffer, 1 tablet of protease inhibitor cocktail
(Sigma, St.Louis, MO) was added to 10 ml of Solulyze-M mammalian extraction buffer
(Genlantis, San Diego, CA). Cell layers were homogenized using PowerGen 125
homogenizer and centrifuged at 10,000 ×g for 15 minutes. The supernatant was collected
and assayed for different proteins of interest. Total soluble protein was quantified using
Peirce BCA protein assay.
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Fastin assay for elastin
Total insoluble elastin deposited in the cell layers and soluble monomeric
tropoelastin released in the media were quantified using Fastin assay (Accurate Scientific
and Chemical Corporation, Westbury, NY). For each treatment group, tropoelastin was
assayed individually after each media change to generate a trend curve, and also
evaluated as cumulative tropoelastin released over 14 days. To quantify the mature
elastin deposited within the cell layers, the cell pellet generated after the protein isolation
procedure mentioned above, was lyophilized and digested in oxalic acid as per
manufacturer instruction manual. Since fastin assay quantifies only soluble α-elastin, the
dried insoluble pellet was subjected to 3 digestion cycles with 0.25 M oxalic acid (100
°C, 1 h in water bath) and the pooled digests were assayed in the exact same procedure as
tropoelastin in media. The total α-elastin was normalized to the total soluble protein
released by the cells which is assumed to be directly proportional to the total cell count.
Cell viability studies
EaRASMCs were treated with 1, 10 µg/ml polyphenols for 48 hours and
proliferation of cells was estimated using the MTT (3-(4, 5-Dimethyl-2-thiazolyl)-2,5diphenyl-2H-tetrazolium bromide) assay. Briefly, 5 mg of MTT (Sigma Aldrich,
St.Louis, MO) was dissolved in 10 ml of serum-free media and added to cells. After 4
hours, media was carefully aspirated and the insoluble formazan dye was collected with
dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO). Absorbance was read at
560 nm and normalized to control (no treatment) readings.
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Gene expression
RASMCs and EaRASMCs were plated as mentioned earlier. At 70% confluency,
cells were switched to serum-free media for 24 hours and treated with polyphenols in
serum-free conditions. Only gene expression studies were conducted in serum free
conditions, to evaluate solely the effect of polyphenols and negate the effects of serum
and growth phase of cells. After 24 hours of treatment, cell monolayers were scraped and
homogenized using a PowerGen 125 homogenizer (Fisher Scientific, MA). The total
RNA from the cells was isolated using the RNeasy mini kit (Qiagen, Valencia, CA). The
quality and quantities of the RNA were analyzed by Take3 micro-volume plate (BioTek,
Winooski, VT). One µg of RNA was reverse transcribed using Qiagen RT kit. The cDNA
samples were then amplified using Qiagen SYBR green kit in Rotorgene RT-PCR
machine (Corbett Research, Mortlake, NSW, Australia). All primers were procured from
Integrated DNA Technologies (IDT, Coralville, IA). Each sample was normalized to the
expression of β-2 microglobulin (β2-MG) as a housekeeping gene and compared to their
respective untreated control groups (cells cultured in DMEM-F12 alone), using the 2∆∆CT

method.273
Gelatin zymography
Active MMP-2 was analyzed in the cell lysates (intracellular soluble proteins) by

gelatin zymography.309 The total protein was quantified using BCA kit and 12 µg total
protein was loaded per well alongside with pre-stained molecular weight standards
(Precision Plus Protein Standard, Bio-Rad, Hercules, CA). All lanes were loaded in
duplicates with equal amounts of protein in each well. After development, coommasie
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staining and de-staining, the gels were photographed and density of clear bands (MMP-2
at 68kDa) was analyzed using ImageJ software and reported as relative density units.
Immunofluorescence for elastin, fibrillin-1
RASMCs/ EaRASMCs were treated in similar conditions as mentioned earlier.
After 14 days, the cell layers were washed twice with PBS and fixed in 4% formaldehyde
for 15 minutes in room temperature followed by incubation with a 5% bovine serum
albumin blocking serum. The primary antibody, rabbit anti-rat elastin antibody (United
States Biological, Swampscott, MA) or a rabbit polyclonal anti-fibrillin I antibody
(Abcam, Cambridge, MA) at 1:100 dilution was applied overnight at 4°C. Alexafluor 488
chicken anti-rabbit IgG secondary antibody (Molecular Probes, Eugene, OR) was applied
at a dilution of 8µg/ml for 2 hours at room temperature. Cell layers were mounted using
aqueous mounting medium with anti-fading agents (Biomedia corp., Foster city, CA).
The samples were examined by fluorescent microscopy. Importantly, all samples were
imaged under exactly similar conditions for impartial analyses.
In-vitro coacervation and maturation of tropoelastin
The kinetics of tropoelastin coacervation and maturation were performed using
UV-Vis plate reader (BioTek, Winooski, VT) equipped with temperature, stir controllers
and kinetic measurement features. 1 mg of human recombinant tropoelastin (Advanced
BioMatrix, Poway, CA) was dissolved in 100% glacial acetic acid (Fisher Scientific,
MA). Polypeptides were diluted in coacervation buffer (50 mM Tris, pH 7.5) to either 25
µM for one set of experiments and 10 µM for another set of experiments. The
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temperature of coacervation was 37°C. Samples were stirred at the rate of 1000 rpm and
absorbance was measured at 440 nm every minute throughout the reaction time.
Polyphenols at 10 µg/ml were added to the polypeptides (in ice) immediately before the
absorbance measurement.
Statistical data analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.
5.3

Results
Polyphenols bind to mature elastin
In order to determine the binding kinetics of polyphenols to elastin, pure porcine

elastin (the method described earlier) was incubated in 1.5 ml polyphenols of different
concentrations (10, 25, 50, 100 µg/ml) and the solutions were assayed for 48 hours.
Respective control polyphenol solutions without elastin were also maintained to evaluate
the stability of polyphenols in solution over time. Within 1 hour of incubation, at 100
µg/ml PGG, there was a reduction of 68.67% ± 6.89% of initial PGG quantity which
further reduced to ~42.09% ± 5.4% after 6 hours and less than 5% ± 0.63% of initial
PGG after 24 hours, clearly indicating the binding of PGG to elastin (Figure 5.1).
Furthermore, the control groups without elastin showed no absorbance variability over
time (data not shown) indicating the stability of PGG in solution and confirming the
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binding of PGG to elastin. The Langmuir rate of adsorption of PGG after 60 minutes was
calculated to be 0.052 µg PGG/mg dry elastin/min. Likewise, EGCG quantities in the
solution reduced by ~72% ± 3.8% after 60 mins, ~45% ± 7.63% after 6 hours and less
than 25% ± 5.35% after 24 hours. The Langmuir rate of adsorption of EGCG after 60
minutes was calculated to be 0.044 µg EGCG/mg dry elastin/min (Figure 5.2). Catechin
quantities in the solution reduced by ~77% ± 1.8% after 60 mins, ~65% ± 0.1% after 6
hours and less than 60% ± 1.25% after 24 hours. The Langmuir rate of adsorption of
EGCG after 60 minutes was calculated to be 0.045 µg catechin/mg dry elastin/min
(Figure 5.3). It is interesting to note that although catechin shows greater and faster
adsorption compared to PGG in the first 6 hours, the total reduction after 24 hours is
greater in PGG compared to EGCG and Catechin groups. This may be attributed to the
smaller molecular weight of catechin and fewer phenolic groups, therefore displaying
higher initial binding but low overall binding. Figure 5.1, 5.2, 5.3 depicts the binding
kinetics of polyphenols to elastin over time. It also indicates the direct positive
correlation of polyphenol concentration to rate of binding.
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Figure 5.1:Binding kinetics of PGG to insoluble elastin. Quantity of PGG bound
to elastin increases with time which was measured indirectly as the
decrease in absorbance of PGG over time.

Figure 5.2:Binding kinetics of EGCG to insoluble elastin. Quantity of EGCG
bound to elastin increases with time which was measured indirectly as
the decrease in absorbance of EGCG over time.
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Figure 5.3:Binding kinetics of EGCG to insoluble elastin. Quantity of EGCG
bound to elastin increases with time which was measured indirectly as
the decrease in absorbance of EGCG over time.

In a separate set of experiments, much higher concentration of polyphenol
solution (10, 100, 1000, 10000µg/ml) was used to validate the binding of polyphenols to
elastin. Figure 5.4 shows the amount of polyphenols bound to elastin after 48 hours of
incubation. At 1:1 polyphenols to elastin w/w ratio (10000 µg/ml polyphenols), ~ 140 µg

PGG, 183 µg EGCG and 105 µg catechin / mg dry elastin was bound to elastin.
Corresponding control groups (without polyphenols) showed no absorbance indicating
the absence of polyphenols.
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Figure 5.4:Quantity of polyphenols bound to elastin after 48 h of
incubation

Further, the binding of polyphenols was histologically verified using a ferric
chloride stain that binds to phenolic compounds imparting a deep purple to black color.

Untreated control groups (Figure 5.5 A) showed no visible stain for phenolic groups
when compared to PGG (Figure 5.5 B), EGCG (Figure 5.5 C) and catechin (Figure 5.5
D) treated groups. All the histological images were representative pictures taken for

elastin samples treated with 10000 µg/ml polyphenol solutions.

Figure 5.5:Phenol specific stain shows incorporation of polyphenols into pure aortic
elastin
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Polyphenols provide vascular elastin with elastolytic resistance
Resistance against elastase degradation was tested using aortic samples
treated with polyphenols followed by porcine elastase degradation. The difference in the
dry weights before and after elastase treatments indicated the elasto-protective effects of
polyphenols. Control elastin preparations (without polyphenol treatment) lost ~80% total
mass (Figure 5.6). Treatment with 10, 100 µg/ml polyphenol solutions did not apparently
prevent from elastolytic degradation (p>0.05) whereas 1000 and 10000 µg/ml reduced
the susceptibility of elastin degradation by ~25% and 88% in PGG, 17% and 88% in
EGCG, 15% and 33% in catechin groups respectively.
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Figure 5.6:Efficacy of polyphenols as elastin-stabilizing agent.

The elasto-protective feature of polyphenols was further confirmed

histologically with VVG staining. Untreated control elastin groups display clear signs of
fiber degradation and matrix degeneration (Figure 5.7 A) while elastin stabilized with
10000 µg/ml polyphenols exhibit little to none fiber degradation (Figure 5.7 B, C, D).
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Figure 5.7:Histology of pure elastin after digestion with elastase. PGG (B),
EGCG (C), catechin (D) show intact elastin fibers compared to
untreated control (A).

Additionally, the digestate after elastase digestion was run through SDS- PAGE to
evaluate the elastin fragments in solution. The untreated control groups showed a dark
smear of elastin fragments at different molecular weights indicating severe elastic
damage which was evidently inhibited by 1000 and 10000 µg/ml polyphenol treatments,
especially in the PGG and EGCG groups (Figure 5.8). It must be noted that the solution

assayed had elastase which might be contributing to the band density.
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Figure 5.8:Degradation products after elastase digestion. Polyphenol treated group show less
band density indicating greater protection against elastase digestion

Polyphenols bind to tropoelastin and accelerate rate of self-assembly in-vitro
Kinetics of tropoelastin coacervation was examined in-vitro using a UVVis spectrophotometer enabled with stir rate controllers and temperature monitoring
device. In initial experiment (Figure 5.9), tropoelastin “coacervation phase” was marked
by a rapid increase in absorption at 440 nm. This initial rise in absorbance is thereafter
followed a steady decrease in absorbance; a stage termed as “maturation phase”.
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Figure 5.9:In-vitro elastin self-assembly kinetics

Addition of polyphenols dramatically increased the rate of coacervation (Figure
5.10 A) (PGG by 1.6-fold, EGCG and catechin by 7.5-fold) and delayed the onset of
maturation (20 mins for pure polypeptides Vs. ~200 mins for polypeptides +
polyphenols).

Figure 5.10:(A) Shows the self-assembly kinetics of tropoelastin after polyphenol
addition. (B) The rate of coacervation and m
maturation
aturation of tropoelastin
after addition of polyphenols
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MTT assay for cellular proliferation
A colorimetric cell proliferation assay was used to evaluate the viability of
aneurysmal smooth muscle cells in vitro. MTT showed a significant retardation in cell
proliferation when cells were exposed to 10 µg/ml PGG and catechin, whereas 1 µg/ml
polyphenols showed minimal difference in cellular proliferation. EGCG appeared
indifferent compared to control groups at both 1, 10 µg/ml concentrations (Figure 5.11).

Figure 5.11:MTT cell proliferation assay after polyphenol treatment

Tropoelastin and cross-linked elastin production
Figure 5.12 A depicts the cross-linked insoluble elastin deposited by

healthy vascular cells after 14 days. Evidently, all the polyphenols significantly enhanced
the deposition of insoluble elastin. Interestingly, the quantity, kinetics and dynamics of
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addition
dition of polyphenols
tropoelastin released in the media were not changed by the ad
(Figure 5.12 B).

Figure 5.12:(A) Shows the deposition of insoluble elastin by healthy RASMCs in
response to polyphenols (B) shows the tropoelastin produced in the
media in response to polyphenols

The exact same trends were also observed in passage matched aneurysmal cells
exert
ert any elastogenic effects, at
(Figure 5.13 A, B). Polyphenols added at 1 µg/ml did not ex
least after 14 days in culture. At 10 µg/ml, PGG induced ~8-fold greater mature elastin in
healthy RASMCs and 6-fold more elastin in aneurysmal EaRASMCs. EGCG at the same

concentration, increased elastin fiber deposition by ~ 4 times in RASMCs and 2 times in
EaRASMCs. Catechins showed ~ 1.7 fold greater insoluble elastin deposition in
EaRASMCs. Due to the infectivity of polyphenols at 1 µg/ml in elastic matrix
enhancement, all further studies were carried out using polyphenol
polyphenolss at 10 µg/ml
concentrations.
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Figure 5.13:(A) Shows the deposition of insoluble elastin by aneurysmal
EaRASMCs in response to polyphenols (B) shows the tropoelastin
produced in the media in response to polyphenols

Figure 5.14 A is a comparative graph displaying the total tropoelastin elastin

production by RASMCs and EaRASMCs. None of the polyphenols influenced the
cellular tropoelastin production after 14 days by both healthy and aneurysmal cells.
Counter-intuitively, aneurysmal cells released ~ 1.6 times greater soluble tropoelastin

compared to healthy cells, however, failed to translate into increased matrix production in
B).
). In addition, even with unchanged
a comparable time period of 14 days (Figure 5.14 B
levels of tropoelastin, healthy RASMCs deposited nearly double the elastin quantity in
the presence of polyphenols when compared to aneurysmal EaRASMCs.
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Figure 5.14: (A) Total tropoelastin released by RASMCs and EaRASMCs after 14
days (B) total insoluble elastin deposited by RASMCs and
EaRASMCs after 14 days of treatment with 10 µg/ml polyphenols

LOX functional activity

The trend curves of LOX activity revealed that healthy RASMCs maintain
relatively stable expression and activity of LOX throughout the culture period (Figure
5.15 A); however, there is a progressive increase in the LOX activity in the presence of

polyphenols in aneurysmal EaRASMCs (Figure 5.5 B), which is not as pronounced in
untreated control groups.
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Figure 5.15:LOX released by (A) RASMCs and (B) EaRASMCs with 10 µg/ml
polyphenols treatment over 14 days

Furthermore, the overall activity of LOX over 14 days was significantly greater
in untreated healthy RASMCs compared to EaRASMC (~ 2 times). PGG addition
enhanced LOX activity by ~ 4 times in healthy and 5 times in aneurysmal cells.

Following similar trends, EGCG up-regulated LOX activity ~ 3-fold and catechin by 1.5
times in RASMCs and EaRASMCs. (Figure 5.16)

Figure 5.16: Total LOX produced by RASMCs and EaRASMCs after 14 days.
healthy
thy control cells
* - significant difference compared to heal
# - significant difference compared to aneurysmal cells
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ELN, Fib-1 immunofluorescence
All cell cultures attained confluency and deposited sufficient extracellular

matrix (confirmed by routine phase contrast microscopy) by the end of 14 days. The cells
were fixed and immunolabeled for elastin and fibrillin-1. It was noted that cell density
was visibly lower in the treatment groups as expected from the MTT results.

Immunofluorescence micrographs of 14 day cultures of EaRASMCs showed higher
amounts and well-oriented elastin fibers (green fluorescence) in the polyphenol groups
(Figure 5.17 B, C, D) as opposed to the control groups (Figure 5.17 A). Nuclear DAPI

stain reveals relatively uniform cell layers in all the groups, however, the groups treated
with PGG and EGCG showed granular localization of elastin fibers indicating greater
deposition of elastic matrix.

Figure 5.17:Immunofluorescence for elastin by EaRASMC in (A)
control, (B) PGG, (C) EGCG, (D) catechin groups
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Fibrillin-1 immunofluorescence also showed slightly greater staining in the PGG
treated groups (Figure 5.18 B) compared to control cell layers (Figure 5.18 A).

Figure 5.18:Immunofluorescence for Fibrillin-1 by EaRASMC in (A)
control, (B) PGG, (C) EGCG, (D) catechin groups

Elastin and LOX relative gene expression
RT-PCR studies revealed that compared to healthy RASMCs, EaRASMCs
have ~ 2-fold elastin gene expression. PGG groups were used as a representative

polyphenol for mRNA expression studies. Addition of PGG did not sig
significantly
nificantly alter the
relative gene expression of elastin gene, implying the extracellular involvement of PGG
in the process of elastic matrix deposition (Figure 5.19).
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Figure 5.19:Relative gene expression of elastin gene by RASMC and
EaRASMC. All groups normalized to β-2mg expression
and healthy RASMC was used as baseline control.

Unexpectedly, there was a dramatic increase (~9 fold greater) in the relative gene
expression of LOX in the EaRASMCs groups compared to the healthy RASMCs (Figure
5.20), which seemed down-regulated by the addition of PGG. The gene expression of

LOX did not translate into co-relatable enzymatic activity. Speculatively, defunct
translation of the LOX gene in aneurysmal cells may be the causal factor for impaired
elastin deposition.
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Figure 5.20:Relative gene expression of LOX gene by RASMC and
EaRASMC. All groups normalized to β-2mg expression
and healthy RASMC was used as baseline control

MMP-2 enzymatic activity

Gelatin zymography revealed that the total MMP-2 (66 kDa) activity was ~ 2-fold
greater in the EaRASMCs when compared to healthy RASMCs, which was reduced by ~
62% ± 12.9% by PGG, 58% ± 2.3% by EGCG and 67% ± 4.4% by catechin. Healthy
cells did not display any difference in their MMP-2 activity under the influence of
polyphenols. (Figure 5.21)
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Figure 5.21:(A) Relative density units of MMP-2 cellular activity (B)
clear bands indicating MMP-2 activity by cells

5.4

Discussion

Abdominal aortic aneurysm (AAA) is a life threatening vascular disease with no
available pharmacological therapy. AAA is a multi-factorial pathology involving several
biological, physical, bio-mechanical and hemodynamic factors that eventually lead to the

pathological thinning of the artery, ballooning and rupture. Current clinical repair options
include surgical repair and deployment of endovascular stent grafts. Both these options
are surgically invasive, have their own demerits and do not prov
provide
ide a permanently viable
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cure to the damaged artery. Given the nature of the disease, poor turnover of elastin
fibers, and eventual failure being a result of acute mechanical loss of elastin, the ideal
treatment option would be a combination of strategies working synergistically towards
preventing elastolytic degradation, halting proteolytic activity, stabilizing matrix and
regenerating arterial proteins and matrix. In a series of prior publications we have
investigated the interactions of polyphenolic compounds with elastin and its ability to
stabilize elastin as a potential AAA treatment.30,233,305,310 It has been previously
demonstrated that tannic acid and PGG bind to elastin and render it resistant to elastolytic
damage, which makes it an attractive elastin-stabilizing agent for cardiovascular
prosthesis.310 In a relevant rodent model, a single time peri-adventitial application of
PGG has also prevented the formation and progression of AAA.305 Although the
polyphenols under investigation proved valuable in stabilizing healthy aortic elastin, the
interaction between polyphenolic compounds and tropoelastin in the process of
elastogenesis was never studied. The aim of this work was to investigate the biological
aspect of polyphenols like PGG, EGCG and catechin in aiding in the process of
elastogenic matrix formation in a cell-culture model.
The first finding of our studies was that polyphenols rapidly bind to insoluble
mature elastin and the interaction is dose dependent. These trends are in agreement with
previous studies.30 The binding kinetics is a time and concentration dependent process. At
concentrations of 1000 µg/ml polyphenol solution, 14 µg PGG/mg elastin, 23 µg
EGCG/mg elastin, 29 µg catechin/mg elastin were bound to elastin after 48 hours. At
these treatment concentrations, pure elastin preparations showed significant protection
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against elastase degradation (Figure 5.4). MMP mediated elastin degradation is a
characteristic feature of AAA leading to progressive degeneration of elastin and
expansion of aorta.311,312 Elastases from various sources such as, macrophage elastase and
neutrophil elastase attack the hydrophobic domains of elastin resulting in enzymatic
cleavage.313 Plant derived polyphenols like tannins and flavanols have demonstrated
their potential in inhibiting human leukocyte elastase activity 314 and preventing MMP-2/9 activity in cancer cells.315 Catechin derivatives have also displayed MMP inhibition
therefore preventing elastin degradation.316 Use of polyphenols such as PGG, EGCG, and
Catechin can therefore provide a novel strategy for stabilization and prevention of AAA
progression.
Stabilizing aneurysmal elastin and protection against proteolytic damage resolves
only one half of the pathological complication of AAA. A larger challenge in treating
AAA is the inherently poor elastin turn-over by adult cells317,318 that prohibits the repair
and regeneration of degraded elastin. Knowing polyphenols bind to hydrophobic amino
acid residues with strong affinity,229 we hypothesized that cellular tropoelastin will
interact rapidly with polyphenols helping the process of coacervation and self-assembly
accelerating the process elastin crosslinking, thereby enhancing elastic fiber deposition.
In this current in vitro cell culture study, we demonstrated that addition of polyphenols to
healthy vascular cells enhances the mature cross-linked elastin fiber deposition at 10
µg/ml concentration. Anti-proliferative effects of polyphenols have been established in
literature before319, however only PGG at 10 µg/ml displayed anti-proliferative
tendencies in our cell culture set-up (Figure 5.11). Although encouraging, we wanted to
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verify if similar trends are evident in a diseased model as well. For this purpose, we used
late-stage aneurysmal cells and treated them with polyphenols. The motive behind using
cell culture models was for better monitoring of intra-cellular and extracellular dynamics.
The aneurysmal cells were procured from rats with advanced abdominal aortic aneurysm
induced by luminal elastase perfusion, the description and characterization for which has
been described elsewhere.308 Under the influence of polyphenols, aneurysmal cells
deposited significant higher quantities of matured elastin compared to untreated control
groups. Interestingly, the trend curve of tropoelastin did not very with or without the
addition of polyphenols (Figure 5.12 B, 5.13 B). Furthermore, the total tropoelastin
released by cells remained constant in all the groups; in both healthy and aneurysmal
cells (Figure 4.14 A). This suggests that polyphenols exert their elastogenic effect extracellularly and do not directly enhance the cellular tropoelastin production. Surprisingly,
the total tropoelastin production was higher in diseased cells compared to healthy cells.
This observation is similar to the past studies showing that AAA tissues produce greater
tropoelastin compared to healthy tissues.320
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However, failure of desmosine crosslinks

cause ineffective elastin maturation. As per our findings, the mRNA expression of elastin
by aneurysmal cells is also greater compared to healthy cells (Figure 5.19). This may be
compensatory feedback mechanism to replenish degraded elastin in AAA. However,
elastic fiber assembly may be the limited by factors acting at the post-transcription level.
It should be noted here that the addition of PGG (representative polyphenol) did not alter
the tropoelastin mRNA expression, therefore substantiating the external role of PGG in
elastic matrix formation.
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To further understand the mechanisms involved in the process of elastic fiber
deposition, we evaluated the LOX mRNA expression and enzymatic activity. LOX is a
vital enzyme required in the process of elastin crosslinking42 and is strongly suppressed
in aneurysmal tissues.321 Our results indicate that aneurysmal cells have significantly
lower LOX activity when compared to healthy cells (Figure 5.16), which is, however,
increased in the presence of polyphenols. Although the mRNA expression does not
correlate with the post-translation enzymatic activity of LOX, it appears that LOX is
regulating the crosslinking of elastin in the cell layers.
To further elucidate the sole interactions between tropoelastin and polyphenols,
we incubated recombinant tropoelastin with polyphenols to study the self-assembly
kinetics of elastin in-vitro. Due to the presence of excess hydrophobic domains in
tropoelastin, coacervation is an endothermic and entropically-driven process. Selfassembly can be broadly divided into reversible “coacervation phase” leading to
increasing turbidity in solution and irreversible “maturation phase” causing the growth of
the coacervates.57 Microfibrillar scaffolding proteins such as MAGP-1, fibulin-5 are
known to interact with tropoelastin coacervates and also recruit LOX for the oxidation of
lysine residues leading to formation of intermolecular crosslinks.322,323 The presence of
microfibrillar proteins have also shown to increase tropoelastin coacervation and retard
maturation in-vitro that aids in better alignment of coacervates and systematic oxidation
of lysine residues.48,57,322 The importance of increased coacervation lies in greater and
more specific increase in the intermolecular structure of individual tropoelastin molecules
facilitating downstream elastogenic events. Our results suggest that the addition of
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polyphenols dramatically alter the self-assembly kinetics of tropoelastin. The interaction
of polyphenols with tropoelastin is evident in the coacervation phase which is
significantly accelerated compared to pure tropoelastin in solution (Figure 5.10). While
control tropoelastin molecules enter maturation by ~ 20 minutes, PGG takes ~ 180
minutes, EGCG and catechin takes ~200 mins to start maturing. In addition, the
polyphenols also increase the rate of coacervation as evident from the sharp increase
initial turbidity. It is thus a safe conclusion that polyphenols dramatically aid in the
process of tropoelastin self-assembly; partly by increasing the rate of coacervation and
partly by inhibiting maturation, thereby providing greater inter-molecular interaction for
lysine oxidation.
5.5

Limitations of the studies
There are certain limitations to this study. Firstly, the ranges of polyphenol

concentrations used were different in the elasto-protective studies and elasto-regenerative
studies (10-1000 times more in the elasto-protective studies). The intent of this
experiment was to determine the ability of polyphenols to provide elastolytic protection.
High concentration of polyphenol (1000 µg/ml) is extremely toxic in cell culture system,
whereas low concentrations of polyphenol (10 µg/ml) fail to show elasto-protective
effects. Previously, a single time application of PGG on rat aorta at ~ 3000 µg/ml did not
show any hepatotoxic effects.225 Therefore, it can be assumed that in-vivo applications of
polyphenols will have higher tolerance compared to cell culture studies. Secondly, the
polyphenols were dissolved in DMSO, the combined effect of polyphenols and DMSO
could have potentially toxic effects on the cells. From the studies done, all the
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experiments were normalized to total soluble protein for fair comparison; however there
was a significantly lower protein concentration in the groups treated with PGG (data not
shown). This might have caused an over-estimation of the quantities of insoluble elastin
reported. Regardless, the absolute quantities of cross-linked elastin in the PGG groups
were still higher compared to control groups. Thirdly, our results show that polyphenols
bind to insoluble elastin and protect from degradation. It is a strong possibility that
polyphenols are merely binding to cross-linked elastin in cell culture system and
preventing it from MMP mediated degradation. It is also unclear if polyphenols are
exerting their effects indirectly by reducing MMP concentrations (as seen in the Figure
5.21). Finally, elastin synthesis and fiber assembly is a well-orchestrated, complex and
relatively poorly understood process (as discussed in Chapter 2). We have not studied the
effect of polyphenols on critical assembly proteins like fibulin-4, 5, latent TGF-β binding
protein, fibrillin-2, and matrix associated gla protein-1. It is clear that polyphenols
accelerate coacervation; however maturation phase is a complex interplay of all the above
mentioned proteins. Further experiments need to be done to understand clearly the exact
stage of elastogenesis at which polyphenols are exerting their effect.
5.6

Conclusion
We show that use of polyphenols works dually, firstly by binding to cross-linked

insoluble elastin and rendering it resistant to elastolytic degradation; secondly by
interacting with monomeric tropoelastin and accelerating the elastic matrix deposition by
vascular cells. Thus such treatments could be locally applied to treat and repair elastic
fiber degradative diseases such as aortic aneurysms. Such treatments would halt the
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progression of elastic fiber degradation and at the same time allow cell secreted
tropoelastin molecules to assemble to create new elastic fiber assembly so that
degradative damaged could be repaired and the disease can be reversed.
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CHAPTER 6

NANOPARTICLE TARGETING TO INJURED VASCULATURE FOR
IMAGING AND THERAPY

6.1

Introduction
Targeting drugs to diseased vessel walls is difficult. Due to high shear flow

conditions in arteries, oral, parenteral, or intra-arterial administrations of therapeutics
have shown limited success and unwanted systemic side effects in treating vascular
diseases.324 For instance, anti-coagulants administered for coronary thrombotic
occlusions present with severe unwanted side-effects of hemorrhage325 and systemic
doxycycline delivery for treatment of abdominal aortic aneurysm (AAA) have negligible
therapeutic benefit due to side-effects such as cutaneous photosensitive reactions, tooth
discoloration, gastro-intestinal symptoms and yeast infection.21 In order to maximize
therapeutic benefit and minimize off-target effects, a considerable effort has been spent in
developing local vascular drug delivery. Various approaches to target vasculature are
mostly focused on cell markers on activated endothelium, vascular smooth muscle cells,
or inflammatory cells such as macrophages. Although abundantly over-expressed in
inflammatory conditions, these markers provide limited targeting as they are
heterogeneous, transiently expressed in the vasculature and also undergo physiological
receptor recycling. As an alternative approach, we developed a novel biodegradable
nanoparticle system that can be targeted to the site of vascular degraded elastic fibers
which is a hallmark of many vascular diseases. For example, elastin degradation is
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observed

in vascular calcification in age-related elastocalcinosis (Monckenberg’s

sclerosis),326 diabetes327 and end-stage renal disease.328,329 Another very different yet
serious disease of vascular matrix is aneurysm. In particular, abdominal aortic aneurysm
(AAA) is a degenerative disease of the artery characterized by severe protease-mediated
degradation of extracellular matrix, especially elastin, causing dilatation of the aortic wall
leading to rupture and in certain cases death.330

In addition, vascular proliferative

diseases of smaller arteries including coronary arterial occlusion and atherosclerotic
mediated stenosis share common pathological features such as elastin degradation331,332
and accumulation of vascular smooth muscle cells in the intima.333 Thus, successful
targeting of only degraded elastin provides the advantage of particle retention in the
extracellular matrix as opposed to rapid cellular uptake thereby enabling delivery of
several agents to the extracellular space.
In this chapter, we show that elastin specific targeting of nanoparticles is possible
by the delivery of Polylactic acid (PLA) nanoparticles decorated with elastin-specific
antibodies on to the surface of the particles. This minimally invasive technique can
augment drug concentrations at the site of vascular damage, mitigate the undesirable
effects of drugs and increase drug efficiency.
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6.2

Methods
Fabrication of nanoparticles
Poly(D,L-lactide) (PLA) nanoparticles were prepared using a nanoprecipitation

method based on solvent diffusion. Briefly, 10 mg PLA (Average MW 75,000-120,000)
(Sigma Aldrich, St.Louis, MO) was dissolved in 1ml acetone (VWR International,
Radnor, PA). ~2.5 mg of 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N[maleimide (polyethyleneglycol)-2000] (PEG maleimide) (Avanti Polar Lipids, Inc.,
Alabaster, AL) and 250 µg of 1, 1-dioctadecyl-3, 3, 3, 3-tetramethylindotricarbocyanine
iodide (DIR) (Biotium, Inc., Hayward, CA) were added to the PLA solution in acetone.
~300 µl of polymer solution was added drop-wise at a uniform rate to 8 ml of water kept
under sonication in a water bath sonicator and solutions were sonicated for 1 hour. The
resulting suspension contained nanoparticle with encapsulated DIR dye. The particles
were purified 3 times by centrifugation at 3000×g for 15 minutes followed by redispersion in water.
Characterization of particle size and surface charge measurement
Particle size in suspension was determined using 90Plus Particle Size Analyzer
(Brookhaven Instruments Co, Holtsville, NY). 10 µl of nanoparticle suspension was
diluted in 3 ml of HPLC-grade water in a disposable plastic cuvette. Particle size and
degree of aggregation were visualized using an Asylum Bio-MFP3D atomic force
microscope (Asylum Research, Santa Barbara, CA).

154

Surface charge measurements (zeta potential) were made by dissolving stock
solutions as 1:100 in water in a disposable cuvette and the zeta potential was measured
using the 90Plus Particle Size Analyzer (Brookhaven Instruments Co, Holtsville, NY).
The zeta potential was expressed in millivolts (mV) as a combined mean (±SD).
Nanoparticles were characterized using an atomic force microscope (Asylum BioMFP3D, Asylum Research, Santa Barbara, CA). AFM experiments were conducted in
tapping mode in ambient conditions using Olympus AC240TS cantilevers backsidecoated with aluminum with a spring constant of ~2 N/m. Nanoparticle samples were
diluted 50 times, and then a 100 µl drop was placed onto freshly peeled Muscovite mica
surface, incubated for 15 minutes, then dried under air flow.
Nanoparticle conjugation with antibodies
10 µg of rabbit anti-rat elastin antibody (United States Biological, Swampscott,
MA) or rabbit anti-rat IgG antibody (Thermo Scientific, Rockford, IL) were thiolated
using 34 µg of freshly prepared Traut’s reagent (G-Biosciences, Saint Louis, MO) in
HEPES buffer for 1 hour. Thiolated antibodies were washed thrice with HEPES buffer
(20 mM, pH=9.0) and dialyzed through 10 kDa MWCO filters to remove Traut’s reagent.
Purified and thiolated antibodies were then added to particles (4µg antibody / mg
polymer) and incubated overnight at room temperature for conjugation. After conjugation
antibody coated particles were purified twice (3000×g for 15 minutes) and suspended in
PBS at 4°C until further use. For optimization experiments, 0.1-25µg antibody/mg
polymer was used.
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Antibody concentration and correlation
An independent set of experiments was performed to establish the effect of
antibody concentration on the binding yield of antibody to the particles. The PLA
nanoparticles were prepared as described earlier, known amounts (0.1-25µg) of Alexa
fluor 594 conjugated IgG solution in HEPES was added to 1 ml of 1 mg/mL PLA
nanoparticles (final volume was 1.025 ml in all cases) and incubated overnight. Samples
were centrifuged, and supernatant was analyzed using fluorescent spectrometry. Three
replicates were used for each concentration. A calibration curve was plotted from
standard solutions (0.1-25µg of antibody in 1.025 ml of HEPES) fluorescence data
obtained under similar conditions. Calibration curve was fitted using 2nd order
polynomial equation, and a reverse equation for accurate calculation of antibody content
from fluorescence data was derived. The differences in the fluorescence of bound and
unbound dyes were used to calculate the binding yield percentage. Concomitantly, the
number of antibody molecules per nanoparticle was calculated by dividing the number of
antibody molecules by the average number of nanoparticle (n) using the following
equation:
n = 6m/(π × D3 × ρ)
where m is the nanoparticle weight, D is the mean diameter determined by DLS, ρ
is the density (assuming PLA density of 1.25 g/cm3).
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Transmission electron microscopy of immunogold-stained nanoparticles
The nanoparticles were prepared as described earlier. The IgG antibody coated
nanoparticles (INPs) (30µg) were incubated with 10 nm gold stained goat-anti-rabbit IgG
(5X1011 gold particles) (Sigma Aldrich, St.Louis, MO) overnight in 0.018M tris buffered
saline (TBS), pH=8, with 0.9% bovine serum albumin and 17% glycerol. Following
incubation, the particles were washed twice with TBS to remove unbound antibodies at
14,000×g for 15 minutes, deposited in a formvar-coated copper grid followed by negative
staining with 2% phosphotungstic acid and examined directly with transmission electron
microscopy.
Cytotoxicity and cellular uptake of ENPs
Rat aortic vascular smooth muscle cells (passage 6) were treated with 2.5, 10 and
25 µg elastin antibody concentration and 100, 500 µg/ml PLA concentrations to evaluate
cytotoxicity and cellular uptake of ENPs. Cells were seeded at 10,000 cells/cm2. At 70%
confluency, cells were incubated with nanoparticles for 4 hours following which cell
viability was determined using a LIVE/DEAD Cell Viability assay (Molecular Probes,
Grand Island, NY). Cells fluorescing green are considered alive while cells fluorescing
red are considered dead. Additionally, proliferation of cells was estimated using the MTT
(3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay. Briefly, 5 mg
of MTT (Sigma Aldrich, St.Louis, MO) was dissolved in 10 ml of serum-free media and
added to cells. After 4 hours, media was carefully aspirated and the insoluble formazan
dye was collected with dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO).
Absorbance was read at 560 nm and normalized to control (no treatment) readings.
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To visualize the internalization of nanoparticles, nanoparticles of different sizes
and surface charge were tested. Low molecular weight PLA (Average MW 9,000) were
used to prepare nanoparticles by the exact same procedure as mentioned earlier. To
modulate the surface charge density, purified ENPs were incubated with 0.2 mg poly-Llysine / mg of polymer (Sigma Aldrich, St. Louis, MO, Average MW 150,000-300,000)
for 2 hours at room temperature. Following incubation, the nanoparticles were thoroughly
purified 2 times (centrifuged at 7000×g for 2 hours) to eliminate excess poly-L-lysine and
re-suspended in water. 24 hours after nanoparticle incubation, the cells were thoroughly
washed with Phosphate buffered saline (PBS) to eliminate unbound nanoparticles, fixed
with 4 vol.% formaldehyde, labeled with the lipophilic membrane stain DiI (Invitrogen,
Carlsbad, CA), and then mounted with Vectashield containing the nuclear dye 40 ,6diamidino-2-phenyindole (DAPI; Vector Laboratories, Burlingame, CA). Imaging of
cells was performed using fluorescent microscopy (EVOS fl. Microscope, Advanced
Microscopy Group, Bothell, WA).
Ex-vivo nanoparticle binding studies for elastase treated aorta
High purity porcine pancreatic elastase (Elastin products company, Owensville,
Missouri) was prepared (5U/ml) in 100mM Tris Buffer, 1mM calcium chloride, 0.02%
sodium azide, pH 7.8. Aortas from Sprague-Dawley rats were explanted, rinsed and
treated with elastase for 10, 20, 30, 60 mins. The aortas were clamped on either ends, and
ENPs/INPs (prepared following the same method as described earlier) were injected
intra-luminally for 1 hour at room temperature. Following injection, the aortas were
thoroughly washed (3 times) with PBS to minimize non-specific adherence of
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nanoparticles. Simultaneously, ENPs/INPs were also injected in control aorta (without
elastase treatment). Following nanoparticle infusion and washing, the aortas were
lyophilized. The dry weights of the aorta were recorded. A small portion was embedded
in Tissue Tek OCT compound for histological analysis. The lyophilized aorta were
homogenized using a PowerGen 125 homogenizer (Fisher Scientific, MA) in Dimethyl
sulfoxide (DMSO), placed in an orbital shaker for 1 hour, 37°C, 200 rpm. Tissues were
centrifuged for 15 minutes at 4000×g. The supernatant was purified by filtering through
0.2 µm nylon membranes were loaded into the HPLC for DIR quantification.
A separate set of experiments was conducted to evaluate the effect of antibody
concentration on nanoparticle surface and binding efficiency to elastase treated aorta.
ENPs were fabricated with 0.1-25µg antibody/mg polymer. Rat aortas were treated with
porcine pancreatic elastase for 60 minutes and washed 3 times with PBS. 1 mg ENP
suspension (0.1-25µg antibody/mg polymer) was injected intraluminally to each rat aorta.
Aortae were washed, lyophilized, weighed, digested and DIR was quantified, as
described previously.
In vivo nanoparticle targeting – calcium chloride injury model
Adult male Sprague-Dawley rats weighing approximately 250-300 g (Harlan
Laboratories, Indianapolis, IN) on a normal diet were used for creating local elastic fiber
damage. All animal procedures were in accordance with the local, state and federal
regulations and approved by the Institutional Animal Care and Use Committee.
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Vascular injury was created in rats (n=6) by peri-adventitial application of 0.5M
CaCl2 for 15 minutes to the infra-renal abdominal aorta using a strip of pre-soaked sterile
cotton gauze. The area was briefly rinsed with warm saline and the abdominal cavity was
closed with subcutaneous suture, followed by surgical staples. The elastin degradation
was allowed to develop for 10 days.334 After 10 days, the rats were anesthetized, PLA
anti-elastin nanoparticles (ENPs) or PLA IgG control nanoparticles (INPs) were injected
in 0.3% rat serum albumin (Sigma Aldrich, St.Louis, MO) through the tail vein of the rats
(10 mg of polymer/kg body weight). The rats were euthanized 24 hours post injection.
The harvested aortae were imaged using Caliper IVIS Lumina XR (Hopkinton, MA) with
Ex/Em of 745/795.
Brain, heart, blood, muscle skin, liver, kidneys, spleen, and lungs, were examined
for fluorescence for determining bio-distribution. Only the organs that presented with
fluorescence were lyophilized and the total fluorescence was normalized to the total dry
weight of each organ. Targeting was calculated as follows:

%targeting 


 

  
   

  100 ) / (dry weight of organ)

The aortic injury was a non-spontaneous locally induced damage. Hence, only the
damaged portion of the aorta was considered “diseased (potential target)” and the dry
weight of the local diseased portion was assumed to be ~10 mg (from separate
experiment).
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In vivo nanoparticle targeting – Warfarin + Vitamin K model
6 week old male Sprague Dawley rats (n=6) were given subcutaneous injections
Vitamin K1 (10 mg/ml, 15 mg.kg-1.day-1 subcutaneous injection, every other day) and
Warfarin (20 mg.kg-1.day-1) in drinking water. Small needles (25 G or smaller) were
used and the subcutaneous injection sites were rotated between the 4 quadrants of the
back to reduce stress. This routine was maintained for 3 weeks. The control group rats
were age-matched and maintained normally with no treatment. At the end of 3 weeks,
elastin antibody coated nanoparticles (ENPs) were injected through the tail vein of the
rats. Following 24 hours of circulation, whole animals were euthanized and imaged using
Calliper IVIS imaging system. The individual organs were also imaged to calculate the
biodistribution and targeting of the nanoparticles. Explanted aorta were rinsed with
phosphate buffered saline (PBS), embedded in Tissue CT compound, and frozen at 80°C.
Local delivery of nanoparticles to damaged abdominal aorta
For local NP delivery, injury to the abdominal aorta was created as mentioned
earlier. After 10 days, the abdominal cavity of the anesthetized rat was exposed, the
injured infra-renal aorta was clamped on either ends, catheterized, and particles (10 mg
polymer/kg body weight) were locally perfused intra-luminally for 5 minutes (100
µl/min). Following local perfusion, blood flow in the aorta was established and animals
were allowed to recover. After 24 hours, animals (n=4) were sacrificed and aortic
sections were imaged using Caliper IVIS Lumina XR (Hopkinton, MA) with Ex/Em of
745/795.

161

Nanoparticle clearance study
To assess the clearance time of nanoparticles in the body, adult male Sprague
Dawley rats were injected with INP (same concentration and preparation as mentioned
earlier). The rats were imaged every other day for 8 days to observe the rate of clearance

of nanoparticles. Live imaging was performed using Caliper IVIS Lumina XR with
Ex.EM of 745/785. The fluorescent signal was normalized to the total body weight of the
rats.

Histological assessment
Explanted aorta were rinsed with phosphate buffered saline (PBS), embedded in
Tissue Tek OCT compound (Sakura Finetek, U.S.A. Inc., Torrance, CA), and frozen at 80°C. 6 µm
m thick sections were cut using a cryostat (Microm HM 505 N, Mikron
Instruments, Inc.) and collected on glass slides. Sections were acclimated at room
temperature for 5 minutes, fixed in cold acetone for 5 minutes and stained with
Verhoeff’s Van Gieson (VVG) (Poly Scientific, Bay Shore, NY) to study structural
integrity of elastin. Sections were also stained routinely with H&E and Alizarin red stain
to observe calcium deposits.

Quantitative assessment
DIR was quantified in all ex-vivo experiments using multi lambda fluorescent
detector Waters 2475 utilizing Waters HPLC sys
system
tem with binary pump 1525 and
autosampler 2707. Since we were interested in analysis of already purified samples,
chromatography column was not used. Samples were injected automatically by the
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autosampler, injection volume was 50 µl. 100% acetonitrile (Sigma Aldrich, St.Louis,
MO) was used as a mobile phase at flow rate of 0.5 ml/min. Spectra were collected with
excitation/emission wavelength of 745/795 nm, using Breeze operating software
(Waters). Samples were prepared in DMSO, and the system was flushed three times after
each injection with DMSO followed by acetonitrile. To eliminate residual signal from
previous injection, blank DMSO was injected prior to sample injection. Preceding the
analysis of the samples the series of standard dilutions of the dye in DMSO was run at the
same conditions, and calibration curve was constructed (R2 = 0.97). In addition, DIR
encapsulation efficiency was calculated as per:



   !  "#$%$" &'()$%
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All measurements were performed at room temperature. Data was collected in
emission units full scale (EUFS) from peak area.
Statistical data analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.
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6.3

Results
Characterization of antibody-nanoparticle conjugates
Particle size was determined using dynamic light scattering (DLS) for bare,

elastin and IgG antibody coated nanoparticles. Over multiple experiments, all groups
consistently sized approximately 200 ± 16 nm (Table 6.1).
Table 6.1: Characterization of nanoparticles
Type of nanoparticle

Size (nm)

Poly dispersity index

ζ- potential (mV)

Blank PLA

222

.136

-27.91

PLA+PEGmaleimide+DIR

226

.152

-66

NP+0.1µg elastin antibody

238

.30

-50.69

NP+0.25µg elastin antibody

208

.326

-45.89

NP+1µg elastin antibody

255

.209

-45.91

NP+2.5µg elastin antibody

242

.277

-41.74

NP+10µg elastin antibody

238

.26

-41.93

NP+25µg elastin antibody

100

.203

-39.57

It was observed that increasing surface density of antibodies decreased the ζ-potential of
the nanoparticles, however; all NPs had negatively charged surfaces (Table 6.1). For all
further experiments, 4 µg elastin antibody/mg total polymer was used for surface
conjugation to nanoparticles. The antibody conjugated nanoparticles were generally
spherical with uniform size when examined under AFM (Figure 6.1A).
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Figure 6.1:Nanoparticle morphology and size characterization. (A) Atomic force
microscopy (AFM) of ENP indicating a general spherical morphology
and ~ 200nm size, (B) TEM fpr immunogold labeling of antibody coated
nanoparticles. Gold-stained IgG (seen as small dark spots) indicate the
presence of antibody on the particle surface. (C) Negative control
without antibody on surface.

PLA-antibody conjugation was studied under TEM. As seen in Figure 6.1B, the
dark 10 nm gold particles are a direct indication of the presence of conjugated antibody
on the nanoparticle surface. Control particles without antibody on the surface showed no
gold staining (Figure 6.1C).
Antibody binding yield depends on initial antibody concentration
The binding yield of antibody increased with increase in the concentration of
antibody used in the experiment (Figure 6.2). The increase in antibody binding leads to
decrease in free PEG hydroxyl groups on the surface. Thus, to balance the amount of
antibody and PEG groups so that optimum circulation time (provided by PEG) and site
specific binding (provided by antibody) could be achieved, we picked the 4 µg/mg
concentration for further studies which demonstrated ~30% binding yield.
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Figure 6.2:Antibody binding yield increases with increasing starting antibody
concentration.

Ex-vivo determination of ENP binding specificity to degraded elastic matrix

To test NPs targeting to degraded elastin in vitr
vitro,
o, isolated rat aortae were treated
with elastase and NPs were delivered intraluminally. Whole rat aortas were exposed to
10, 20, 30, 60 minutes of elastase treatment in vitro to create increasing degrees of elastic
damage. The elastic fiber damage was confirmed by VVG stain (Figure 6.3A, 6.3B).
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Figure 6.3:(A) VVG stain on untreated aorta depicting native
wavy elastin fibers. (B) VVG stain for elastase treated
(60 min) aorta showing disrupted elastic fibers. Insets
show damaged fibers (marked by red arrows).

On intraluminal injection of INPs and ENPs, an increasing adherence of ENPs
with greater elastic damage was observed (Figure 6.4) as assessed by quantitative
fluorescence in the tissue. After 60 minutes of elastase mediated elastic lamina
degradation, there was ~2 fold greater ENP attachment in comparison with INP groups.
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The aortas that were not treated with elastase (control grou
groups)
ps) showed negligible
adherence of NPs suggesting that elastic fiber degradation is essential for NP targeting.

elastase
se for various times showing
Figure 6.4:Rat aorta treated with elasta
NP attachment. INPs/ENPs were administered
intraluminally and incubated for 60 minutes.

An increase in ENPs attachment efficiency was found with increase in surface
6.5).
). At 2.5 µg/ mg polymer ~2.8 fold increase in
antibody concentration (Figure 6.5
control
ol group. Further increase in
attachment was recorded when compared to INP contr
surface antibody concentration did not increase attachment efficiency. ENP uptake by
aorta was reconfirmed with histological assessment, where NPs were visualized as purple
dots along the fragmented media (Figure 6.6A) which were evidently absent in the
control INP groups (Figure 6.6B).
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Figure 6.5:Increasing antibody surface density enhances target attachment
efficiency up to 0.25 µg /mg polymer and stabilizes with further
increase in surface antibody density.

Figure 6.6:ENPs attach to elastase treated aorta (A) compared to lack of INPs
adherence in elastase treated aorta, (B). Original magnification=200X
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In-vitro cell culture studies
Determination of concentration specific toxicity of ENPs
The effect of elastin antibody coated NPs on the viability of rat aortic smooth
muscle cells in vitro was assessed using quantitative (MTT) and qualitative (LIVEDEAD) assays. MTT assay showed a significant retardation in cell proliferation when
500 µg/ml NP were placed in the cell culture media with more than 10 µg/mg levels of
surface antibody concentration. Reducing NP concentration to 100 µg/ml still led to
retardation of cellular proliferation. Positive control (70% ethanol) showed more than
~95% cell death (Figure 6.7A). As gauged by the absence of any dead (red) cells in the
Live/Dead assay (Figure 6.7B), none of the groups appeared cytotoxic at any of the tested
concentrations.
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Figure 6.7:Cell viability and evaluation of cellular uptake of ENPs. (A) MTT
assay quantifying the viability of cells when treated with 100
µg/ml and 500 µg/ml of 2.5,10,25 µg/mg polymer ENPs. (B) Live dead assay on cells treated with an
and
d without ENPs; green = viable
cells, red = dead cells). At 100 µg/ml, 10 µg/mg polymer does not
show significant morphological changes or cytotoxicity compared
to untreated controls.

ENP internalization by vascular smooth muscle cells
We examined the effect of particle size and charge on the intracellular uptake of
DIR loaded-ENPs. Majority of the particles (>200nm) were excluded in the extracellular

space at the end of 24 hours (Figure 6.8A) while particles below 100 nm were taken up
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by cells (Figure 6.8B). To determine the effect of surface charge on cellular uptake of

NPs, ENPs were incubated with poly-L-lysine to create positively charged particle
surface (ζ-potential ~28.76 mV). When cells were presented with these positively
charged particles, an enhanced cellular uptake was found; more so in smaller positively
charged ENPs (Figure 6.8C) when compared to larger positively charged ENPs (Figure
6.8D). Overall, both size (>200 nm) and negative charge of the ENPs was essential to
target them to the extracellular matrix with minimal cellular uptake.

Figure

6.8:Cellular exclusion of ENP of large (>200nm)
nanoparticles (A) and uptake of small (<100nm)
nanoparticles (B), small particles treated with poly-Llysine (C) and large particles treated with poly-L-lysine
(D). Negatively charged ENPs are excluded by cells
when size >200nm compared to <100nm particles.
Increasing positive surface charge enhances cellular
uptake even of larger particles.
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In vivo model for targeting NPs to diseased vasculature
We created calcium chloride mediated injury in the abdominal aorta of rats that
has been shown earlier to create elastic lamina degradation305,334 to assess in vivo
targeting of NPs. We confirmed elastic lamina fragmentation and degradation in this
model by histological assessment. Perivascular application of 0.5 mol/L CaCl2 to the
infra-renal abdominal aorta induced elastic fiber degradation (Figure 6.9A) showing a

distinct discontinuity/ thinning of elastic fibers in the medial layer of the artery while
uninjured control aorta showed undisturbed wavy elastin fibers (Figure 6.9B).

Figure 6.9:(A) VVG of rat aorta after 10 days of calcium chloride treatment, (arrow
marks indicate fragmented elastin fibers) (B) healthy rat aorta.

We then evaluated the targeting efficacy of the ENPs/INPs to the vasculature

with degraded elastic lamina after intravenous delivery. Based on our in-vitro cytotoxicity
experiments, we determined ~100 µg/ml nanoparticle concentration is well within
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tolerable range. Assuming 20 ml total blood volume in rats, we administered 10 mg of
polymer/kg body weight NPs suspended in PBS as one time bolus intravenous injection.

We allowed NPs to circulate and target for 24 hours. Nanoparticles with surface elastin
antibody showed ~3.5 times greater targeting to the injured abdominal aorta as compared
to nanoparticles with surface IgG antibody as measured by % total fluorescence/g tissue
weight (Figure 6.10).

Figure 6.10:Targeting of ENPs to degraded elastic lamina in rat abdominal aorta.
% targeting of INPs vs ENPs at 24 hours after intravenous injection

When the whole aortae were imaged with IVIS instrument, we observed strong

fluorescence in the area of elastin degradat
degradation
ion site in ENP group (Figure 6.11A, boxed
area). In comparison, control nanoparticles with surface IgG antibody showed no
fluorescence in the damaged aorta (Figure 6.11A). Histological assessment showed

nanoparticles with surface elastin antibody were located deeply within medial layers of
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aorta, clearly showing that they penetrate the aorta even under high shear flow conditions
while no detectable fluorescence was observed in INP control group (Figure 6.11B). This

data clearly suggests the targeting of elastin antibody coated NPs to sites of elastic
damage.

Figure 6.11:Targeting of ENPs to degraded elastic lamina in rat
abdominal aorta. (A) IVIS imaging of whole aorta at 24
hours after intravenous injection of INPs/ENPs. Boxed
area indicates the site of elastic damage. (B)
Fluorescent microscopy of damaged abdominal aortic
with INPs/ENPs. Purple coloration indicates the
presence of nanoparticles in ENP group while no
staining in INP group.
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We also assessed organ distribution of NPs by measuring fluorescence. At the
end of 24 hours, no residual fluorescence was found in the blood, heart, brain, muscle and
skin. A biodistribution plot of the organs that exhibited fluorescence, revealed that high
amount of signal was detected in the organs of mononuclear phagocytic system (MPS),
namely the liver and spleen (Table 6.2). Splenic uptake was ~ 2.7 times lower in the ENP
group than INP groups, possibly because of the higher accumulation in the damaged
aorta. It must be noted that rabbit-anti-rat antibodies were utilized for this experiment
which might be a major contributing factor to the splenic activation. Also, a small amount
of fluorescent signal was observed in the kidneys probably because of the partial
metabolism of low molecular weight un-encapsulated DIR molecules.
Table 6.2: Biodistribution of nanoparticles at 24 hours after intravenous delivery

Organ

% total fluorescence/ g dry weight

% total fluorescence/ g dry weight

(INP)

(ENP)

liver

16.97 ± 1.24

19.09 ± 1.00

aorta

11.19 ± 5.74

33.19 ± 5.19

lungs

14.304 ± 2.96

13.37 ± 7.62

kidneys

3.58 ± 1.95

1.05 ± .32

spleen

175.61 ± 35.12

63.79 ± 13.97
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We tested these ENP in another clinically relevant animal model (discussed in
Chapter 2) for medial arterial calcification (MAC). 24 hours after delivery of ENPs via
tail veins of diseased rats, we harvested the aorta and imaged under IVIS and observed a

strong florescence in the aortic arch and iliac bifurcation whic
which
h was not seen in healthy
animals treated with ENPs (Figure 6.12). VVG also confirmed elastin damage in
warfarin+vit K treated rats (Figure 6.13).

Figure 6.12:Targeting of ENPs to sites of damaged artery in MAC.
Boxed area indicates elastin damage.

Figure 6.13:Elastin damage confirmed
with VVG stain in MAC
artery
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Next, we tested if local perfusion of NPs at the site of elastic damage would
increase accumulation of NPs. Thus, nanoparticles were endoluminally perfused into the
damaged artery via a catheter mediated micro-vascular surgical procedure. 24 hours after
injection, direct local perfusion of ENPs into site of matrix damage showed ~10 fold

higher adherence and retention when compared to INPs control groups (Figure 6.14)
(ENPs groups were assumed to display 100% attachment).

Figure 6.14:Local administration of INPs/ENPs to degraded elastic
lamina in rat abdominal aorta. Relative adherence of
INPs/ENPs at 24 hours after local delivery of
nanoparticles to injured abdominal aorta.
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The imaging of the whole ao
aorta
rta and histological assessment further confirmed that
targeting of nanoparticles with surface elastin antibody was significantly higher than
control INPs (Figure 6.15A, 6.15B) and the nanoparticles penetrated deep in the medial
layers. The relative amount of ENPs attached to the injured area was ~43 times higher
when delivered locally as compared to systemic delivery.

administration
ation of INPs/ENPs to degraded elastic
Figure 6.15:Local administr
lamina in rat abdominal aorta. (A) IVIS imaging of whole
aorta at 24 hours after local perfusion of INPs/ENPs. (B)
Fluorescent microscopy of damaged abdominal aortic with
INPs/ENPs. Purple coloration indicates the pre
presence
sence of
nanoparticles. Dashed lines indicates the intima of the
aorta.
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NP clearance study

Whole body animal imaging revealed minimal to no fluorescent signal
after 8 days of INP injection (Figure 6.16). However, upon imaging the organs
individually, there was distinct signal observed largely from the liver and spleen even

after 8 days of injection. The signal observed in the liver was ~ 40 times lesser after 8
days compared to day 1 , whereas spleen showed almost 50% reduction in signal after
day 8. These results are encouraging as it shows the ability of the nanoparticles to clear

out RES therefore making multiple dosages a possible option.

Figure 6.16:NP clearance study. Undetectable fluorescence after 8
days of INP injection
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6.4

Discussion
There are a number of challenges associated with developing nanoparticles that

specifically target the site of diseased artery for drug/gene therapy applications. First, the
heterogeneous nature of vascular diseases poses a significant challenge for spatial and
temporal delivery of drugs or imaging agents to the diseased site. Secondly, the
hemodynamic environment in major arteries exposes the delivery vehicle to both
convective and diffusive forces which retards target-specific binding and local retention.
Thirdly, cellular and molecular targets of the vasculature that are intermittently expressed
during different stages of the pathology, although useful for molecular imaging, may
prove sub-optimal for site-specific delivery of therapeutic payload. Our overall goal was
to develop a minimally invasive nanoparticle system that can achieve matrix targeting of
a compromised vasculature. We have achieved this goal by employing elastin antibody
coated PLA nanoparticles that recognize specific sites of matrix damage and adhere to
the damaged vessel. This delivery technology can potentially be used for medical
diagnostic as well therapeutic applications.
Most of the previous research has been primarily focused on delivering
drug/genes to arteries by targeting vascular cells. For example, several researchers have
used molecular markers which are transiently over-expressed in sites of vascular
inflammation. In particular, endothelial cell adhesion molecules (CAMs) have been
extensively studied as potential targets for homing drug delivery vehicles.23,24 Antivascular cell adhesion molecule-1 (VCAM-1) liposome targeting has shown some
promising results in an ldlr-/- mice model in mitigating atherosclerosis.25 Although, these
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constitutively expressed endothelial markers show several fold increase in its surface
density in local sites of inflammation, they pose a major obstacle in serving as consistent
and heterogeneous molecular target due to their shedding from the plasma membrane as a
negative feedback mechanism to prevent leukocyte adhesion.335 Besides, cellular
targeting leads to uptake and intracellular delivery of drugs. We wanted to develop a
delivery system for drugs intended to function in extracellular environment. For example,
MMP inhibitors known to prevent degradation of matrix in diseases such as aortic
aneurysm need to be present in the ECM for effective function.336 Similarly compounds
that specifically bind to elastic fibers such as polyphenols and prevent elastic fiber
degradation
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need to be delivered to the ECM with minimal to no cellular uptake.

Deliveries of fibrinolytic agents in the case of coronary thrombosis also need an extracellular drug release for rapid clot dissolution. In such cases, negligible cellular uptake of
drug-loaded nanoparticles maximizes the therapeutic benefit. Previous research has
utilized exposed collagen type IV of basement membrane as a viable vascular target.337
However, insufficient quantity of the fibrous protein may provide sub-optimal matrix
targeting.
We wanted to develop NPs that specifically target degraded elastin and prevent
non-specific attachment to native elastic fibers hence localizing NPs only to diseased site
and not throughout the vasculature. Elastic fiber degradation which is a characteristic
feature of several vascular pathologies including aortic aneurysms and arteriosclerosis
can be used as a stable and abundant extracellular matrix target for nanoparticle
adherence and delivery. Elastic fiber consists of two main components- 90% of the
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mature elastic fiber is a core of amorphous cross-linked elastin protein while the
remaining 10% consists of 10-12 nm fibrils that are located around the periphery of the
amorphous elastin that include fibrillins, fibulins, and some other glycoproteins like
microfibril-associated glycoproteins (MAGPs).39,338 It has been shown earlier that MMPs
in vascular disease pathologies specifically degrade peripheral glycoprotein cover on
elastic fibers prior to elastin degradation.339,340 This proteolytic degradation exposes the
hydrophobic core of elastin allowing us to target only elastic fiber degradation site and
not healthy aorta.
We first tested NP targeting in ex-vivo conditions using whole rat aortas.
Inducing elastase mediated matrix damage exhibited a nanoparticle adherence that was
elastin-specific (high in ENP group and minimal in INP groups) and damage-dependent
(minimal ENP attachment in healthy undamaged aorta) (Figure 6.4). This data clearly
suggested that ENPs were specifically attaching to degraded elastic lamina and not to the
healthy aorta. The data also confirmed that intraluminal delivery was possible as NPs
could pass through intact endothelium.
Next we decided to test if such NPs with surface elastin antibody could be
targeted to diseased aorta in vivo. One of the biggest barriers faced by nanoparticle
mediated targeted therapy in vivo is the rapid clearance of particles by the mononuclear
phagocytic system (MPS), especially by the liver and spleen.341,342 It has been established
that PEGylation of carrier surface significantly increases circulation time, minimizes
immune responses and increases flexibility and hydrophilicity.342,343 In our preliminary
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studies, we used un-PEGylated PLA nanoparticles and confirmed a rapid hepatic
clearance (<1 hour) as opposed to PEGylated ENPs (>24 hours) (data not shown). We
specifically chose ~200 nm particle size and negatively charged surfaces to avoid cellular
uptake. Nanoparticle size is an important determinant in its cellular uptake and tissue
accumulation. Studies have shown that 100 nm sized nanoparticles show greater uptake
compared to 500 nm nanoparticles in vascular smooth muscle cells.344 Similarly, particle
size plays an important role in penetrating the endothelium when delivered
endoluminally. It has been shown that smaller size nanoparticles (~ 100 nm) achieve 3fold greater arterial uptake compared to larger (~ 275 nm) in an ex-vivo canine carotid
artery model.264,345 Our result indicated that nanoparticles with ~200 nm size were able to
penetrate endothelium and basement membrane. Another vital parameter that determines
the endocytosis or the lack thereof is the surface charge of nanoparticles. Due to the
inherent negative charge on mammalian cell membrane, positively charged nanoparticles
show superior cellular uptake when compared to negatively charged particles.346-348 We
also confirmed in our studies that positively charged surfaces increased cellular uptake.
Overall, keeping size to ~ 200 nm and sufficient surface negative charge, we were able to
keep nanoparticles in the extracellular matrix with minimum cellular uptake by SMCs.
Although our results suggest that size and charge are important parameters in deciding
the cellular uptake of nanoparticles, other critical factors like surface protein density,
nanoparticle concentration, antibody affinity and shear rate may all contribute to the
phagocytic effect of nanoparticles.
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Overall, our results indicate that specifically designed NPs with elastin targeting
antibody on the surface can be used to deliver agents to the site of elastic lamina damage
while avoiding uptake by healthy vasculature (Schematic in Figure 6.17). One of the
most exciting observations was that NPs only accumulated where elastic lamina injury
was induced and remaining healthy vasculature was spared. In addition, ENPs delivered
in healthy rats failed to display targeting (Figure 6.12) proving the specificity of ENPs
and the need for elastic tissue degradation as seen in various vascular disease pathologies
such as aortic aneurysms. However, there are several unanswered questions that need to
be addressed with further research. The possible assimilation of NPs by inflammatory
cells like macrophages present locally at the site of vascular disease is unclear. The
maximum duration of NP retention at the damaged site is also unknown, however, such
systems can be used to deliver imaging agents349 or drugs that act quickly such as elastin
stabilizing compounds.265 Also this study was performed with single dose; one can
envision using multiple doses to achieve constant supply. We used antibody mediated
elastin targeting. However, presence of antibodies on the surface makes nanoparticles
highly prone to Fc-receptor-mediated phagocytosis which causes rapid clearance by liver
and spleen.341,350 Antibodies have been investigated extensively in the last couple decades
and antibody-mediated tissue targeting for clinical practice has been approved by the
FDA.351-353 Besides, with advancements in hybridoma technology, antibodies can be
engineering and chimeric, humanized and fully human antibodies with minimal
immunogenicity can be exploited for active site targeting.354 This study was performed
with encapsulated fluorescent labeled dye for tracking particle trajectory. Further studies
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with drug or imaging agents loaded particles are underway to see effectiveness of the
targeting in vivo.

Figure 6.17:Schematic showing elastin antibody coated nanoparticle attaching
to fragmented elastin of aorta

6.5

Conclusion

We show that nanoparticles can be designed to specifically target degraded elastic
lamina, which is a key feature of a variety of vascular diseases, for ssite
ite specific delivery
of therapeutics and imaging. After several optimization experiments, we developed a
nanoparticle system which was minimally cytotoxic, displayed ex-vivo and in vivo
specificity, and hydrodynamic stability. Our results indicate that el
elastin
astin antibody coated
PLA nanoparticles are excluded by cells, display high affinity to degraded elastin when
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delivered ex-vivo in rat aorta, injected intravenously and perfused locally into damaged
arteries in rats. Nanoparticles with irrelevant control antibody (INPs) did not show such
specificity. The ENP attachment was specific to injury site and healthy elastic lamina was
spared. Thus such systems can be used to target vascular pathologies such as aortic
aneurysms or arteriosclerosis.
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CHAPTER 7

PENTAGALLOYL GLUCOSE (PGG) ENCAPSULATED NANOPARTICLES AS
POTENTIAL THERAPY FOR MEDIAL ARTEIRAL CALCIFICATION AND
ABDOMINAL AORTIC ANEURYSM

7.1

Introduction
From the previous chapters, we identified the elastogenic and elastoprotective

properties of polyphenols making it a desirable candidate for AAA and MAC repair. In
addition, we also developed a minimally invasive nanoparticle technology that can target
sites of damaged elastin in the artery. The next goal was to load these polymeric
nanoparticles with polyphenols for delivery to sites of diseased vessel for therapeutic
benefit. We chose PGG as a model polyphenol for the same.
7.2

Materials and methods
Preparation of PGG loaded nanoparticles
Poly(D,L-lactide) (PLA) nanoparticles were prepared using a nanoprecipitation

method based on solvent diffusion. Briefly, 10 mg PLA (Average MW 75,000-120,000)
(Sigma Aldrich, St.Louis, MO) was dissolved in 1ml acetone (VWR International,
Radnor, PA). ~2.5 mg of 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N[maleimide (polyethyleneglycol)-2000] (PEG maleimide) (Avanti Polar Lipids, Inc.,
Alabaster, AL) and 500 µg/ 1 mg PGG were added to the PLA solution in acetone. ~300
µl of polymer solution was added drop-wise at a uniform rate to 8 ml of water kept under
sonication in a water bath sonicator and solutions were sonicated for 1 hour. The
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resulting suspension was expected to contain nanoparticle with encapsulated PGG. The
particles were purified 3 times by centrifugation at 3000×g for 15 minutes followed by
re-dispersion in water. Three different groups were tried: (a) blank (without PGG) (b)
500 µg PGG in 3 mg polymer (c) 1000 µg PGG in 3 mg polymer.
Percentage loading calculation
After purification of the nanoparticles, the samples were lyophilized, weighed and
digested in DMSO and quantified against a standard curve of PGG in DMSO. The %
loading was calculated as follows:

% )"# 

,#  -..
,#  ) &),$' * ,#  -..

Release profile of PGG in PLA nanoparticles
Known amounts of nanoparticles were taken and added to dialysis units (Slide-ALyzer® MINI Dialysis Units, Thermo Scientific, Rockford, IL) and incubated at 37°C in
infinite dilution conditions in phosphate buffered saline (PBS). After each time interval,
PGG loaded nanoparticles were removed, lyophilized and digested to evaluate the
amount of PGG remaining in particles.
7.3

Results
Using high molecular weights of PLA yielded very poor % loading in the PGG

groups. We obtained 1% PGG loading (2% encapsulation efficiency) and 3% PGG
loading (5% encapsulation efficiency) with initial 500 µg and 1000 µg of loading PGG.
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Such low encapsulation efficiency indicates that majority of the PGG was eliminated in
the bulk aqueous phase instead of staying in the organic phase.
We tried another approach of using low molecular weight PLA (Average MW
9,000) for the nanoparticle preparation using the same nanoprecipitation method. We
noted a 25% encapsulation of PGG in ENPs using 50mg/ml PGG solution (Figure 7.1).

Figure 7.1:Increasing concentration of PGG starting solution shows
greater PGG loading percentage

Further, we selected the highest loading percentage to quantify the release
profiles, however ~ 90% of PGG was released 46 hours (Figure 7.2).
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Figure 7.2:Release profile of PGG up to 46 hours

7.4

Conclusion

We tried loading PGG into PLA nanoparticles but achieved very poor drug
loading efficiency. Although varying the molecular weight of PLA increas
increased
ed the loading
efficiency by ~ 8 times (3% with high MW PLA vs. 25% with low MW PLA) almost

90% of PGG was released by 46 hours. Since PLA displays relatively show rate of
hydrolytic degradation, the initial release of PGG appears to be a diffusive loss and not
due to degradative properties of PLA.
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CHAPTER 8

CONCLUSIONS AND RECOMMENDATIONS

8.1

Conclusions
Elastin is an extracellular matrix protein found in abundance in vascular tissue.

Elastin degradation is a natural part of ageing; however pathological elastin degradation
can lead to severe vascular diseases including abdominal aortic aneurysms (AAA) and
medial arterial calcification (MAC). Unfortunately, innate ability of cells to repair
degraded elastin is highly diminished in adults and cells cannot recapitulate elastic fiber
assembly that happens during development. The broad goal of this project was to
understand the role of elastin degradation in diabetic vascular calcification and to develop
minimally invasive drug therapy that can target degraded elastin and deliver polyphenolic
compounds to prevent disease progression. We show the following:
1) In the first part of the project, we set out to determine the pathological
relevance of elastin degradation products and TGF-β1 in a hyperglycemic
milieu. Hyperglycemia is a hallmark feature of diabetes mellitus. There is an
overwhelming amount of evidence linking diabetes with medial arterial
calcification (MAC). In fact, calcified arteries are the unfortunate fate of
diabetic patients’ arteries eventually requiring amputation of lower
extremities. Of the several factors causing calcification of diabetic arteries,
our experiments isolated three clinically relevant parameters - elastin peptides,
TGF-β1, and glucose – and tested their effects on vascular smooth muscle
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cells. Our results indicate that in the presence of elastin peptides and TGF-β1,
smooth muscle cells turn into osteoblast like cells, an effect which is
dramatically aggravated in the presence of high glucose concentrations.
Conversely, without the elastin peptides and TGF-β1, high glucose
concentrations alone did not cause this osteogenic shift, indicating the
importance of elastin peptides in the process of calcification. Our results
therefore validate the importance of intact elastin, the degradation of which
plays an acute role in diabetic vascular calcification.
2) The second stage of this project was examine the elasto-protective and elastoregenerative effects of polyphenols like PGG, EGCG and catechin. All the
three polyphenols bound to elastin in a concentration and time dependent
manner, providing resistance against elastolytic damage. Furthermore, these
polyphenols exhibited a strong affinity for binding to soluble tropoelastin,
thereby aiding in the coacervation and maturation of tropoelastin to crosslinked elastin. Aneurysmal smooth muscle cells generated greater tropoelastin
compared to healthy vascular cells; however they did not produce
commensurate amounts of lysyl oxidase, a key enzyme needed for crosslinking elastin. Polyphenols helped aneurysmal cells to deposit greater
quantities of mature elastin without altering the quantity of tropoelastin in the
media. These features of polyphenols make them a desirable candidate for
treating elasto-degradative diseases like AAA and MAC.
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3) In anticipation of using these polyphenols as elastin protective agents, we
invented a novel minimally invasive method that can recognize degraded
elastin. We fabricated PLA nanoparticles loaded with a tracer dye and elastin
antibodies attached on the surface. One time intravenous injection of these
nanoparticles showed ~ 33% attachment of nanoparticles which was ~ 3.5
times greater than non-specific control. Furthermore, these nanoparticles were
relatively cyto-compatible and bio-compatible. After 8 days of nanoparticles
injection, ~ 55% of the particles were removed by the reticulo-endothelial
system. Therefore, this technology can be used to load therapeutics, imaging
agents, drugs, and molecules for site specific delivery to damaged vascular
matrix.
8.2

Limitations of this project and recommendation for future work
1) Scope for improvisation in the physical aspect of nanoparticle system (synthesis
and characterization)
In this project we have chosen PLA nanoparticles to test our hypothesis
that degraded elastin is a stable and viable target for therapeutic delivery.
Spherical nanoparticles have been traditionally used both clinically and in
research laboratories. The importance of size has been discussed in Chapter 6.
However, the importance of geometry has been neglected in this project.
Nanovector geometry has shown to play an important role in defining its transport
in vasculature and its adhesion to target receptors as well as mode of nanovector-
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cell interactions such as endocytosis, vesiculation, and phagocytosis. Geng et al.
have shown that long cylindrical micelles display longer and higher tumor
targeting compared to spherical counter parts.355 Muro et al. have also shown that
large elliptical discs exhibited higher targeting efficiency compared to spheres.356
Champion and group also show that “worm-shaped” particles exhibit negligible
phagocytosis compared to spherical particles of equal volume.357 With current
advancements in “shape engineering”, it is possible to formulate nanosized
particles of different shapes that are capable of achieving greater molecular
targeting with minimal off-target accumulation.358
The PEG used in our studies has a molecular weight of ~ 3000. We have
tested nanoparticles made of only one molecular weight of PEG and a single
PLA:PEG ratio (4:1). It has been shown often times in literature that surface PEG
groups

are

easily

tunable

and

provide

a

“hairy”

outer

surface

to

nanoparticles.359,360 The greater and longer the PEG chains on the surface, the
longer the circulation time, thereby greater targeting efficiency. However, higher
circulation time also makes the particles prone to untimely degradation, thereby
reducing its effectiveness. On the other hand, lesser PEG groups on the surface,
makes the particles more prone to protein adsorption (opsonization), thereby
activating the RES system and leading to an accelerated undesirable clearance of
the nanoparticles. Further studies need to be done to investigate the effect of
varying PEG molecular weight and ratio on the targeting efficiency. However, in
doing so, the available maleimide groups available for antibody conjugation must
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not be compromised; as such groups decide the eventual functional capacity of the
nanoparticles. An elaborate experimental analysis must be performed such as
employment of surface plasmon resonance (SPR) to investigate the interaction of
elastin antibody coated nanoparticles with elastin. Further, the in-vivo response to
varying PEG groups must be studied for creating a more effective delivery
system.
It must be noted that the nanoparticles tested for our use were fabricated in
pure deionized water as the bulk aqueous phase. Since the intent of nanoparticle
formulation was in-vivo testing, this system helped with the preparation of
nanoparticles free from toxic surfactants. However, this compromised the stability
of the particles. Since we used freshly prepared particles for each experiment, the
stability was not a critical component of our system. However, as we envision a
clinical scalability of this project, sterile formulation and stable storage becomes a
crucial parameter that needs much research. In addition, as we are dealing with
biodegradable systems, it is imperative that the nanoparticles must be stored in a
dry environment. Nanoparticles are commonly isolated by freeze-drying. This
process should have certain desirable characteristics such as (a) preservation of
physical and chemical characteristics of polymeric system (b) an acceptable
relative humidity (c) long term stability (d) functional retention of antibodies.
Freeze drying is a stressful process that can de-stabilize colloidal suspension of
nanoparticles especially during dehydration. This process may cause unwarranted
and sometimes permanent fusion of nanoparticles dramatically changing its
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physical properties. To avoid this, either cryoprotectants (prevents freeze stress)
or lyoprotectants (prevents drying stress) are used for long term storage. Some
commonly used stabilizers are sucrose, lactose, glucose, mannitol, treahlose,
glycerol, hydroxymethyl starch, etc.361 It has been shown that PLGA
nanoparticles could be freeze-dried successfully without changing structural
conditions after freezing, (no macroscopic aggregation) when sucrose and glucose
were added.362 Thus experiments must be performed on the PLA nanoparticle
system proposed in Chapter 6 to confirm its storage, shelf-life, and stability.
2) Scope for improvisation in the biological aspect of nanoparticle system
(biological response to nanoparticles)
The nanoparticles have been tested in two different animal models as
described in Chapter 6. Although these models simulate the pathological
presentation of MAC and AAA, the induction of the pathology is very acute and
clinically dissimilar. Especially, the calcium chloride injury model causes an
acute caustic injury to the aorta leading to elastin fragmentation. In addition, the
model is devoid of atherosclerosis and fatty deposition (a common clinical
presentation). As evidenced, there is a direct positive correlation between the
quantity of nanoparticle attachment and degree of elastin damage. An important
question, and possibly a limiting parameter of this project, is if the amount of
elastin damage in the calcium chloride model is comparable to that in diseased
patients. Therefore, it becomes necessary to test the functionality of these
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particles in a clinically relevant animal model such as Angiotensin II in ApoE-/mice (discussed in detail in Chapter 2).
Due to the size of nanoparticles tested (~ 200 nm) it is clear that a vast
majority of the particles are cleared by the Kupffer cells of the liver and spleen.
This is due to a rapid opsonization of nanoparticles which causes instant (minutes
to hours) trafficking of nanoparticles to liver and spleen (non-targets). The
clearance study indicates that ~ 50% of the particles are cleared from the liver and
spleen by 8 days. Thus this technology can be used to safely deliver multiple
doses of nanoparticles to attain required therapeutic effect. However, clearance
follows a first order exponential decay rate, thus it becomes important to identify
the time that particles take for complete clearance, as multiple dosing should not
cause toxic accumulation of nanoparticles in off-target organs.
3) Loading of polyphenols for drug delivery
The greatest shortcoming, thereby the largest future scope, of this project
is the un-successful loading and release of drugs in the nanoparticle system. We
attempted PGG loading two times using two different molecular weights of PLA
and obtained sub-optimal encapsulation efficiency. It has been documented in
literature several times about the challenges of loading water-soluble drugs in
PLA/PLGA nanoparticle systems. Consequently, the advent of liposomes
provided a novel solution to loading water soluble drugs. Liposomes are bilipid
micelles that mimic cell membranes but lack membranous proteins. Liposomes
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can be single membrane layer or multiple membrane layers.363 Just like polymeric
nanoparticles, liposomes can be manipulated to add surface PEG groups,
conjugate proteins on surface and engineered for controlled release of drugs.
Thus, liposomes can be used for encapsulating water soluble drugs such as PGG,
EGCG and catechin to achieve desirable loading efficiency and release profiles,
which can then be administered for elastin stabilization.
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